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ABSTRACT 
 
Plasma volume (PV) rises by up to 50% in normal pregnancy, a phenomenon 
associated with a favourable pregnancy outcome. A previous study of pregnant 
women with sickle cell (haemoglobin SS) disorder found that PV paradoxically 
contracts in late pregnancy.  
  
A cross-sectional study was performed to determine PV (Evans blue method) and 
volume regulatory hormones and electrolytes in pregnant women with haemoglobin 
(Hb) SS and in non-pregnant and Hb AA controls.   
 
PV rose in pregnant HbAA and was significantly correlated with plasma 
angiotensinogen. Non-pregnant Hb SS women had supranormal PV measurements 
and reduced glomerular filtration rate (GFR). Their PV did not rise in pregnancy and 
was not correlated with angiotensinogen. Their plasma renin concentration also 
failed to rise significantly by 36 weeks gestation and was significantly less than in 
Hb AA pregnancy although aldosterone concentration was raised as expected.  
 
A general vasoconstriction in pregnancy can cause inactivation of the renin-
angiotensin system and could explain this, with aldosterone being elevated by non 
Angiotensin II dependent stimulation such as plasma potassium, which was 
significantly higher in the pregnant Hb SS women. Further studies demonstrating a 
deficiency of vasodilator substances in pregnant Hb SS women will strengthen this 
hypothesis. 
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1. INTRODUCTION 
 
The Cardiovascular system undergoes significant changes in pregnancy. Plasma 
volume is known to increase during the course of normal pregnancy and is 
associated with a positive pregnancy outcome (Hytten & Paintin, 1963; Pirani et al., 
1973; Hays et al., 1985). Sickle cell disorder (SCD) is a haemoglobinopathy that is 
relatively common in Nigeria; in fact the country probably has the highest 
population of individuals living with the disorder worldwide (WHO, 2006a) and 
many afflicted women are surviving till pregnancy and beyond. In this thesis I 
explored plasma volume changes in pregnant Nigerian women with sickle cell 
disorder as well as hormones and electrolytes that are known to regulate body fluids. 
In doing so, I compared them with non-pregnant women with SCD and pregnant and 
non-pregnant women with normal haemoglobin AA. This Introduction begins by 
describing the context in which the study is carried out then goes on to comment on 
the physiology of sickle cell disorder in pregnant and non-pregnant women, starting 
with general then cardiovascular physiology in the non-pregnant before going 
further to discuss what is known to happen in pregnancy. It then explores the control 
of plasma volume in the non-pregnant and pregnant states.  
 
The second chapter of my thesis is the Methods chapter where I specify and discuss 
the subject selection, specimen collection and processing, as well as the laboratory 
methods, data handling and analysis.  
 
The third chapter details the results in non-pregnant women, starting with the 
demographic characteristics to the plasma volume measurements and ending with 
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the various hormone and electrolyte measurements and their interactions. The fourth 
chapter continues with the results of the pregnant sickle cell women in the same vein 
and also compares all the parameters of the pregnant with the non-pregnant women. 
I then discuss the findings of the two chapters in the fifth chapter and end the thesis 
with a final chapter that summarises my conclusions. 
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1.1. OVERVIEW AND GENERAL PHYSIOLOGY OF SICKLE CELL 
DISORDER                                                                        
Sickle cell disorder (SCD) is an abnormality of haemoglobin that was first 
recognized in people of West African ancestry (Serjeant & Serjeant, 2001). 
Approximately 230,000 babies are born in Africa yearly with SCD (Modell & 
Darlison, 2008) and about 150,000 of these are born in Nigeria (WHO, 2006a). 
More than 50% of the children born with severe forms of the disease such as sickle 
cell anaemia i.e. those with haemoglobin (Hb) SS, die before the age of 5 years 
(WHO, 2006b) from bacterial and malarial infections. However, in recent times 
there has been increased survival due to increased access to hospital services 
particularly in Nigeria (Akinyanju et al., 2005) and more girls are surviving till 
pregnancy and beyond.  
 
I carried this study out in the Lagos University Teaching Hospital, in Lagos, Nigeria, 
a 761-bed hospital, 89 of which are obstetric and 60 gynaecological. It is one of 
two tertiary hospitals in Lagos state, the population of which is just under 10 
million people. The ethnicity of the patients is homogenous; despite the fact that 
there is a mixture of tribes mostly from the South of Nigeria, where Lagos is 
situated, the women are all black African. Majority of the women have tertiary 
education although their earning power is not commensurate to their educational 
status as more than 60% of Nigerians live below $1 a day (Klugman, 2010) 
Despite the fact that the study hospital is a public one, patients still have to pay 
for all their services, albeit at a subsidised rate. There is a relatively new 
National Health Insurance Scheme in the country but it does not as yet cover 
deliveries or other secondary care. 
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Nigeria is an oil rich company but plagued with problems of infrastructure such 
as irregular electricity and water supply, poor roads and maintenance culture in 
general. The electricity supply to the hospital is also affected and is epileptic at 
best thus power generating sets which consume huge amounts of diesel have to 
be provided as back up. There is a blood bank within the hospital that prepares 
and provides blood for transfusion but rare blood types often have to be sourced 
from outside the hospital.   
 
Another issue that requires a brief mention at this stage is that of malaria, a 
disease that is endemic to Nigeria. Malaria is caused by infection of the red 
blood cells by the protozoan genus Plasmodium, which is spread by the bite of 
an infected anopheles mosquito. This causes a flulike illness characterised by 
fever, chills, muscular aches and headache, which can be fatal especially in non-
immune individuals if not promptly treated (Greenwood et al., 2005). In 
pregnancy, the acquired immunity to repeated episodes of malaria is transiently 
lost and it can become very severe, causing organ failure and death. Even in 
moderate cases, it can cause anaemia and miscarriage in the mother and low 
birth weight, prematurity and congenital malaria in the fetus (Duffy & Fried, 
2005; Menendez et al., 2000). In order to prevent these complications, pregnant 
women are given prophylactic antimalarial therapy (Falade et al., 2007). Women 
with SCD who are more likely to suffer serious complications from malaria are 
given a daily antimalarial prophylactic drug – Proguanil, which is very effective 
(Garner & Gulmezoglu, 2006). Non-pregnant women with SCD are also asked 
to take Proguanil daily, as they are prone to severe morbidity and mortality from 
malaria as well (Ibidapo & Akinyanju, 2000). Pregnant women without SCD are 
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given sulphadoxine/pyrimethamine as intermittent preventive therapy, twice in 
the pregnancy after the first trimester at least one month apart, according to 
national guidelines (Health, 2010).  
 
The genesis of SCD is as follows: A single point mutation in the 6th codon of 
the  globin haemoglobin subunit leads to substitution of glutamic acid for 
valine, resulting in the formation of ‘sickle haemoglobin’, or HbS. Upon 
deoxygenation, HbS forms hydrophobic interactions with adjacent S globins, 
ultimately resulting in the polymerisation of HbS (Bunn, 1997). This 
polymerization of HbS is the pathophysiological hallmark of SCD, leading to its 
various clinical manifestations (Bunn, 1997). The homozygous disease in which 
two S globin genes are inherited is known as sickle cell anaemia (HbSS) 
(Schnog et al., 2004). Other genotypes that cause SCD include double 
heterozygous types such as HbSC and HbS-thalassaemia, with HbSC being the  
more common of the two. People who carry just one S globin gene are said to 
have the sickle cell trait (HbAS) and are generally asymptomatic (Serjeant & 
Serjeant, 2001). 
 
Various triggers can induce this polymerization. Decrements in pH, increase in 
temperature (Schnog et al., 2004), a high concentration of HbS in the 
erythrocytes and the presence of other haemoglobins are all determinants of 
polymerization (Schnog et al., 2004). The presence of HbF and HbA2 limits the 
polymerization to a certain extent. HbSS individuals have about 85% of HbS but 
those with relatively high levels of HbF tend to have less severe disease 
manifestation (Bunn, 1997; Schnog et al., 2004).  
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For this polymerisation to occur, the time taken for the red cells to traverse the 
circulation – transit time (tt) has to be longer than that taken for the red cells to 
form polymers – delay time (dt) (Bunn, 1997). Adherence of sickle cells to 
vascular endothelium results in intimal hyperplasia in larger vessels and causes 
increased tt (Hebbel et al., 1980). The exact cause of this adherence is unknown 
but several red blood cell surface molecules, factors and proteins have been 
implicated (Setty et al., 2002). These include red blood cell surface receptors 
and molecules such as the very late activation antigen 4 (VLA4) and the 
thrombospondin receptor CD36, and proteins such as fibrinogen and fibronectin 
(Joneckis et al., 1996). However, because the transit time in the smaller vessels 
(arterioles and capillaries) is much shorter, polymers do not form in most of the 
cells during blood flow in the microcirculation (Mozzarelli et al., 1987). 
Adherence to leucocytes and platelets as well as the vascular endothelial cells is 
now thought to contribute to the increased transit time (Frenette, 2002). Also the 
high white blood cell count found in most patients with sickle cell anaemia 
results in the production of injurious cytokines such as tumour necrosis factor – 
alpha (TNF-). This together with the endothelial adherence mentioned above 
and a hypercoagulable state contribute to sickle cell vaso-occlusion (Hebbel et 
al., 1980; Frenette, 2002; Ataga & Key, 2007). 
 
The polymerisation of HbS causes the change of the affected red blood cells into 
stiff sickle shaped cells which then obstruct the capillaries resulting in early 
destruction i.e. haemolysis, and ischaemia from the resulting occlusion of the 
vessels. These lead to the various clinical manifestations which include clinical 
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jaundice and gallstones due to haemolysis, anaemia, increased bilirubin 
excretion and subsequent formation of pigment stones, splenic manifestations 
(splenic sequestration, hypersplenism), susceptibility to infections, stroke, 
complications in pregnancy, bone pain crises and acute chest syndrome (Serjeant 
& Serjeant, 2001; Schnog et al., 2004). The pregnancy complications include 
anaemia, severe crises (the term used for the various clinical manifestations of the 
disease especially the vaso-occlusive type), pulmonary disease and infections and 
death (Rajab et al., 2006; Villers et al., 2008; Afolabi et al., 2009). Perinatal 
mortality rates are higher than those for their haemoglobin AA counterparts 
worldwide often caused by fetal growth restriction, prematurity and intra-uterine 
fetal death (Villers et al., 2008; Al Jama et al., 2009; Barfield et al., 2010). 
 
Life expectancy and disease manifestation also vary with environmental and 
socioeconomic factors. There is a high early mortality in sub-saharan Africa due 
to malaria, malnutrition and infections and the average survival is less than 5 
years (Serjeant & Serjeant, 2001). However, with improving medical conditions 
and early diagnosis, many affected individuals are surviving to the age of 40 and 
beyond. In areas with more developed public health and services, average 
survival is better. The Cooperative study of sickle cell disease, which was 
carried out in the USA, showed a median survival for SS disease at 42 years for 
males and 48 years for females (Platt et al., 1994). A study carried out in 
Jamaica reporting on 3301 people attending a dedicated sickle cell clinic 
between 1987 and 1996 found a median survival of 53 years for men and 58.5 
years for women (Wierenga et al., 2001). 
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An additional reason for differences in survival between individuals with SCD is 
the variability in severity of clinical and haematological factors of the disease in 
the different genotypes, with a minority having few complications, particularly 
those with haemoglobin SC, and the rest with intermediate to severe 
complications, the latter being more common with haemoglobin SS individuals 
(Kato et al., 2007). 
 
The most common cause of death varies between different environments. In a report 
of 241 Jamaican SS individuals, acute chest syndrome (a syndrome consisting of 
chest pain, fever, cough and dyspnoea with abnormal radiological chest signs), acute 
splenic sequestration (a condition in which the spleen enlarges significantly and 
traps a large amount of red blood cells causing a profound anaemia), renal failure 
and meningitis were the most common causes of death (Thomas et al., 1982). In 
sub-Saharan Africa, other causes such as malaria, bacterial infections, malnutrition 
and sudden death during pregnancy have been reported (Athale & Chintu, 1994; 
Serjeant & Serjeant, 2001; Van-Dunem et al., 2007). 
 
1.1.1. Cardiovascular physiology 
 
One of the consequences of haemolytic anaemia in HbSS individuals is a 
hyperdynamic circulation and an expanded plasma volume as a result of an 
attempt to compensate for the reduced oxygen carrying capacity (Schnog et al., 
2004). Cardiac output was reported to be about 50% above normal in steady 
state HbSS individuals with a haemoglobin concentration of 6 – 8 g/dl (Lindsay 
et al., 1974). Heart rate has been found to be higher at rest in sickle cell anaemia 
patients (Balfour et al., 1984) but the contribution of heart rate to the increase in 
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cardiac output is minimal; the main cause is an increase in stroke volume 
(Covitz et al., 1995). It is thus expected that their heart chambers are dilated and 
this has been found in several studies (Gerry et al., 1976; Rees et al., 1978; 
Balfour et al., 1984). In a prospective, multicentre study of 191 sickle cell 
subjects with blinded echocardiography readings, all the heart chambers were 
found enlarged and all except the right ventricle had dimensions that were 
inversely proportional to haemoglobin concentration (Covitz et al., 1995). 
However, contrary to other findings (Rees et al., 1978; Denenberg et al., 1983), 
left ventricular contractility was found to be normal in most patients suggesting 
that the individual with SCD has a dilated heart but normal left ventricular 
function (Covitz et al., 1995). This difference could be because the numbers 
studied were fewer, 44 in one study (Rees et al., 1978) and 11 in the other 
(Denenberg et al., 1983) respectively than in Covitz et al, and patient selection 
was unbalanced with more severely affected patients being included in the 
studies which found abnormal left ventricular function.  
 
1.1.1.1. Plasma volume    
 
As mentioned above, plasma volume is supranormal in individuals with sickle cell 
disorder in the steady state (Barreras et al., 1966; Steinberg et al., 1977; Hatch et al., 
1989). Several reports have found a decrease during crises (Jenkins et al., 1956; 
Erlandson et al., 1960; Barreras et al., 1966) although one Jamaican study (Wilson 
& Alleyne, 1976) found no significant change in plasma volume during the painful 
crisis. An explanation for this may be the differences in severity or duration of the 
crises at the time of plasma volume estimation (Serjeant & Serjeant, 2001).   
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The mechanism of the plasma volume expansion is not known. Despite the fact 
that most anaemias are associated with some degree of expansion of plasma 
volume (Serjeant & Serjeant, 2001), that in SCD exceeds that found in other 
haemolytic anaemias with similar haematocrits (Erlandson et al., 1960; 
Steinberg et al., 1977). It is thought that the extra volume expansion could be an 
adaptation in order to reduce the blood viscosity found in them (Serjeant & 
Serjeant, 2001). The regulation of plasma volume depends on the balance of 
fluids between the extracellular and the intracellular compartments, which in 
turn is dependent on osmotic forces exerted by plasma proteins and electrolytes 
and the hydrostatic forces (Jordan & Marshall, 1995). 
 
Plasma volume is particularly dependent on the quantity of sodium in the body 
(Ganong, 2005) thus dietary intake and excretion of sodium is important. All the 
hormones that affect sodium regulation (e.g. renin-angiotensin-aldosterone 
system, progesterone and prolactin) also control plasma volume (Ganong, 2005) 
and will be discussed in detail in the section on the control of plasma volume 
below. In addition, although a lot of fluid may be lost from the skin in hot 
climates, most of the fluid lost from the body is by excretion through the 
kidneys (Jordan & Marshall, 1995) thus renal function greatly affects plasma 
volume regulation. Finally, ingestion of water inspired by thirst is another factor 
that can affect plasma volume and this brings osmolality and the hormones that 
control it such as vasopressin into play.  
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1.1.2. Renal physiology 
1.1.2.1. Haemodynamics 
The kidneys function to filter a plasma-like fluid through the glomerular 
capillaries into the renal tubules (Ganong, 2005) in a process known as 
glomerular filtration. In a normal adult the glomerular filtration rate (GFR) is 
about 120-130 ml of fluid per minute. In children with SCD, renal hemodynamic 
parameters are generally supranormal (Addae, 1975; Ataga & Orringer, 2000). 
The renal plasma flow (RPF), blood flow and GFR have been found to be 
increased in young SCD patients (Etteldorf et al., 1952; Allon et al., 1988) but 
fall with increasing age.  However, although these parameters appear to be 
influenced by age, the age at which the decline sets in is not certain. Previous 
studies found RPF and GFR declined to normal levels towards adolescence 
(Etteldorf et al., 1952; Etteldorf et al., 1955; Hatch et al., 1970) but a more 
recent study found that GFR, RPF and blood flow were still supranormal at a 
median age of 20.8. (Thompson et al., 2007) and other authors found that 
although GFR (measured by creatinine clearance) tended to decline below 
normal over the age of 40, there was significant variability and two patients over 
the age of 60 had creatinine clearance of 120 ml/min/1.73m2 or more (Morgan & 
Serjeant, 1981). It is difficult to determine the timing of the decline in GFR as it 
may be influenced by the frequency and severity of crises (Addae, 1975). GFR 
has been reported as reduced during crises (Addae, 1975). 
 
The cause of the supranormal GFR in children and young adults is not known. 
The GFR in many other types of anaemia is either normal or reduced (Addae, 
1975). Also correction of the anaemia has not been shown to alter the GFR in 
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short-term studies (Keitel et al., 1956; Statius van Eps et al., 1967). It has been 
postulated that the increased renal haemodynamic parameters are as a result of 
increased prostaglandin synthesis in the kidneys of SCD individuals (de Jong et 
al., 1980). The use of indomethacin, a prostaglandin inhibitor, resulted in 
significant falls in GFR and RPF in them compared with normal controls, 
despite having high or normal values at the beginning of the experiment (de 
Jong et al., 1980; Allon et al., 1988). It is thought that the high prostaglandin 
synthesis in them could be as a result of renal medullary ischaemia due to 
sickling (Serjeant & Serjeant, 2001). The low oxygen tension, acidic pH and 
hypertonicity found in the renal medulla are conducive to sickling, resulting in 
vaso-occlusion within the vasa recta (Statius van Eps et al., 1970a). This 
hypothesis has been extended to explain the decline in renal function with age in 
SCD individuals. The authors of a review of the pathophysiology of sickle cell 
nephropathy suggest that the prostaglandin mediated glomerular hyperfiltration 
may eventually promote the occurrence of glomerulosclerosis, leading to a  
decline in renal function and ultimately renal failure (de Jong & Statius van Eps, 
1985). The proteinuria that is frequently seen in these individuals may be as a 
result of this glomerulosclerosis.  
 
Nitric oxide may also play a role in the increased GFR as increased levels of 
nitric oxide synthases have been found in transgenic mice with high levels of 
haemoglobin S, compared with normal control mice. The transgenic HbS mice 
also demonstrated an increased GFR compared to the control mice (Bank et al., 
1996).  
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1.1.2.2. Hyposthenuria 
Another major renal manifestation of SCD is hyposthenuria. Hyposthenuria, an 
inability to concentrate urine maximally, is the most widely known renal 
abnormality in sickle cell disease patients (Addae, 1975; Ataga & Orringer, 
2000). The urine is both profuse in volume and dilute, resulting in a significantly 
lower osmolality than in normal controls after an 8-10 hour water deprivation (Allon 
et al., 1988). The administration of vasopressin does not improve urine 
concentration in them thus it is not thought to be due to a deficiency of this hormone 
(Statius van Eps et al., 1970b; De Jong et al., 1982), but could be due to down-
regulation of the V2 receptors as has been shown in nephrectomised rats 
(Teitelbaum & McGuinness, 1995). Although blood transfusion has been shown to 
reverse the concentration defect in younger SCD individuals, the effect is less after 
the age of 15 (Statius van Eps et al., 1970b). Another reason why anaemia alone is 
not the likely cause of the hyposthenuria is that it does not occur in other chronic 
anaemias and it still occurs with normal haemoglobin levels in both HbSC and 
HbAS individuals (Serjeant & Serjeant, 2001). As hyposthenuria has been noted to 
develop in a normal donor kidney following its transplantation into a patient with 
SCD (Spector et al., 1978), it can be surmised that the defect is likely due to a 
sickling related pathology in the kidneys. The current thinking is that the destruction 
of the vasa rectae system in SCD individuals leads to a loss of the deep 
juxtamedullary nephrons that are necessary for maximal urine concentration (Ataga 
& Orringer, 2000; Serjeant & Serjeant, 2001).  
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1.1.2.3. Water balance 
As the outer medulla is relatively spared, individuals with SCD are capable of 
concentrating their urine to the required extent in the steady state (Statius van Eps et 
al., 1970a). In the steady state, they also excrete large volumes of urine and 
consequently drink large amounts of fluid (Saxena et al., 1966; Addae & Konotey-
Ahulu, 1971).  However, during crises and water deprivation states, they are known 
to often be in negative water balance (Addae, 1975). The urine volume is reduced 
from their usual polyuric state but it remains dilute (Hatch & Diggs, 1965). It is 
thought that the relative oliguria seen in crisis states may be due to the dehydration 
that occurs before crises (Hatch & Diggs, 1965). 
 
Sodium excretion in steady state sickle cell patients has been found to be similar to 
(Hatch et al., 1989; Olowu et al., 1995) or less than (Addae & Konotey-Ahulu, 
1971) their haemoglobin AA counterparts. This is likely to be an important defence 
against their tendency to being dehydrated as sodium conservation is linked with the 
maintenance of an adequate, in their case often supranormal intravascular volume 
(Addae, 1975). A study that found high urinary sodium losses and hyponatraemia in 
a group of sickle cell patients, actually studied non-steady state sickle cell disease 
children (Radel et al., 1976). Urinary potassium excretion was however found to be 
reduced in 6 individuals with SCD when compared with 5 age-matched healthy 
controls after receiving intravenous potassium chloride infusion (DeFronzo et al., 
1979). This was despite normal plasma renin activity (PRA) and aldosterone levels 
and it has been corroborated in other studies of individuals with SCD (Batlle et al., 
1982; Yoshino et al., 1982). It is thought to be due to the ischemia caused by vasa 
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recta occlusion from the sickling process, which affects the distal tubules more 
despite overall renal function still being adequate (DeFronzo et al., 1979).  
  
There are varying reports on PRA in SCD individuals. It appears that PRA and 
aldosterone concentration are generally normal in the steady state (DeFronzo et al., 
1979; de Jong et al., 1980) although high levels have also been reported (Matustik, 
1979). The study reported by Matustik (Matustik, 1979) was in a much younger 
group (ages 6-20) whilst that reported by de Jong (de Jong, 1980) had an older age 
range (14-63, mean 28 years), and that by DeFronzo (DeFronzo et al., 1979) also 
had older subjects (19-37, mean 25). As there was no clinical evidence of hyper-
activity of the RAAS in the subjects studied by Matustik (Matustik, 1979), a 
possible explanation of this finding is that the high levels found may be a 
compensatory mechanism in order to conserve sodium in these individuals.  
  
1.1.3. Physiology in pregnancy 
 
There is limited data available on the physiology, especially cardiovascular, of SCD 
in pregnancy perhaps due to the infrequency of this condition in affected individuals 
in the past, as well as the high incidence of maternal mortality in them (Serjeant et 
al., 2004; Rajab et al., 2006). In a study comparing 15 women with SCD in their 
third trimester of pregnancy with 40 AA women, cardiac output was found to be 
significantly higher in the SCD women and their left ventricular systolic function 
was found to be normal (Veille & Hanson, 1994), similar to findings in the large 
study of non pregnant subjects mentioned in section 1.1.1 above (Covitz et al., 
1995). As expected, the ventricular heart chambers were also found to be enlarged in 
the SCD women (Veille & Hanson, 1994) as they were in the non-pregnant subjects. 
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It would be interesting to compare pregnant SCD with non-pregnant to discover 
whether the heart chambers are more enlarged in pregnancy and if the enlargement 
is a reversible one i.e. if they revert to previous sizes post-partum. The clinical 
significance of this could also be examined by observing if pregnancy increases the 
risk of SCD women for future cardiovascular disease when compared to those who 
were never pregnant.  
 
Another study comparing plasma volume in pregnant and non-pregnant SCD and 
HbAA women found a decrease in plasma volume at 36 weeks gestation in the SCD 
women compared with their 16 week values, and a 17% increase over non-pregnant 
HbSS females as opposed to a 68% increase at 36 weeks gestation in the HbAA 
women over values from non-pregnant HbAA women (Abudu & Sofola, 1988). 
Low aldosterone levels were found in three pregnant haemoglobin SS patients in 
their third trimester but the significance was not certain, as dietary and sodium 
excretion parameters were not evaluated and the numbers were small (Lindheimer et 
al., 1987). If this finding is consistent, it could mean that the activity of the renin 
angiotensin aldosterone system (RAAS) is reduced in HbSS pregnant women and 
could explain the contracted plasma volume reported. The examination of the other 
hormones and electrolytes discussed in section 1.2 below, as well as renal water 
handling would also be useful. 
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1.2. CONTROL OF PLASMA VOLUME IN PREGNANCY 
Plasma is the fluid component of blood and suspended in it are the formed elements 
– the red cells (erythrocytes), white cells (leukocytes) and platelets (thrombocytes). 
On centrifuging a blood sample, the formed elements fall to the bottom of the tube 
and the plasma is seen above as a clear yellow liquid above them (Pocock, 2004). 
Before I discuss the plasma volume (PV) in pregnancy, I must first of all mention 
the components of plasma and the control of its volume in the non-pregnant state. 
 
The body has three fluid compartments – the intracellular fluid (ICF) within the 
cells, and the extracellular fluid (ECF) outside the cells, which are separated by the 
barrier of the cell membrane. The ECF is further divided into interstitial fluid and 
plasma. The distribution of water amongst these compartments is that the ICF 
contains about 67% of the body’s water while the ECF contains 33%. This 33% is 
further split between the interstitial fluid (75% of ECF water) and plasma (25%), so 
that the plasma volume is <10% of the total (Silverthorn, 2007). Despite accounting 
for a small proportion of total body water, plasma is a very important compartment 
as it contains a large number of components and is responsible for many essential 
bodily functions. The functions of plasma include the transport of nutrients, waste 
products, hormones and gases, maintenance of acid-base balance and body 
temperature, defence due to its carriage of antibodies and antitoxins, haemostasis 
and maintenance of blood pressure (Pallister, 1994; Frenkel, 2006; Silverthorn, 
2007; Stanfield, 2008). 
 
As only highly permeable capillary membranes separate plasma and interstitial fluid, 
their ionic composition is similar, the main difference being the higher concentration 
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of proteins in plasma. This is because the capillary membranes have a low 
permeability to the plasma proteins (Guyton, 2006; Stanfield, 2008).  
 
1.2.1. Components of plasma 
The plasma volume in normal adults is about 35 – 45 ml per kilogram body weight. 
The PV when corrected for height and body surface area is significantly higher in 
males than females (Boer, 1984) and it accounts for about 4% of body weight. In 
general, water constitutes about 50% of total body weight in females of age 17 to 39, 
and about 60% in males of the same age group (Silverthorn, 2007). Apart from 
water, plasma is made of mineral and non-mineral ions such as sodium, potassium, 
calcium, chloride, bicarbonate, inorganic phosphate, magnesium and hydrogen. 
Small organic molecules such as amino acids, fatty acids and glucose, cholesterol 
and plasma proteins such as albumin, α-, -, and - globulins, fibrinogen, 
prothrombin and transferrin are also plasma components (Pocock, 2004). Albumins 
provide most (~70%) of the colloid osmotic pressure (oncotic pressure) that 
regulates the passage of water and solutes through the capillaries and are thus 
important in body fluid balance and help to regulate plasma volume. This is because 
the capillary membranes are impermeable to albumin, which exerts a force of about 
25mm Hg and pulls water into the blood (Pocock, 2004). 
 
The chief inorganic cation of plasma is sodium with a concentration of 135-145 
mmol/L. Other cations of much lower concentration are potassium (3.5 -5.0 
mmol/l), calcium (2.1 – 2.6 mmol/l), magnesium, iron and trace metals. The latter 
are important in enzyme activity. Chloride is the principal anion (100 – 106 
mmol/L) and plasma is neutralized by the presence of other anions such as 
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bicarbonate (24 – 30 mmol/l), phosphate, sulphate, protein and organic anions. The 
ions maintain the osmolality (280 – 300 mOsm/kg water) and pH of plasma (7.35 – 
7.45), particularly bicarbonate and phosphate, within physiological limits (Pocock, 
2004). Sodium is the most important determinant of plasma volume because of its 
effect on plasma osmolarity and will be discussed further below. Osmolarity is a 
measure of the concentration of biological solutions and is the number of particles 
per litre of solution i.e. osmoles per litre. Osmolality, on the other hand, is 
concentration expressed in osmoles per kilogram of water. As biological solutions 
are dilute, e.g. plasma, and very little of their weight comes from solute, both terms 
are used interchangeably (Silverthorn, 2007). Osmolality is used more in clinical 
situations as it is more accurately measured.   
 
1.2.2. Factors affecting plasma volume regulation 
Plasma volume is a dynamic quantity that can vary under physiological conditions. 
Its regulation depends on the balance of fluids between the extracellular and the 
intracellular compartments, which in turn is dependent on osmotic forces exerted by 
plasma proteins and electrolytes and hydrostatic forces (Jordan, 1995). 
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1.2.2.1. Sodium 
The amount of sodium (Na+) in the ECF is the most important determinant of ECF 
volume because sodium and chloride are the most abundant osmotically active 
solutes in the ECF and changes in chloride are mostly secondary to changes in 
sodium (Ganong, 2005). The equilibrium between the ECF and plasma volume is 
determined by Starling forces (i.e. the forces governing the movement of fluid 
across capillary walls which include capillary and oncotic pressure) so any change in 
total body sodium will affect both the ECF and the plasma volume (Pocock, 2004). 
 
In healthy individuals, the effective circulatory volume is constant and sodium and 
water loss are balanced by dietary intake. There is an appetite for salt that is mainly 
regulated according to need. However, tastes differ and some people ingest salt in 
excess of what they need. The stimulus for water intake is thirst, which may be 
defined as an appetite for water (Pocock, 2004).  
 
Sodium excretion is controlled by several mechanisms. The glomerular filtration 
rate (GFR) and tubular reabsorption are thought to be the major determinants of 
sodium and water regulation in the body (Schrier & Niederberger, 1994). About 
96% of filtered sodium is reabsorbed into the ECF (Ganong, 2005). In the late distal 
tubules and the cortical collecting tubules, sodium is re-absorbed according to the 
needs of the body (Pocock, 2004). This is in exchange for potassium or hydrogen 
that are secreted into the tubular lumen and occurs in specialized cells known as the 
principal cells of these tubules (Silverthorn, 2007;Guyton, 2006) through the activity 
of the sodium potassium adenosine triphosphatase (Na+ K+ ATPase) pump. The 
early part of the distal tubule reabsorbs sodium and chloride ions via a symporter, 
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which is a membrane protein that transports 2 or more substances simultaneously 
(Pocock, 2004). When ECF decreases, the blood pressure falls leading to a reduction 
in glomerular capillary pressure and consequently, GFR. This reduces the amount of 
sodium filtered by the kidneys (Ganong, 2005). 
 
The factors affecting sodium reabsorption include the circulating level of 
aldosterone and other adrenocortical hormones, atrial natriuretic peptide (ANP) and 
other natriuretic hormones and the rate of tubular secretion of H+ and K+ (Ganong, 
2005). Plasma volume contraction can also occur via salt and water shift into the 
interstitial space and the lymphatic system, and a diuresis. ANP and endothelin play 
a central role in this transcapillary efflux (Zimmerman et al., 1990; Zimmerman et 
al., 1992).  
 
1.2.2.2. Effects of adrenocortical steroids on sodium regulation 
Aldosterone is a mineralocorticoid i.e. a steroid hormone with predominant effects 
on sodium and potassium excretion (Ganong, 2005). It increases the tubular 
reabsorption of sodium in the late distal and cortical collecting tubules as mentioned 
above, together with chloride and in association with the secretion of potassium 
ions, or hydrogen ions when total body potassium concentration is low. 
 
As well as primary hyperaldosteronism, conditions that increase aldosterone 
secretion include reduction of dietary intake of salt, a decrease in the ECF, increase 
in dietary potassium, standing, and secondary hyperaldosteronism e.g. some cases of 
congestive cardiac failure and cirrhosis. Others include surgery, anxiety, physical 
trauma and haemorrhage (Ganong, 2005). The actual regulatory factors involved 
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include adrenocorticotropic hormone (ACTH) from the pituitary, renin from the 
kidney via Angiotensin II (AII) and a direct stimulatory effect of a rise in potassium 
ions on the adrenal cortex. 
 
Desoxycorticosterone is also a mineralocorticoid but has only 3% of the 
mineralocorticoid activity of aldosterone (Ganong, 2005). Its effects on sodium 
excretion are therefore usually negligible (Ganong, 2005). Cortisol is a 
glucocorticoid i.e. a steroid hormone with predominant effects on glucose and 
protein metabolism. It possesses weak mineralocorticoid activity but plasma levels 
are much higher than those of aldosterone (Ganong, 2005) and it is thus potentially 
important. However, in the kidney, its mineralocorticoid actions are regulated by the 
action of the enzyme 11-β-hydroxysteroid dehydrogenase, which inactivates 
circulating cortisol by conversion to cortisone (Ganong, 2005). 
 
1.2.2.3. Effects of Angiotensin II (AII) and renin  
AII is formed in the body from angiotensin I (AI) through the action of renin on 
circulating angiotensinogen. Renin is secreted from the juxtaglomerular cells that 
surround the renal afferent arterioles as they enter the glomeruli and aldosterone 
secretion is regulated via the increase in AII in a feedback fashion (Ganong, 2005). 
A very recent paper reports that AII influences expression of a group of genes which 
themselves modulate the transcription of the two end-point genes affecting 
aldosterone synthesis, 11β-hydroxysteroid dehydrogenase and aldosterone synthase 
(Romero et al., 2007). 
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A drop in extracellular fluid volume leads to a reflex decrease in renal nerve 
discharge and a fall in renal arterial pressure. Both these changes increase the 
secretion of renin, which in turn normally increases AII and the rate of secretion of 
aldosterone. Aldosterone then causes sodium and water retention, expanding ECF 
volume and shutting off the initial stimulus that caused the increased renin secretion 
(Ganong, 2005).  
 
AII also acts directly on the proximal nephron to increase the reabsorption of 
sodium (Navar, 1999). AII receptors are located on both the proximal and the distal 
nephron segments but it is those of the proximal segment that have been studied 
most extensively (Navar, 1999). These dual effects of AII, i.e. increase in 
aldosterone and direct effect on proximal tubules, act synergistically to enhance 
sodium reabsorption in the renal tubules (Navar, 1999).   
  
Dietary sodium restriction also increases aldosterone secretion via the RAAS 
probably due to a reflex increase in the activity of the renal nerves. This is thought 
to occur because aldosterone and renin release are increased when there is reduced 
dietary sodium intake before any consistent fall in blood pressure takes place 
(Ganong, 2005).  
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1.2.2.4. Effect of ACTH 
 
ACTH stimulates the output of aldosterone as well as that of glucocorticoids and sex 
hormones, when first administered. ACTH appears to prime the glomerulosa cells 
for the action of AII. It increases aldosterone secretion by binding to the 
glomerulosa cell-surface melanocortin-2 receptor, by activating adenylate cyclase 
and increasing intracellular cyclic adenosine monophosphate (cAMP) (Arai, 2007). 
However, the effect is transient and even if ACTH levels remain high, aldosterone 
output declines in 1 – 2 days (Ganong, 2005).  
 
1.2.2.5. Effects of electrolytes 
 An acute decline of plasma sodium of about 20 mmol/L stimulates aldosterone 
secretion although such large changes are rare. However, increases in plasma 
potassium of just 1 mmol/L (a 20 – 25% rise) are enough to stimulate aldosterone 
secretion and a meal rich in potassium e.g. bananas, tomatoes and spinach can cause 
this. Potassium acts on the steroid biosynthetic pathway to increase the production 
of aldosterone. Low dietary potassium also decreases the sensitivity of the AII 
producing areas of the kidney to a low sodium diet (Ganong, 2005). 
 
1.2.2.6. Arginine Vasopressin (AVP) 
Apart from the sodium control of extracellular volume, there is also volume control 
of water excretion (Ganong, 2005). A rise in ECF volume inhibits AVP secretion 
while a decline in ECF increases AVP secretion. AVP is also increased by an 
increase in osmotic pressure but volume stimuli override the osmotic stimulation of 
AVP secretion (Ganong, 2005).  
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AVP increases the permeability of the collecting ducts of the kidney so that water 
enters the interstitium of the renal pyramids. The urine thus becomes concentrated 
and its volume decreases thus it is also called the antidiuretic hormone. Water is thus 
retained when there is an increase in the secretion of AVP. Other factors that 
increase AVP include pain, emotion, surgical stress and exercise, nausea and 
vomiting, standing, clofibrate and carbamazepine, and angiotensin II (Ganong, 
2005). 
 
1.2.2.7. Osmoreceptors 
The state of water balance is monitored by the osmoreceptors of the anterior 
hypothalamus, which regulate the amount of AVP secreted by the posterior 
pituitary, increasing it during dehydration and decreasing it during a water load. 
When osmolarity rises by about 4 mOsm/l the desire to drink is stimulated (Pocock, 
2004). Thus the osmoreceptors influence water balance in two ways – via AVP and 
by inducing thirst. This mechanism is triggered by the osmolality of the body fluids 
(Pocock, 2004).  
 
Angiotensin II is a direct dipsogen i.e. it induces thirst and promotes the ingestion of 
fluids. It does this centrally by acting on the subfornical organ, a specialized 
receptor area in the diencephalons, to stimulate the neural areas concerned with 
thirst (Ganong, 2005). It is thought that it may also act on the organum vasculosum 
of the lamina terminalis (Ganong, 2005). However, angiotensin-blocking drugs do 
not completely block the thirst response to hypovolaemia. Thus baroreceptors in the 
heart and blood vessels may also be involved in this. On the other hand, fluid 
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volume per se is regulated by adjustment of sodium intake and excretion. Thus 
osmolality and fluid volume are regulated independently of each other.  
 
1.2.2.8. Prolactin and dopamine 
Prolactin has also been reported to be implicated in osmoregulation by a possible 
effect on renal retention of water, sodium and potassium (Campbell, 1982;Cowie, 
1973). This has apparently been documented in sheep and not humans. However, 
water retention and release of vasopressin and oxytocin have been documented in 
hyperprolactinaemic women (Laczi, 1998). The water retention may be due to 
increased renal retention of sodium and chloride as seen in other mammals 
(Horrobin, 1980). Alternatively, the secretion of vasopressin and oxytocin may also 
be implicated (Laczi, 1998). More recent studies in rats found prolactin to be a 
natriuretic and diuretic hormone that acts by inhibiting proximal convoluted tubule 
sodium potassium adenosine triphosphatase (Na+ K+ ATPase) activity, achieving its 
full effect by interacting with the intrarenal dopamine system (Ibarra et al., 2005). 
Dopamine is also involved in osmoregulation and is thought to act as an intrarenal 
natriuretic agent, which acts by inhibiting the action of Na+ K+ ATPase (Hansell & 
Fasching, 1991; Eklof et al., 1997). 
 
1.2.2.9. Atrial natriuretic peptide (ANP) and brain natriuretic peptide 
(BNP) 
These two hormones are peptides that are secreted by the heart. C-type natriuretic 
peptide is also a member of this family but very little of it is present in the heart and 
circulation and it appears to be primarily a paracrine mediator. They are released 
when there is a stretch on the atrial myocytes caused by expansion of ECF. 
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ANP and BNP act on the kidneys to increase sodium excretion by apparently 
dilating afferent arterioles and relaxing mesangial cells, thus increasing glomerular 
filtration. They also act on the proximal collecting tubules and cortical collecting 
ducts of the kidney to inhibit sodium reabsorption. Other actions include an increase 
in capillary permeability, relaxation of smooth muscle in arterioles and venules and 
inhibition of renin secretion. When the plasma volume is expanded due to an 
increase in total body sodium, the action of renin is inhibited by ANP (Pocock, 
2004). ANP also decreases the responsiveness of the zona glomerulosa to AII thus 
reducing aldosterone secretion (Ganong, 2005) and consequently inhibiting sodium 
chloride uptake from the distal tubules and collecting ducts of the kidneys (Pocock, 
2004). All this ultimately reduces the ECF and blood pressure (Sabrane et al., 2005). 
The overall action of these peptides is to counter increases in blood volume caused 
by the RAAS. 
 
1.2.2.10. Nitric oxide (NO) pathways 
NO pathways have been found to be involved in the regulation of plasma volume, 
with chronic inhibition causing a decrease in plasma volume in rats injected with  
NG-nitro-L-arginine methyl ester (L-NAME) (Filep & Foldes-Filep, 1993; 
Balaszczuk et al., 2002). NO is locally generated and has a very short half-life so it 
plays a role in the moment-to-moment homeostatic control of renal sodium 
excretion and extracellular fluid volume. 
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1.2.3. Pregnancy 
 
The control of plasma volume in pregnancy is a fascinating area, involving the 
interplay of most of the substances mentioned above. Plasma volume rises by up to 
50% in pregnancy and this rise has been shown to begin as early as 6 weeks after the 
last menstrual period (Whittaker & Lind, 1993; Bernstein et al., 2001). One of the 
earliest cardiovascular changes in pregnancy is peripheral arterial vasodilation, 
which is thought to trigger haemodynamic and hormonal responses leading to 
sodium and water retention and subsequently, plasma and extracellular fluid volume 
expansion (Schrier & Niederberger, 1994). 
 
The initiating factor for plasma volume expansion in pregnancy is now thought to be 
the early peripheral arterial vasodilation (Schrier & Niederberger, 1994). Arguments 
for this include the fact that systolic and diastolic blood pressures fall during the first 
trimester of pregnancy, despite an increase in blood volume (Davison, 1987; 
Duvekot et al., 1993; Chapman et al., 1998). Also activity of the RAAS increases in 
pregnancy (Weinberger et al., 1976; Wilson et al., 1980; August et al., 1990) and 
this is noticed from as early as the 6th week of gestation (Chapman et al., 1998). This 
supports an arterial vasodilation stimulus as opposed to a primary volume expansion 
one as the RAAS usually kicks in when there is a reduction in peripheral vascular 
resistance (Ganong, 2005).  
 
Since similar cardiovascular changes to those in pregnancy, i.e. reduction in arterial 
pressure and peripheral resistance and activation of the RAAS, occur in the luteal 
phase of the menstrual cycle, it is likely that the hormonal stimulus responsible for 
the overall decrease in vascular tone is also present in the luteal phase of the 
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menstrual cycle (Chapman et al., 1997). Likely candidates are oestradiol, 
progesterone, prostacyclin and nitric oxide. Indeed it may be due to the interaction 
of some of these substances. Plasma oestradiol, which is increased in both the luteal 
phase of the menstrual cycle and in pregnancy, has been shown to increase local 
prostacyclin production and to increase nitric oxide synthase production (Weiner et 
al., 1994) which cause vasodilation. Supporting this is the finding that oestradiol 
levels appear to be reduced in pre-eclamptic pregnancies, a condition in which 
plasma volume is reduced and the activities of the RAAS are also reduced (August 
et al., 1990; Weiner et al., 1994; Salas et al., 2006). Why interplay of factors is 
likely is that individual factors do not appear sufficient to cause the large differences 
seen. Prostaglandins have been postulated to contribute (Everett et al., 1978; 
Pedersen et al., 1983) but do not appear to be fully responsible for the degree of 
vasodilation found (Venuto & Donker, 1982; Conrad & Colpoys, 1986). A 
prospective study of urinary prostacyclin and thromboxane metabolites during the 
first three months of pregnancy also showed that these did not rise significantly until 
rather later (Al Kadi et al., 2005). Furthermore, in studies done with chronically 
instrumented conscious pregnant rats, the administration of indomethacin did not 
result in a reversal of the AII mediated blood pressure attenuation (Conrad & 
Colpoys, 1986). However, there are some subtle differences in cardiovascular 
change in pregnancy between rats and humans and the above evidence may not be 
sufficient to disregard the prostaglandin hypothesis. Maternal plasma volume, for 
example, expands to a maximum before the end of pregnancy and is maintained till 
term in humans, whilst it continues to expand progressively till term in rats (Baylis, 
1984). 
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Nitric oxide (NO) has also been postulated to be important because increased levels 
of NO and those of its secondary messenger, cyclic guanosine 3’5’ –monophosphate 
(cGMP) have been found in animal pregnancy (Conrad et al., 1993; Conrad & 
Vernier, 1989; Weiner et al., 1994). Hormones known to increase in pregnancy, 
such as oestrogen and progesterone, have been shown to induce nitric oxide 
synthase in in-vitro experiments (O’Connor & Moncada, 1991; Hayashi et al., 
1992). However, reduced plasma levels of NO and increased urinary levels of its 
secondary messenger, cGMP, have been found in human pregnancy (Chapman et 
al., 1998), which is another difference between human and rat pregnancy. This latter 
negative finding may also be accounted for by the problems in assessing nitric oxide 
levels in humans (Benjamin, 2001). Nitric oxide is rapidly oxidized to inorganic 
nitrate, which has a very complex metabolism including active reabsorption in the 
kidney by an anion pump that appears saturable (Benjamin, 2001). As such the 
measurement of plasma nitrate is a poor indicator of nitrate synthesis. Urinary 
excretion of nitrate is also unreliable because of the fact that its reliability depends 
on a low nitrate diet and Western diets and even water are rich in nitrate (Benjamin, 
2001). 
 
Placental oestrogen may also play a role in volume expansion through hepatic 
stimulation of angiotensinogen synthesis. However, oestradiol concentration has 
been found to be no different from normal controls in women with pre-eclampsia 
and idiopathic fetal growth restriction who had inadequate plasma volume expansion 
at the time when they were studied (Salas et al., 2006).     
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The osmolar threshold for the release of AVP is reduced in pregnancy, thus as 
plasma volume increases and osmolality falls, AVP still continues to be released 
(Davison et al., 1984). Despite a significantly lower plasma osmolality, AVP was 
found to be similar in pregnant Sprague-Dawley rats compared to virgin ones (Durr 
et al., 1981). This allows the expanded plasma volume of pregnancy to be viewed as 
normal (Barron et al., 1984). A study that examined eight pregnant women also 
found a reduced osmotic threshold for the release of AVP and for thirst (Davison et 
al., 1988). 
 
The role of ANP in maintaining plasma volume in pregnancy has been more 
controversial. Many studies found conflicting results including an increase in ANP 
(Milsom et al., 1988; McCance et al., 1990; Steegers et al., 1991) and no change in 
ANP (Lowe et al., 1992). However, none of the studies that found an increase 
controlled sodium intake. In a longitudinal study where sodium intake was 
controlled by restricting the women to 100mmol of sodium for 4 days before the 
study, there was no significant change in plasma ANP levels from the first to the 
third trimester (Lowe et al., 1992). This was thought to be because the increased 
plasma volume in pregnancy may be “perceived” as normal. A meta-analysis 
showed a 41% increase in ANP levels in the third trimester, compared with non-
pregnant and it also suggested that atrial stretch receptors sense the expanded blood 
volume in pregnancy as normal or moderately raised (Castro et al., 1994). However, 
as noted, a majority of these studies did not control for sodium intake. 
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1.2.3.1. Maintenance of plasma volume expansion in pregnancy 
Plasma volume increases steadily from early pregnancy to at least 30 weeks 
gestation on average, by approximately 1250 ml, after which it remains fairly steady 
till term (Pirani et al., 1973; Whittaker & Lind, 1993). Salas et al found that it 
reached a maximum between 34 and 36 weeks gestation (Salas et al., 2006), while 
the first 2 studies suggested a maximum at 30 – 34 weeks, and at 28 – 36 weeks 
respectively. The findings in these 3 studies are very similar and the slight 
differences in maximum plasma volume expansion may be due to the different 
intervals of gestational age at which the women were studied.  
 
Posture appears to affect plasma volume in late pregnancy. Studies performed with 
the women in the supine position cause an apparent decrease in plasma volume due 
to an incomplete mixing of the Evans blue dye because of the weight of the pregnant 
uterus on the inferior vena cava (Chesley & Duffus, 1971; Letsky, 1991). When 
lying on their sides, apparent plasma volume is greater and mixing of the dye 
complete within 10 minutes (Chesley & Duffus, 1971; Pirani et al., 1973).  
 
The prime determinant of ECF in pregnancy as well as in the non-pregnant, is renal 
sodium handling (Brown & Gallery, 1994). Approximately 950 mmol of sodium 
accumulates in the body during pregnancy (Baylis & Davison, 1998).  As greater 
than 30,000 mmol/day of sodium is filtered by the glomeruli, an increase from non-
pregnant levels of about 10,000 mmol/day, several changes occur to effect the 
reabsorption required to maintain maternal and fetal stores (Baylis & Davison, 
1998). Antinatriuretic hormones such as aldosterone and desoxycorticosterone 
increase substantially during pregnancy, as there is increased activity of the RAAS 
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(Baylis & Duffus, 1998; Chapman et al., 1998). Specifically, it appears that 
maternal adrenal secretion maintains the normal increase in plasma volume in 
pregnancy. A study that gave aldosterone or cortisol to adrenalectomised pregnant 
ewes, found that reduction of aldosterone or cortisol resulted in a decrease in plasma 
volume (Jensen et al., 2002). The concentration of natriuretic hormones also 
increases in pregnancy however (Baylis & Davison, 1998). Perhaps ECF volume is 
therefore maintained by the response of the antinatriuretic hormones to the 
perceived hypovolaemia created by the natriuretic hormones, as well as the 
peripheral vasodilation of pregnancy. More likely, plasma volume regulation in 
pregnancy is multifactorial and not due to a simple rise in the level of one or more 
antinatriuretic hormones (Khraibi et al., 2002). 
!
With this likelihood and the fact that a previous study in my centre had reported a 
contraction in plasma volume in SCD women later in pregnancy (see 1.1.3 above), I 
decided to perform a study to examine several different hormones and electrolytes 
that could affect plasma volume. I felt this was pertinent because SCD pregnancies 
are also often complicated with intrauterine growth restriction and perinatal 
mortality (section 1.1). If the reported plasma volume contraction was an accurate 
representation, it would be similar to what occurs in pre-eclampsia, a condition in 
which there is also a contraction in plasma volume associated with low birth weight 
and increased perinatal mortality, and a disruption of the renin- angiotensin system 
(Brown et al., 1997; Al Kadi et al., 2005).    
 
This thesis was thus designed to test the following hypotheses: 
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Hypothesis 1. The Evans blue PV distribution in pregnant SCD women is lower 
than their haemoglobin AA counterparts.  
 
Hypothesis 2. The activity of components of the RAAS is reduced in pregnant SCD 
women compared to their haemoglobin AA counterparts.  
 
Hypothesis 3. Plasma vasopressin concentration and urinary osmolality are lower, 
and plasma osmolality is higher in pregnant SCD women than their haemoglobin 
AA counterparts.  
 
Hypothesis 4. Plasma sodium concentration is reduced and fractional excretion of 
sodium is increased in pregnant SCD women as compared with their haemoglobin 
AA counterparts. 
 
The primary outcome measures were thus plasma volume in millilitres and in 
millilitre per metre squared, plasma renin concentration in ng/ml/hour, plasma 
angiotensinogen concentration in µg/ml and serum aldosterone concentration in 
ng/ml. The secondary outcome measures were plasma vasopressin concentration in 
pg/ml, plasma and urinary osmolality in mosmo/kg and plasma sodium 
concentration in mmol/l.
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2. METHODS 
This study was conducted at the Lagos University Teaching Hospital (LUTH), 
Lagos, Nigeria, which is a 761 bed hospital, 89 of which are obstetric and 60 
gynaecological. It is one of two tertiary hospitals in Lagos state, the population 
of which is just under 10 million people.  
 
The study protocol was approved by the Research and Ethics Committee of the 
Lagos University Teaching Hospital, Reference number ADM/DCST/221/Vol.9, 
dated 11th February 2004. All women gave written, informed consent to 
participation. They were allowed to take the ‘volunteer information leaflet’ 
(Appendix 1) home to show their partners and were included after they had 
understood the information and signed the consent forms (Appendix 1). 
 
2.1. SUBJECT SELECTION AND INCLUSION CRITERIA 
There were 4 groups of subjects: 
1. Pregnant haemoglobin SS genotype (Hb SS) women.  
2. Non-pregnant haemoglobin SS genotype women.  
3. Pregnant Haemoglobin AA genotype (Hb AA) women.  
4. Non-pregnant haemoglobin AA genotype women.  
 
All the women were healthy at recruitment and in a steady clinical state. The 
pregnant women were recruited from the antenatal clinic of the consultant out-
patient department at booking, where they were fully counselled about the study. 
The non-pregnant haemoglobin AA women were recruited from members of 
staff and students while the non-pregnant haemoglobin SS women were 
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recruited from the sickle cell clinic, which is a clinic run by the internal 
medicine department of the hospital. All women were between ages 20 and 40 
and all had normal regular menstrual periods. The pregnant women all had 
known last menstrual periods, all had their gestational ages checked by early 
ultrasound scans and were non-smokers. The pregnant AA women had oral 
ferrous gluconate 300 mg three times daily, folic acid 5 mg daily and 
intermittent preventive treatment for malaria with sulphadoxine/pyrimethamine 
(500mg/25 mg) twice, 8 – 10 weeks apart during the pregnancy, avoiding the 
first trimester and the last 4 weeks of pregnancy, as is routine for antenatal 
patients in this hospital (see section 1.1). All the SS women (pregnant and non-
pregnant) had routine folic acid 5mg twice daily and proguanil 200mg daily, the 
latter for malaria prophylaxis (see section 1.1). They are not routinely given iron 
supplements in my hospital as they have been reported to usually have sufficient 
iron stores presumably due to recurrent haemolysis (Akinyanju et al., 1987; 
Abudu et al., 1990; Aken’Ova et al., 1997). Anaemia in pregnancy is common in 
Nigeria (Anorlu et al., 2006; Dim & Onah, 2007; Kagu et al., 2007; Ukaga et 
al., 2007) thus all pregnant women without contraindications to iron 
supplements are given supplements in the form of ferrous sulphate and folic 
acid.  
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2.2. EXCLUSION CRITERIA 
1. Women who had received or donated blood in the 6 months prior to the 
study. 
2. Women with a history of sickling crises in the 4 weeks prior to the study. 
3. Women with known cardiovascular disease (including chronic 
hypertension), thyroid, renal or metabolic disease, and diabetes mellitus.  
4. Women on the oral contraceptive pill or other hormonal preparation. 
 
2.3. SAMPLE SIZE 
It was calculated that 15 pregnant SCD women and 15 age and parity matched 
pregnant haemoglobin AA controls would give an 80% power of reproducing the 
difference in plasma volume (PV) between both groups of about 1 litre, seen at 
36 weeks gestation in a previous study (Abudu & Sofola, 1988) at the 5% 
significance level. An attempt was made to recruit at least 20 women each to 
allow for dropouts.  
 
2.4. STUDY DESIGN 
Measurement of plasma volume using the Evans blue dye dilution method (el-
Sayed et al., 1995), and of concentrations of osmoregulatory hormones, 
including vasopressin, aldosterone, progesterone and prolactin, plasma renin 
concentration, plasma angiotensinogen concentration, urinary and plasma 
electrolytes – sodium and potassium, urinary creatinine, full blood count 
including haemoglobin concentration and white cell count, and genotype 
estimation were carried out on all the women. All measurements were done in 
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the follicular phase of the menstrual cycle for the non-pregnant women.  
 
For the pregnant women, all the measurements were done at 16 and 36 weeks 
gestation. It was originally intended to study all the pregnant women 
prospectively i.e. a longitudinal study but due to the invasive nature of the study 
and also to the fact that the women with SCD often had to have a blood 
transfusion during pregnancy or developed severe crisis or other illness, they 
could not be studied again at 36 weeks. Thus other women had to be recruited to 
take their place and it became a cross-sectional study.  
 
2.5. INTERVENTION 
The general outline of the study is presented in this section, which is then 
followed by the detailed methodology. The women were admitted for 24 hours 
from the night before the PV measurements. They were weighed and had their 
heights measured and it was these measurements and the calculated body mass 
index (BMI) figures that were recorded in the study data. All urine passed by 
them during that time was collected and the volume carefully measured. About 
half of the women, evenly spread amongst the groups, did not want to be 
admitted and rather than lose them for that reason, they were instructed on 
collecting their urine at home. They were all verbally instructed on 24-hr urine 
collection (see below: “24h urine collection”), given a form with the instructions 
written on it (See Appendix 2) and asked at the end of the collection about the 
completeness of their collection. Urinary osmolality and fractional excretion of 
sodium, potassium and creatinine were estimated for each sample. Free water 
clearance was then calculated.  
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During the estimation of plasma volume, blood was taken for the measurement 
of plasma sodium, potassium and creatinine, plasma angiotensinogen 
concentration (Aogen), plasma renin concentration (PRC), progesterone, 
prolactin, aldosterone and vasopressin levels in the steady state (see Appendix 
3). All but Aogen and PRC were measured by Dr O.O. Oladipo, a senior lecturer 
and consultant chemical pathologist in the Lagos University Teaching Hospital. 
Dr Peter Marsters measured the Aogen and PRC in Nottingham.  
 
The blood collection was done between 0900 and 1100 hours in the morning, at 
the midpoint of the urine collection. The women were fasted overnight and 
rested for 30 minutes before the blood was taken. They were however allowed to 
drink clear fluids liberally, particularly because dehydration is a trigger factor 
for Hb SS crises and they are usually encouraged to drink a lot of water.  
 
Plasma and urinary osmolality, electrolyte and creatinine concentrations were 
measured using standard clinical chemistry techniques (Appendix 3) also by Dr 
Oladipo. I then calculated the fractional excretions of sodium and potassium as 
well as the free water clearance. 
 
Haemoglobin concentration (Hb) and packed cell volume (PCV) were estimated 
in all the patients at the time of study. Haemoglobin genotype was also 
confirmed in all the patients using cellulose paper electrophoresis at an alkaline 
pH of 8.4. The babies were carefully weighed at birth and data collected on their 
mothers’ gestational age at delivery, their birth weight and their gender. 
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2.6. PLASMA VOLUME MEASUREMENT AND SPECIMEN COLLECTION 
2.6.1. 24-hour urine collection 
The 24-hour urine collection was done as follows: The women were given a 5-
litre plastic container (jerry-can) and a 1-litre plastic jug. They were instructed 
to note the time and date of starting the urine collection and to write these on a 
label on the 5-litre container which also bore their names and study code. They 
were to pass urine into the toilet at the start time and to subsequently collect all 
other urine passed into the jerry can. They were instructed to pass urine and put 
in the jerry can before starting to take a shower or bath, or before going to move 
their bowels, as these were times when urine could be inadvertently lost from 
collection. They were to stop the collection at exactly 24 hours after they 
started, with the difference being that they were to also put the last bit of urine 
into the jerry can. This was gone over several times with each patient and they 
were asked to repeat it as understood, emphasizing that the first urine at the start 
time was to go into the toilet, the last urine, into the container, and all others in-
between into the container. The women were also given the instruction sheet 
(Appendix 2). At the end of the collection, the women were questioned about 
their method of collection and they all reported proper collection.  
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2.6.2. Blood collection 
The materials required for the plasma volume and blood collection experiment 
are listed in Appendix 4. All clinical disposables were supplied by the hospital 
community pharmacy unless otherwise stated. 
 
The Evans blue was prepared in 3-monthly batches for the duration of the study. 
It was supplied in powder form (Sigma-Aldrich, Missouri, U.S.A.) and prepared 
as follows: One gram of Evans blue dye was weighed each time and dissolved in 
distilled water. The solution was then made up to 1L with distilled water and 
dispensed into 40 ml glass tubes, sealed and autoclaved. Two random samples 
from each batch were cultured after each preparation and found to be negative 
for organisms. The remaining tubes were then stored in the refrigerator till they 
were used.  
 
Prior to each visit, all necessary specimen tubes were labelled with the subject’s 
study code and one of the two ethylenediamine tetra-acetic acid (EDTA) tubes 
was put in ice.   
 
Two syringes were filled with heparinised saline 10IU/ml – one 10ml and one 
5ml. Fifteen millilitres of Evans blue dye solution was withdrawn into a 20ml 
syringe. Unfortunately they could not be weighed as I did not get sufficient 
funding to buy a sensitive weight balance and there was no functional one 
available for me to use on a regular basis. The Evans blue was thus carefully 
drawn out by me 80% of the time and by another person – Dr Olaleye, a senior 
registrar – (trained by me) about 20% of the time. I later managed to borrow a 
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weight balance and I measured the before and after weights of 10 syringes into 
which I drew Evans blue and calculated a coefficient of variation (CoV) for 
these. The between sample CoV for the syringes with Evans blue was 0.4%, the  
CoV for the syringes emptied of Evans blue was 1% and the CoV of the 
difference between both weights was 0.7%. The mean weights were 24.89, 9.85 
and 15.05 grams respectively. 
 
As each woman arrived, she was welcomed into the research room and her 
details taken down into a data form (Appendix 4). After she had been lying 
down for 30 minutes, a 20-gauge (G) cannula was inserted into a large vein 
(usually one of the veins in the antecubital fossa). Twenty-two millilitres of 
blood was withdrawn each time and handed to an assistant who gently released 
it into the specimen tubes in the following volumes:  
 
5ml each (15ml) into the plain serum separator tube (SST) gel tubes 
3ml into the lithium heparin tube 
2ml each (4ml) into the cold and room temperature EDTA tubes 
 
The 3-way tap was attached and the cannula stuck down with plaster. The 
cannula was flushed with a small volume of heparinised saline and the 3-way 
tap was closed. The stopwatch was then set to 10 minutes. 
 
Fifteen ml of Evans blue dye was injected into the cannula within 1 minute. As 
the injection was started, we also started the stopwatch. The cannula was flushed 
with heparinised saline through the pink covered outlet and through the 3-way 
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tap, till all traces of dye were gone. After this, another 1ml of heparinised saline 
was pushed in and the 3-way tap was closed.  
 
At 10 seconds, 5ml of blood was slowly withdrawn and the stopwatch was reset 
to 10 minutes. The 5 ml syringe filled with blood was gently emptied into the 
plain tube labelled “10 minutes”. The syringe containing the mixture of blood 
and heparinised saline was then reattached and 5ml of this was pushed back into 
the vein in order to keep it patent.  
 
The cycle was repeated after 10 minutes and then after another 10 minutes, 
putting the blood into the “20” and “30 minute” plain bottles, respectively. All 
the blood/heparinised saline mixture was re-injected after the 30-minute sample 
had been taken and the cannula was taken out of the vein. This method of using 
the same venous line has been validated by a previous study (el-Sayed et al., 
1995).   
 
2.6.3. Specimen processing 
The plain SST tubes were left to stand for one hour so the serum could separate. 
All the tubes were centrifuged at 3000 revolutions per minute (rpm) for 10 
minutes. The EDTA tube on ice was centrifuged in a cold centrifuge at -4o 
degrees centigrade I, at the same speed. The serum from the plain bottles was 
separated and 2ml was stored in a plain tube at -20o centigrade I, for the 
analyses of aldosterone, progesterone and prolactin (see Appendix 5). The 
remaining approximately 5 – 7 ml was used for the standard curve, the 
preparation of which will be discussed below. 
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The plasma from the cold EDTA bottles was separated and split into two parts – 
one part was for the analysis of plasma angiotensinogen concentration and 
plasma renin concentration, while the other was for the analysis of vasopressin.  
 
The plasma from the lithium heparin and the EDTA bottles was also separated 
and put in plain tubes. All the tubes containing serum and plasma were stored at 
-20 degrees centigrade until they were ready to be analysed. 
 
2.7. LABORATORY METHODS 
2.7.1. Plasma volume measurements  
The dye-dilution method of PV measurement works on the principle that when a 
substance is added to a compartment and allowed to mix freely and completely 
without being lost, its concentration at a point in time can be used to calculate 
the volume of the compartment (Jacob et al., 2007). This is by calculating the 
volume of distribution of the substance. 
 
The volume of the compartment is calculated thus: Amount of substance added 
to the compartment divided by the concentration of substance after complete 
mixing within the compartment. The concentration at the point of injection of 
the substance is unknown but can be obtained by taking blood samples at timed 
intervals after complete mixture, measuring the concentration of the substance 
using colorimetry, and extrapolating back to time zero by plotting a 
time/concentration graph (el-Sayed et al., 1995). 
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Measurement of plasma volume requires a substance or tracer which is mostly 
limited to the plasma compartment, is evenly distributed and non-toxic. This is 
achieved by using a tracer that binds to albumin. The tracers commonly used are 
the azo dye known as Evan’s blue (or T1824), which binds avidly to albumin, or 
radio-iodine labelled serum albumin (RISA) or indocyanine green (Jacob et al., 
2007). The strengths and weaknesses of these various types of tracer are 
discussed in section 2.9.4.  
 
2.7.2. Plasma volume measurements in this thesis 
The plasma volume measurements were done using the Evans blue dye-dilution 
technique as previously described (el-Sayed et al., 1995; Bernstein et al., 1998). 
 
Known concentrations of Evans blue were prepared using the stock 1mg/ml 
solution as described above. In this case, the concentrations used were 5, 10 and 
20 µg/ml respectively. Equal volumes of each of these known concentrations 
were then diluted with equal volumes of the serum for the standard curve. In this 
case we used 1ml of known Evans blue to 1 ml of serum, resulting in 
concentrations of 2.5, 5 and 10 µg/ml of Evans blue respectively. Two millilitres 
of plain serum was used as a blank. 
 
An ultraviolet spectrophotometer with a visible range (Agilent 8453; Supplier) 
was used to measure the absorbances at a wavelength of 610 nanometres. The 
blank and the three Evans blue/plasma serum mixtures were measured each time 
with the absorbances plotted against the concentrations in order to draw a 
 55
standard curve (Figure 2.1). 
 
The concentrations of the timed samples were then obtained from the curve and 
plotted against time and extrapolated to zero (Figure 2.2). The time zero 
concentration was used to calculate the plasma volume using the calculation 
mentioned above. 
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Figure 2.1. An example of a standard curve
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Figure 2.2. An example of a concentration/time plot
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2.7.3. Radioimmunoassay and enzyme immunoassay 
All the hormones were measured by enzyme immunoassay (EIA) or 
radioimmunoassay (RIA). First, I will outline the general principles of RIA and 
EIA then go on to discuss the specific methods used in this thesis. 
 
Radioimmunoassay (Skelley et al., 1973) is a very sensitive method for 
measuring small amounts of substances in blood using the antigen-antibody 
binding principle. Unknown amounts of substances, hormones in this case, can 
be determined by their competitive binding for the binding sites of antibodies 
bound to known concentrations of radiolabelled hormones, thus displacing the 
radiolabelled hormone. Small amounts of radiolabelled samples (known antigen) 
of the substance to be measured are mixed with antibody and then incubated 
either with known concentrations of standard antigen or with a plasma sample 
containing an unknown concentration of the hormone to be measured. The 
unknown antigen in the plasma sample then displaces the labelled known 
antigen proportionally to its concentration and binds with the antibody. As more 
unknown antigen is added, more known is displaced and becomes free known 
antigen. Higher concentrations displace more, reducing the ratio of bound to 
free known antigen. The bound antigens are then physically separated from the 
free or unbound ones and the radioactivity of the free fraction is measured. This 
is used to determine the concentration of unknown antigen (hormone). Berson 
and Yalow developed RIA in 1959 (Yalow & Berson, 1960) and Rosalyn Yalow 
was awarded the Nobel Prize in Physiology or Medicine in 1977 for her work on 
the development of the RIA for insulin (Kahn & Roth, 2004).  
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In EIA, an enzyme, as opposed to radioactivity, acts as the measurable label. An 
antigen is labelled with an enzyme and then reacted with an antibody thus 
inhibiting the enzymatic reaction. An unknown amount of antigen or substance 
to be measured is then added and mixed with the antigen-enzyme-antibody 
complex. If the unknown substance is the same as the known antigen, it 
competes with it for the limited amount of antibody thus reducing the amount of 
antibody available to inhibit the enzyme. Enzyme substrate is then added and 
the quantity of the unknown antigen can be measured (Voller, 1978). In 
‘traditional’ or homogenous EIA, the measurement is performed without any 
physical separation during the analysis. In heterogeneous EIA which is often 
used synonymously with ELISA, the bound antigen is separated from the free 
material by washing the microtiter plate before enzyme activity is estimated by 
addition of substrate (Voller, 1978; Lequin, 2005).  
 
Plasma samples were air freighted on dry ice to Nottingham for assay of plasma 
renin and angiotensinogen concentrations (PRC; Aogen), using established 
radioimmunoassay (Tetlow & Broughton Pipkin, 1983; Broughton Pipkin et 
al., 1984). Samples were assayed in duplicate, and all samples from individual 
patients were run in the same assay. Dr Peter Marsters assayed all the samples in 
the City Hospital, Nottingham. The reagents used and techniques are as in 
Appendix 3. The inter- and within assay coefficient of variation (CoV) was 
14.8% and 5.6% for PRC respectively and 13% and 5.1% for Aogen 
respectively.   
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2.7.4. Aldosterone 
Serum aldosterone was assayed with an aldosterone ELISA kit Catalogue 
number 1875, manufactured by Alpha Diagnostic International, Texas, USA. All 
the assays were done by one person- Dr O. O. Oladipo as mentioned above. The 
technique is as shown in Appendix 3. A formal validation in pregnancy was not 
done, as there is very low cross-reactivity with other steroids. The between 
assay CoV was 6.2% (n=5) and the intra-assay CoV was 3.4% (n=20). The 
minimal detectable concentration was 15pg/ml (n=10). 
 
2.7.5. Arginine-Vasopressin (AVP) 
Arginine-vasopressin was assayed with an EIA kit Catalogue number 900-017, 
manufactured by Assay Designs, Michigan, USA. The details of the technique 
and its rationale are as shown in Appendix 3. A formal validation in pregnancy 
was not done, as here again the cross-reactivity to other related compounds such 
as oxytocin is extremely low. The between assay and intra-assay CoV were 7.8% 
(n=5) and 6.6% (n=10) respectively.  
 
2.7.6. Progesterone 
Progesterone was assayed with an EIA kit Catalogue number PrOG-96 
manufactured by Teco Diagnostics, California, USA; the details of the technique 
and rationale are as in Appendix 3. The intra and inter-assay CoVs were 3.8% 
(n=10) and 4.7% (n=6) respectively.  
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2.7.7. Prolactin 
Prolactin was assayed with an EIA kit Catalogue number PROL-96 
manufactured by Teco Diagnostics. The intra and inter-assay CoVs were 4.5% 
(n=10) and 8.7% (n=10). The details of the technique and rationale are as in 
Appendix 3. 
 
2.7.8. Osmolality measurements 
The Wescor Vapor Pressure Osmometer (Wescor Incorporated, Utah, USA) was 
used for all the osmolality measurements (Appendix 3). Although it is an 
indirect method, it has a significant advantage over the previous methods of 
indirect measurements i.e. that of freezing point depression or boiling point 
elevation. This is because it can be performed without the necessity for a change 
in the physical state of the specimen and is thus free from measurement artefacts 
that can occur due to physical alteration (Tornheim, 1980; Knepper, 1982). The 
intra- and inter- assay CoVs were 1.4 % (n=10) and 3.5% (n=10) respectively.  
 
2.7.9. Creatinine 
The principle used was the colorimetric reaction – Jaffe reaction (Hervey, 1953), 
of creatinine with alkaline picrate measured kinetically at 490nm without any 
pre-treatment step (Appendix 3). The kit was provided by Biolabo Reagents 
(Maizy, France) and measured using a VWR spectrophotometer by Dr Oladipo. 
The intra- and inter- assay CoVs were 3.6% (n=10) and 5.4% (n=10) 
respectively. 
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2.7.10. Electrolytes (Sodium and Potassium) 
Flame photometry was used to analyse plasma sodium and potassium, the 
principle of which is as follows:  
Atoms on ground state get excited and unstable by the absorption of energy 
(heat). The atoms immediately return to ground state and release energy in the 
process in the form of light. The light emission is at wavelengths specific for 
each element and can be quantified.  
 
Plasma separated from lithium heparin tubes was used. The intra- and inter- 
assay CoVs for sodium were 2.3% (n=10) and 4.2% (n=10) respectively. Those 
for potassium were 3.9% (n=10) and 4.8% (n=10) respectively. The Jenway 
Flame Photometer (Jenway, Essex, England) was used for the assays and the 
details are in Appendix 3.  
 
2.8. DATA HANDLING 
The baseline characteristics of each patient were entered from the data form 
mentioned above (Appendix 5) into the Statistical Package for the Social 
Sciences (SPSS) version 15 for Windows (SPSS Inc, Chicago, IL, USA) 
statistical software programme, using a file structure which I developed. As the 
collected blood and urine samples were analysed, the results were entered into 
the same file. All the data in which the samples were noted to have haemolysed 
before analysis were omitted. Any measurements that fell outside the range 
compatible with life were also omitted from analysis, as it was assumed that the 
results generated were erroneous. The data were initially entered into SPSS by a 
research assistant and subsequently checked over completely by me. 
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Missing data and outliers were checked in the original proformas and corrected 
if transcription errors were found. Checking the patient’s case files or calling the 
patient to request for them e.g. birth weights and sex of their babies retrieved 
other data. 
 
2.8.1. Statistical analysis 
Data were tested for normality of distribution using the frequency distribution 
analysis.  If they were not normally distributed, they were normalised by 
logarithmic transformation or non-parametric tests were used as necessary. 
Normally distributed data were expressed summarised and presented as means ± 
standard deviation (sd), with subsequent analysis by Student t-test or ANOVA as 
appropriate. Pearson’s correlation coefficient was used for measurement of 
association between variables. The Mann-Whitney U test and Kruskal Wallis 
ANOVA were used for non-parametric data, which were presented as median 
and interquartile ranges. 
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2.9. DISCUSSION 
2.9.1. Subject selection and inclusion criteria 
As mentioned earlier, iron supplements are not given to individuals with HbSS in 
our centre as they are known to haemolyse frequently without external bleeding, due 
to the fragility of their red blood cells, which have a short life span. Most studies 
measuring the red cell survival rate give an average of less than 20 days (McCurdy, 
1969; Solanki et al., 1988; Serjeant et al., 1996). They therefore conserve body iron 
and for this reason, iron deficiency is not thought to be a cause of their anaemia 
(Akinyanju et al., 1987; Abudu et al., 1990). In order to avoid the risk of iron 
overload in them, supplementary iron is only given if they have proven iron 
deficiency anaemia. Although there are reports, which have found pregnant Hb SS 
women to be iron deficient (Anderson, 1972; Oluboyede, 1980), the weight of 
evidence for iron sufficiency in pregnant women with Hb SS (Fleming, 1969; 
Akinyanju et al., 1987; Abudu et al., 1990) is more than that for its deficiency.  
 
The consequences of malaria in pregnancy include miscarriage, severe malaria 
(which can cause coma, renal failure and death), preterm labour and perinatal 
mortality from prematurity and intrauterine growth restriction (Sholapurkar et al., 
1988; Menendez et al., 2000; Duffy & Fried, 2005). As malaria is endemic in 
Nigeria, with pregnant women being particularly susceptible despite being semi-
immune when not pregnant, they are given antimalarial prophylaxis during 
pregnancy. Intermittent sulphadoxine/pyrimethamine is used for non-HbSS women 
and has been found to be very effective in preventing malaria and its consequences 
(Rogerson et al., 2000; Garner & Gulmezoglu, 2006; Falade et al., 2007). Proguanil 
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is known to be very effective (Mutabingwa et al., 1993; Garner & Gulmezoglu, 
2006) but relatively more expensive and has to be taken daily. As pregnancy is 
fraught with complications in pregnant HbSS women, they are given proguanil and 
regularly screened for malaria so as to ensure they do not get the disease. None of 
the volunteers for this study contracted malaria during the period of the study.   
 
One of the exclusion criteria was anyone who was transfused in the 6 months prior 
to the study. This was to ensure the study participants, especially those with SCD, 
were truly in a steady clinical state. Thus they were not representative of the average 
person with SCD. It was important to select them in this manner, as my primary 
objective was to examine the physiological determinants of their plasma volume 
differences.  
 
2.9.2. Sample preservation 
Most frustratingly, I lost a lot of data during the course of this study for various 
reasons, the most significant being the poor power supply in my country generally, a 
situation that also prevails in universities and hospitals. The freezers were thus often 
thawing out and I could only analyse samples where I was sure of their authenticity 
i.e. those that I could salvage before a major power failure. The freezer in which the 
urine samples were kept was different from that of the plasma and serum samples; 
the creatinine assays were done last and only a few of the samples could be salvaged 
for analysis. 
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2.9.3. Twenty-four hour urine collection 
Twenty-four hour urine collection is notoriously inaccurate, thus despite instructing 
all the subjects in a study carefully on the proper method of collection and the 
importance of accuracy, it is still important to check the completion of sample 
collection objectively. The ideal way to do this is by getting the studied women to 
ingest p-aminobenzoic acid (PABA), which can then be measured in urine in which 
it is completely excreted (Bingham & Cummings, 1983). Thus if at least 85% of the 
total dose of PABA is recovered, the collection can be deemed complete. However, 
as it may be a bit cumbersome and costly to add this to a study, an alternative 
method based on the examination of the 24-hour creatinine output in relation to 
body weight is usually used. In a study comparing five different urinary creatinine 
based methods with the PABA method, the Knuiman method which uses a formula 
based on 24-hour urinary creatinine excretion (Knuiman et al., 1986), was found to 
be the most useful as it had a moderate sensitivity and excellent specificity 
(Murakami et al., 2008). I could not use it in this study however as I did not get a lot 
of creatinine results (see above).  
 
2.9.4. Plasma volume measurement 
There are various methods of plasma volume measurement and most of them are 
based on dilution principles that measure the apparent volume of distribution of the 
particular substance used (Wilson & Mills, 1970). The radio-labelled albumin 
method is thought to be the most reliable and reproducible method (1980) but is 
usually not used in pregnancy as it involves the administration of radioactive 
substances and human blood products to the individual.  
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The dye-dilution method includes the use of substances such as Evans blue (also 
known as T-1824), Coomassie blue and Indocyanine green. Other substances such 
as dextran (labelled and unlabelled) and iron-dextran (Semple et al., 1958; Wilson & 
Mills, 1970; van Kreel et al., 1998) have also been used. Evans blue is one of the 
most commonly used dye-dilution methods, particularly in pregnancy. It and the 
other dyes all bind to albumin and thus measure the albumin distribution which 
reflects the true plasma volume only if the capillaries remain impermeable to 
albumin and the dye stays within the intravascular space. As this is not often the 
case e.g. with traumatic injuries, renal impairment and with pre-eclampsia where 
albumin escapes from leaky capillaries, they tend to overestimate the plasma volume 
(Valeri et al., 1973; Campbell & Campbell, 1983). Another problem with Evans 
blue is the variability of its absorbance in turbid plasma (Brown et al., 1992a).  This 
can be overcome by the use of methods such as extraction procedures which were 
popular in the 1950s and 60s (Allen, 1951; Hobsley & Dew, 1958; Discombe, 1961; 
Hobsley & Thurn, 1963), a two wavelength method at 610 and 740 nm ((Nielsen & 
Nielsen, 1962; Brown et al., 1992a) and the polyethylene glycol method (Brown et 
al., 1992a). 
 
In the ‘Recommended Methods for the Measurement of Red Cell and Plasma 
Volume’ by the International Committee for Standardisation in Haematology 
published in 1980 (1980), it was noted that there was evidence for the use of a 
protein with molecular weight larger than albumin which would give a more 
accurate indication of the true plasma volume, but that this was not yet in routine 
practice. Substances such as gamma globulin (Andersen, 1962), fibrinogen (Baker & 
Wycoff, 1961) and alkaline phosphatase (Posen et al., 1965), have been used. The 
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problem with the use of dextran is that its chemical assay is tedious and using iron 
(59Fe) labelled dextran which is less laborious, introduces the use of radioactivity. 
Dextran 70 has been used successfully to measure plasma volume and found to be 
comparable to iodine-labelled albumin with a simpler laboratory method required 
for its quantification. This involves the estimation of glucose, which is a product of 
its hydrolysis (van Kreel et al., 1998). The CoV of this method was found to be 5% 
compared to 3% using 125I-labeled albumin that is taken as the gold standard (van 
Kreel et al., 1998). However, I could not use it in this study because I did not have 
access to some of the equipment required to carry out the complete experiment in 
my laboratory in Lagos.  
 
2.9.5. Renin-angiotensin assays 
I could not set up the renin and angiotensinogen assays in Lagos, as we do not have 
a gamma counter or safety procedures for handling 125I. The assay was developed 
and standardized in Nottingham and all the expertise is available there (Tetlow & 
Broughton Pipkin, 1983; Broughton Pipkin et al., 1984). I learnt to do the method 
myself whilst in Nottingham but did not do the actual assays of my samples as I 
could only spend a limited time in Nottingham at each visit. There was a very 
experienced technologist in the laboratory that did all the assays. I however did all 
the data analysis.  
 
2.9.6. Study design and recruitment. 
Longitudinal studies provide a stronger methodology to study the natural history or 
aetiology of disease (Vandenbroucke, 2008; Kirkwood & Sterne, 2003) unlike cross-
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sectional ones which are carried out at one point in time and are best suited to 
measuring prevalence of disease (Kirkwood & Sterne, 2003). 
 
The study was originally meant to be longitudinal but the plan failed due to a 
number of reasons. The greatest problem was the fact that pregnant women with 
sickle cell disease frequently suffer various crises (during which their red blood cells 
get haemolysed or sequestrated in their spleens or livers), and infections that cause 
them to require blood transfusion. As the study was to measure plasma volume, one 
of the exclusion criteria had to be a recent blood transfusion. Unfortunately more 
women were transfused than expected, possibly because of the worsening socio-
economic condition of average Nigerians, leading to poor nutritional habits and 
increased susceptibility to infections and crises. The endemicity of malaria in 
Nigeria and the increased susceptibility of people with sickle cell disorder and 
pregnant women in particular, even despite the use of prophylactic medication in 
pregnancy, contribute to the increased risk of haemolysis, severe anaemia and need 
for blood transfusion in them. 
 
I also encountered some difficulty in persuading a few of the Hb AA women to 
return for either their 36 weeks’ session. This was due to a general suspicion about 
medical research particularly that necessitating the provision of bodily fluids, the 
fact that these women were not actually the study group; rather they were healthy 
with uncomplicated pregnancies and because of the inconvenience of coming to the 
hospital when they have no clinical complaints. 
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2.9.7. Study data 
2.9.7.1. Calculation of body surface area 
The body surface area (BSA) was calculated using the Mosteller formula as it has 
been found to be more applicable regardless of body weight and age, and also easier 
to calculate than most other formulae (Verbraecken et al., 2006; Ahn & Garruto, 
2008). The Dubois and Dubois formula that was popularly used was derived from 
just 9 subjects (DuBois & DuBois, 1916).  
 
2.9.7.2. Calculation of glomerular filtration rate (GFR) 
Historically GFR used to be calculated by using a 24-hour urine collection. 
However, 24-hour collections have been found to be inaccurate both in non-pregnant 
and pregnant populations (Cote et al., 2008) usually because they are time 
consuming and inconvenient.  Also as age, gender, weight and race are known to 
affect the relationship of serum creatinine and GFR, it is now generally 
recommended that creatinine based equations be used to estimate GFR rather than 
creatinine clearance measurements from 24 hour urine collections (Lamb et al., 
2005). 
 
The “Modification of Diet in Renal Disease” (MDRD) equation and the Cockcroft-
Gault (CG) are two of the most frequently used ones. Although the MDRD equation 
(Levey et al., 1999) is now preferred for use outside pregnancy, its use has been 
heavily criticised in pregnancy as it was found to underestimate the GFR 
substantially in women studied serially from early through late pregnancy and post-
partum (Smith et al., 2008). Both the CG and the MDRD were reported to 
respectively overestimate and underestimate GFR in pre-eclamptics in a 
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retrospective study (Alper et al., 2007) and to correlate poorly with creatinine 
clearance in third trimester pregnant women in a brief communication (Delemarre & 
Schoenmakers, 2008). However, as it is easier to calculate and has not been 
discredited in early pregnancy, as has the MDRD, I decided to use the CG in this 
study. Furthermore, none of the women I studied developed pre-eclampsia. 
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3. NON-PREGNANT SICKLE CELL STUDY RESULTS 
I have split the sickle cell results section into two as it covers a lot of material. I will 
therefore be commenting on and displaying the results from all the non-pregnant 
women in this chapter and that from all the pregnant women in the 4th chapter. I will 
then discuss both sets of results in the 5th chapter.  
 
3.1. STUDY DESIGN AND RECRUITMENT 
The study was originally designed to be longitudinal, with samples taken at 16 and 
36 weeks of gestation (see section 2.4). Additional, opportunistic, cross-sectional 
data were to be added as they became available, and non-pregnant women would be 
studied as controls. However, logistic problems (see section 2.9.6) meant that 
longitudinal data were only collected from 7 women, all haemoglobin AA (Hb AA). 
Thus, for the final analysis it was decided to use a cross-sectional design. 
 
One hundred and fifty-four women were approached in total, 56 non-pregnant and 
98 pregnant.  A total of 140 women agreed to participate, comprising 51 non-
pregnant women and 89 pregnant.  The five non-pregnant women who declined all 
had haemoglobin AA and were either afraid of needles (3) or gave no reason (2). Of 
the 9 pregnant women who declined, 6 were haemoglobin AA while 3 were SS. The 
reasons given by the AA women were ‘husband disapproved’ (2) and ‘afraid the 
blue dye might harm baby’ (3). The sixth woman gave no reason. The three SS 
women were afraid it might make them unwell.  
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Out of the 140 women, measurements of plasma volume were made in 45 non-
pregnant women, 37 women at ~16 weeks’ gestation, 29 at ~36 weeks and 11 at ~8 
weeks post-partum, a total of 122 women. Plasma volume measurements were 
technically unsuccessful in the remaining 18 women. Eighty-eight women were 
eventually studied in the final cross-sectional analysis as 34 women were excluded 
for statistical reasons (see 3.1.2). Below are the reasons for elimination of the 52 
women not studied. 
 
3.1.1. Technical reasons (18 women) 
Non-pregnant women (6): One woman initially identified as SS was subsequently 
found to be SC; erythrocytes in samples from 4 Hb SS women haemolysed due to 
difficulty with collection. One AA woman’s plasma volume result was lost. 
 
Pregnant women (12): Erythrocytes in samples from four SS women haemolysed 
due to difficulty with collection; a further six SS women became ineligible since 
they were found to have been transfused before the plasma volume was measured. 
One AA woman had clotted samples and one became ineligible after being 
diagnosed as diabetic. 
 
3.1.2. Methodological reasons (34 results) 
In a true cross-sectional study, only one measurement from one volunteer can be 
used otherwise there will be autocorrelation as data from each individual tends to 
behave in a similar way even though the stages of gestation are different. The data 
were therefore balanced by systematically removing the first repeated measure of 
each pregnant woman. By doing this, data from 34 women became ineligible. 
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3.2. CHARACTERISTICS OF STUDIED WOMEN  
Most of the women were nulliparous and in their third decade of life (Table 3.1). 
 
Table 3.1. Characteristics of all studied women, irrespective of pregnancy 
status. 
 Age (y) 
(mean±SD) 
Parity 
(median 
& IQR) 
Weight (kg) 
(mean±SD) 
Height (m) 
(mean±SD) 
Body mass 
index (kg/m2) 
(mean±SD) 
N            88 88 87 88 87 
Mean/median            26 0 61.8 1.62 23.4 
SD or IQR              5 0 (0,0) 11.9 0.06 3.9 
N = Number in each group, SD = standard deviation and IQR = Interquartile range.  
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3.2.1. Characteristics of studied women within groups (Table 3.2) 
Haemoglobin AA women. The non-pregnant Hb AA women were significantly 
younger and more likely to be nulliparous than the pregnant AA women and, as 
would be expected, weighed less and thus had lower BMI. 
Haemoglobin SS women. In this case, the non-pregnant were younger and had a 
lower BMI than the pregnant women. 
Non-pregnant Hb SS were significantly younger and had a significantly lower 
weight and BMI than the Hb AA.   
At 16 weeks of pregnancy, Hb SS women had fewer children and were shorter, 
lighter and as such had a lower BMI than Hb AA women as expected.  
At 36 weeks of pregnancy, Hb SS women were lighter and had a lower BMI than 
their Hb AA counterparts. 
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Table 3.2 Comparison of studied women within groups. 
 AA (N=39) 
 Non-pregnant 
(N=19) 
16 weeks 
pregnant (N=10) 
36 weeks 
pregnant (N=10) 
Age (y) 25.1±4.3 28.8±4.7 * 30.4±4.9 ** 
Parity 0 (0,0) 1(0,2) ** 0 (0,1) * 
Weight (kg) 60.5±9.0  74.0±10.3 *** 78.6±10.6 **** 
Height (m) 1.63±0.06 1.66±0.05  1.64±0.04 
BMI (kg/m2) 22.7±3.3   27.0±3.3 *** 29.3±3.4 **** 
 SS (N=49) 
 
Non-pregnant 
(N=25) 
16 weeks pregnant 
(N=12) 
36 weeks 
pregnant (N=12) 
Age (y)  22.3±3.3 # 30.1±3.6 **** 28.4±4.6 **** 
Parity 0 (0,0) 0 (0,1) # 0 (0,0) 
Weight (kg) 53.3±6.9 ### 57.2±7.9 #### 62.3±6.6 *** 
#### 
Height (m) 1.61±0.07 1.59±0.05 ## 1.63±0.06 
BMI (kg/m2) 20.6±1.9 #  22.6±2.9 * ### 23.4±1.8 *** 
#### 
N = number studied in each group. Age, body weight, height and BMI are reported 
as mean ± standard deviation. Parity is reported as median and interquartile range 
in parentheses. * refers to comparisons of pregnant groups with non-pregnant, # 
refers to comparison of SS women with AA. *P< 0.05, **P<0.01, ***P<0.005, 
****P<0.001; #P<0.05, ##P<0.01, ###P<0.005, ####P<0.001. 
 77
3.3. NON-PREGNANT WOMEN 
3.3.1. Haematological variables amongst non-pregnant women 
As expected from the two genotypes, there were very marked differences in 
haematological variables between the HbAA and HbSS women. Summary data are 
shown in Table 3.3. The much greater degree of scatter in the samples from HbSS 
women was particularly marked with respect to the white blood cell, neutrophil and 
lymphocyte counts, for each of which the F (also known as Levene) test was also 
statistically highly significant (P<0.005 for all). 
 
3.3.2. Plasma volume amongst non-pregnant women  
The mean plasma volume in the 44 non-pregnant women studied was 2477±825ml. 
Women of genotype HbSS had significantly higher plasma volumes than women of 
HbAA (2714±949ml compared with 2165±417ml; P = 0.018). The range of values 
was considerably higher in HbSS women, and an F test showed this to be statistically 
significant (F = 5.092, P =0.029). 
 
 
 78
Table 3.3. Comparison of haematological values between the non-pregnant 
women.  
 HbAA  HbSS  
Hb concentration (g/L) 115±11 (N=19) 79±11 (N=24) **** 
Haematocrit (%) 0.37±0.02 (N=14) 0.24±0.04 (N=23) **** 
Mean cell volume (fl) 89.6±6.7 (N=14) 87.3±8.3 (N=22) 
Mean cell haemoglobin (pg) 28.6±2.0 (N=14) 29.0±3.4 (N=23) 
Mean cell Hb concentration (g/l) 319.4±9.8 (N=14) 329.4±19.0 (N=23) * 
RBC count x 109 (cells/L) 4.1±0.4 (N=14) 2.8±0.5 (N=23) **** 
WBC count x 109 (cells/L) 4.3±0.8 (N=14) 8.4±2.2 (N=21) **** 
Lymphocyte count x 109 (cells/L) 2.1±0.3 (N=13) 3.5±1.0 (N=18) **** 
Neutrophil count x 109 (cells/L) 1.7±0.6 (N=11) 3.9±1.6 (N=13) **** 
Platelet count x 109 (cells/L) 183±54 (N=14) 367±141 (N=23) **** 
Hb – haemoglobin concentration, fl – femtolitres, pg – picograms, WBC – white 
blood cell. (N) refers to number of women studied in each group. Data are reported 
as mean ± standard deviation. *P<0.05, ****P<0.001. 
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Plasma volume is often quoted per unit weight (Lund & Donovan, 1967; Hutchins, 
1980), or per unit BSA (Viart, 1976; Boer, 1984). Table 3.2 shows that women with 
Hb SS were significantly lighter than those with HbAA and had significantly lower 
BMIs. There are a number of equations for calculating the BSA, usually based on 
those of DuBois & DuBois (DuBois & DuBois, 1916). That of Mosteller (Mosteller, 
1987) is now widely-used, and was used to calculate BSA for the women of this 
thesis. 
BSA = 
3600
* heightweight
      Equation 3.1 
where weight is measured in kg and height in cm. 
 
The mean BSA for HbSS women was 1.54±0.13m2 while that for HbAA women 
was 1.65±0.14m2 (P = 0.007). Table 3.4 summarises the plasma volume in the two 
groups expressed in terms of body weight, BMI and BSA; significantly higher 
values are noted in the Hb SS women whichever correction factor is used. There is a 
statistically significant higher degree of scatter in the Hb SS women when plasma 
volume is expressed in terms of BMI and BSA respectively (P<0.05 in both cases).  
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Table 3.4. Comparison of plasma volume measurements between the non-
pregnant women 
 HbAA (N=19) HbSS (N=25) 
PV/bodyweight (ml/kg) 36.1±8.3 51.1±16.8*** 
PV/BMI (ml/kg/m2) 97.1±24.4 131.4±42.8*** 
PV/BSA (ml/m2) 1308±281 1762±593*** 
PV – plasma volume, BMI – body mass index, BSA – body surface area. Data are 
reported as mean ± standard deviation. ***P<0.005.  
 
3.3.3. Plasma and urinary osmolality and electrolytes 
It was expected that HbSS women would have higher urine outputs and lower 
plasma and urinary osmolality and that this would be reflected in the plasma and 
urinary concentrations of the major electrolytes. The results are summarised in Table 
3.5. 
 
However, although both plasma sodium and potassium are slightly higher in SS than 
AA, this difference is not statistically significant.  Both the urinary sodium 
concentration and urinary Na:K ratio are significantly lower in Hb SS women, 
though urinary potassium is not. That being so, I went on to calculate the urinary 
outputs for sodium and potassium, and their fractional excretions, together with the 
osmolar and free water clearances (Table 3.6). It should be noted that, unfortunately, 
not all laboratory measurements were available for all samples (see section 2.9.2).  
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Table 3.5. Urine volume, plasma and urinary electrolyte concentrations in 
non-pregnant HbAA and HbSS women 
 HbAA  HbSS  
Urine volume (L) 1.1 (0.8,1.3) N=18 1.9 (1.4,2.4)**** N=23 
Posmo (mosmo/kg) 277 (269,283) N=18 273 (268,280) N=25 
Uosmo (mosmo/kg) 377 (231,486) N=18 306 (158,386) N=24 
Plasma Na (mmol/L) 142(138,145) N=15 143 (138,146) N=22 
Urinary Na (mmol/L) 86 (59,118) N=17 58 (46,77)* N=23 
Plasma K (mmol/L) 3.8 (3.6,3.9) N=16 3.9 (3.7,4.3) N=25 
Urinary K (mmol/L) 8.7 (6.8,22.8) N=17 13.1 (7.5,22.4) N=22 
Urinary Na:K ratio 8.1 (4.4,10.3) N=17 5.7 (3.0,7.2)* N=22 
Posmo – plasma osmolality, Uosmo – urinary osmolality, Na – sodium, K – 
potassium. Data are reported as median (interquartile range). N – number of women 
studied. *P<0.05, ****P<0.001.  
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Table 3.6. Comparison of osmolar indices between the non-pregnant women  
 HbAA  HbSS  
Total urinary Na 
(mmol/day)  
78.9 (64.9,128.1) N=17 100.7 (84.2,189.6)* N=23 
Total urinary K 
(mmol/day) 
      9.4 (7.4,24.0) N=17 22.6 (14.5,38.6)* N=22 
FE Na 0.77 (0.46,1.22) N=12 0.76 (0.45,1.44) N=12 
FE K 6.14 (3.04,8.05) N=13 6.04 (4.35,14.02) N=13 
Osmolar clearance 
(L/day) 
1.20 (0.90,2.03) N=18 1.71 (1.32,2.50)* N=23 
Free H20 clearance 
(L/day) 
-0.35 (-0.69,0.18) N=18  -0.10 (-0.68,0.67) N=23 
FE Na – fractional excretion of sodium, FE K – fractional excretion of potassium, 
Free H20 clearance – free water clearance. Data are reported as median 
(interquartile range). N – number of women studied. *P<0.05. 
 
 83
It can be seen from the above that total urinary sodium and potassium outputs, as 
well as osmolar clearance, are higher in the HbSS women. It was felt that these 
differences might reflect alterations in the GFR and this was thus calculated. 
Although the gold standard for measuring GFR is from 24-hour urine collections, a 
number of formulae are now available for approximating the GFR from single urine 
measurements, mostly based on the CG equation (Cockcroft & Gault, 1976). 
Although the MDRD equation (Levey et al., 1999) is now preferred for use outside 
pregnancy, its use has been heavily criticised in pregnancy (Smith et al., 2008) and I 
have accordingly used the original CG equation in this thesis.  
 
GFR = ][
04.1**)140(
creatinineplasma
weightage−
    Equation 3.2 
 
where weight is measured in kg and plasma [creatinine] in mmol/L. 
The GFR for Hb AA women (N=16) was higher than that of Hb SS (N=14) – 134 
(92,156) vs 92 (68,118) ml/min respectively but this stopped short of being 
statistically significant, p = 0.051.  
 
3.3.4. Hormones  
The increased plasma volume in association with HbSS was identified over 30 years 
ago (Barreras et al., 1966; Steinberg et al., 1977) but the cause is unknown. 
Endocrine factors that might influence renal tubular sodium handling have not 
previously been systematically studied. Table 3.7 summarises the median and 
interquartile range (IQR) values for plasma renin, angiotensinogen and arginine 
vasopressin concentrations, and serum aldosterone, progesterone and prolactin 
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concentrations by genotype. No statistically significant differences were observed 
between non-pregnant HbSS and HbAA women except in prolactin concentration, 
which was higher in HbAA women. 
 
Table 3.7. Comparison of hormone concentrations in the non-pregnant 
women 
 HbAA  HbSS  
PRC (ng/ml/hr) 12.6 (6.6,20.8) N=16 11.8 (7.2,18.2) N=23 
Aogen (g/ml) 0.95  (0.45,1.20) N=15 0.98 (0.46,1.48) N=24 
ADH (pg/ml) 4.00 (3.40,4.58) N=16 3.80 (3.40,4.73) N=22 
Aldosterone (ng/ml) 80.1 (55.8,96.7) N=19 62.7 (42.6,104.0) N=24 
Progesterone (ng/ml) 0.8 (0.1,2.1) N=18 0.6 (0.3,1.0) N=23 
Prolactin (ng/ml) 80.1 (31.6,138.0) N=19 35.0 (16.3,104.3)* N=25 
PRC – Plasma renin concentration, Aogen – angiotensinogen, ADH – arginine 
vasopressin. Data are reported as median (interquartile range).*P<0.05. 
 
3.3.5. Association between plasma volume and measured indices  
With the differences noted above, I went ahead to see if there were any correlations 
with plasma volume. I also examined other parameters that were likely to be 
associated. These are shown in figures 3.1 to 3.7 below.  
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Figure 3.1. A scatter plot showing the relationship between serum progesterone 
concentration and plasma volume, in non-pregnant Hb AA (N=18) and Hb SS 
(N=23) women. The computed best line of fit for both groups of women, derived 
from a linear equation, is displayed. The equation is y = mx + c, where y = plasma 
volume, x = serum progesterone concentration, c = constant and m = slope.  
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There is a significant negative correlation between serum progesterone 
concentration and plasma volume both overall (r = -0.335; P = 0.033) and in Hb AA 
women as shown in Figure 3.1. There was a substantial scatter of plasma volumes in 
the Hb SS group that was not reflected in the serum progesterone concentrations; in 
these women, the association between the two variables was largely dependent on 
data from a single woman with high progesterone concentration. 
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Figure 3.2. A scatter plot showing the relationship between serum progesterone 
concentration and plasma volume per unit body surface area in non-pregnant Hb AA 
women (N=18), and Hb SS (N=23) women. The computed best line of fit for both 
groups of women is displayed as in Fig 3.1. There is a significant negative 
correlation in Hb AA women as shown. 
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Here also (Figure 3.2), there was a significant negative correlation between serum 
progesterone concentration and plasma volume both overall (r = -0.316; P = 0.044) 
and in Hb AA women as shown. There was also a greater scatter in the Hb SS 
women’s plasma volume per unit BSA measurements than in the Hb AA women. 
 
There was a positive correlation between serum prolactin concentration and plasma 
volume in Hb AA women (r = 0.442; P = 0.058), which stopped short of being 
statistically significant. However, as shown in Figure 3.3, when plasma volume was 
expressed per unit BSA, the correlation was statistically significant.               
 
The trend of much greater variability in Hb SS women continues with the positive 
correlation of plasma volume (Figure 3.4) and plasma volume per unit body surface 
area (Figure 3.5), with plasma renin concentration in Hb AA women. The greater 
scatter in Hb SS women’s measurements was seen in both scatter plots as well.  
 
With plasma ADH concentration, there is a significant negative correlation with 
both plasma volume and plasma volume per unit BSA (Figures 3.6 and 3.7 
respectively) in Hb SS women, albeit with a larger scatter than that seen in the Hb 
AA measurements. 
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Figure 3.3. A scatter plot showing the relationship between serum prolactin 
concentration and plasma volume per unit body surface area in non-pregnant Hb AA 
(N=19) and Hb SS (N=25) women. The computed best line of fit for both groups of 
women is displayed as in Fig 3.1. There is a significant positive correlation in Hb 
AA women as shown. 
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Figure 3.4. A scatter plot showing the relationship between plasma renin 
concentration and plasma volume in non-pregnant Hb AA (N=16) and Hb SS 
(N=23) women. The computed best line of fit for both groups of women is displayed 
as in Fig 3.1. There is a significant positive correlation in Hb AA women as shown. 
 
 
 91
 
 
Figure 3.5. A scatter plot showing the relationship between plasma renin 
concentration and plasma volume per unit body surface area in non-pregnant Hb AA 
(N=16) and Hb SS (N=23) women. The computed best line of fit for both groups of 
women is displayed as in Fig 3.1. There is a significant positive correlation in Hb 
AA women as shown. 
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Figure 3.6. A scatter plot showing the relationship between plasma Arginine 
Vasopressin (ADH) concentration and plasma volume in non-pregnant Hb AA 
(N=16) and Hb SS women (N=22). The computed best line of fit for both groups of 
women is displayed as in Fig 3.1. There is a significant negative correlation in Hb 
SS women as shown.  
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Figure 3.7. A scatter plot showing the relationship between plasma Arginine 
Vasopressin (ADH) concentration and plasma volume per unit body surface area in 
non-pregnant Hb AA (N=16) and Hb SS women (N=22). The computed best line of 
fit for both groups of women is displayed as in Fig 3.1. There is a significant 
negative correlation in Hb SS women as shown. 
 
 
 94
 
4. PREGNANT SICKLE CELL STUDY RESULTS                                                
In this chapter, I will report results from all the pregnant women, compare them with 
the non-pregnant and also compare Hb SS pregnant with the Hb AA pregnant 
women. 
 
4.1. ALL PREGNANT WOMEN 
I decided to compare all the pregnant women together first, as done with the non-
pregnant women, before splitting them into early and late pregnancy as appropriate. 
 
4.1.1. Haematological variables amongst pregnant women  
As in the non-pregnant women, there were also marked differences in most of the 
haematological parameters between HbAA and HbSS women (Table 4.1) but there 
was not much difference in scatter between the variables except with respect to 
platelet count (F = 7.635, P = 0.009).  
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Table 4.1. Comparison of haematological values between the pregnant women 
 HbAA  HbSS  
Hb concentration (g/L) 102±12 (N=19) 73±12 (N=23) ****  
Haematocrit (%) 0.32±0.04 (N=17) 0.22±0.04 (N=23) ****  
Mean cell volume (fl) 87.7±5.3 (N=16) 91.8±8.9 (N=23) 
Mean cell haemoglobin (pg) 28.1±2.2 (N=16) 30.2±3.5 (N=23) * 
Mean cell Hb concentration 
(g/L) 
320.8±12.1 (N=16) 329.0±13.5 (N=23) 
RBC count x 109 (cells/L) 3.7±0.4  (N=16) 2.4±0.4  (N=23) **** 
WBC count x 109 (cells/L) 5.9±2.2 (N=16) 10.4±2.6 (N=22) **** 
Lymphocyte count x 109 (cells/L) 1.5±0.5 (N=15) 3.0±1.3 (N=22) **** 
Neutrophil count x 109 (cells/L) 4.2±1.8 (N=14) 6.5±1.8 (N=20) **** 
Platelet count x 109 (cells/L) 192±60 (N=16) 429±129 (N=23) ****  
Hb – haemoglobin concentration, fl – femtolitres, pg – picograms, WBC – white 
blood cell, RBC – red blood cell. (N) refers to number of women studied in each 
group. Data are reported as mean ± standard deviation. *P<0.05, ****P<0.001.  
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4.1.2. Plasma volume amongst pregnant women  
Unlike the non-pregnant state, there was no significant difference in the various 
plasma volume measurements between all pregnant Hb AA and Hb SS women taken 
together (Table 4.2). There was also no significant difference when the two 
genotype groups were compared separately at 16 and 36 weeks gestation 
respectively.  However, comparisons between pregnant and non-pregnant HbAA 
and HbSS women revealed some interesting differences (see Section 4.2 below). 
 
Table 4.2. Comparison of plasma volume between all pregnant women 
 Hb AA (N=20) Hb SS (N=22) 
Plasma volume (ml) 3000±1004 2881±1150 
PV/bodyweight (ml/kg) 40.3±14.9 49.5±22.1 
PV/BMI (ml/kg/m2) 108.3±37.9 128.0±57.9 
PV/BSA (ml/m2) 1626±569 1785±744 
 PV – plasma volume, BMI – body mass index, BSA – body surface area. Data are 
reported as mean ± standard deviation. 
 
4.1.3. Plasma and urinary osmolality and electrolytes  
There was no significant difference in urine volume or plasma and urinary 
osmolality and electrolytes with the exception of plasma potassium, which was 
significantly higher in Hb SS women than Hb AA respectively (Table 4.3). Due to 
the limited urinary data available during pregnancy, fractional excretions, clearances 
and glomerular filtration rate were not subjected to statistical analysis. 
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Table 4.3. Urine volume, plasma and urinary electrolyte concentrations in 
pregnant Hb AA and Hb SS women 
 Hb AA  Hb SS  
Urine volume (L) 1.8 (1.2,2.4)  N=17 2.4 (1.3,2.8)  N=19 
Posmo (mosmo/kg) 270 (264,275) N=15 268 (264,272)  N=12 
Uosmo (mosmo/kg) 323 (122,379)  N=16 245 (222,287)  N=16 
Plasma Na (mmol/L) 142(138,147) N=18 138 (132,144)  N=19 
Urinary Na (mmol/L) 77 (59,113)  N=17 68 (51,120)  N=11 
Plasma K (mmol/L) 3.4 (3.2,3.8)  N=19 3.9 (3.6,4.6)  N=21* 
Urinary K (mmol/L) 8.8 (5.8,31.2)  N=17 11.6 (7.6,14.7)  N=11 
Urinary Na:K ratio 7.0 (3.2,11.6)  N=17 8.4 (4.9,10) N=11 
Posmo – plasma osmolality, Uosmo – urinary osmolality, Na – sodium, K – 
potassium. Data are reported as median (interquartile range). N – number of women 
studied. *P<0.05. 
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4.1.4. Hormones (Table 4.4)  
All the hormones studied apart from ADH usually rise in normal human pregnancy. 
When they were compared between genotypes there were no significant differences 
except in PRC and the scatter in this case was greater in Hb AA women than in Hb 
SS (Figure 4.1). 
 
Table 4.4. Comparison of hormone concentrations in pregnant women 
 HbAA  HbSS  
PRC (ng/ml/hr) 49.85(20.53,66.88) N=17 21.97(11.15,33.93) N=19** 
Aogen (g/ml) 2.19(1.59,3.64) N=17 2.37(1.30,4.11) N=18 
ADH (pg/ml) 4.00(3.80,8.20) N=19 3.65(3.40,4.28) N=10 
Aldosterone (ng/ml) 149.4(87.1,200.6) N=18 126.4(81.4,151.3) N=16 
Progesterone (ng/ml) 41.4(17.9,68.0) N=16 31.1(19.4,65.1) N=16 
Prolactin (ng/ml) 156.1(133.0,312.2) N=19 162.1(83.9,291.1) N=17 
PRC – Plasma renin concentration, Aogen – angiotensinogen, ADH – arginine 
vasopressin. Data are reported as median (interquartile range). **P<0.01. 
 
 
 99
Figure 4.1. Box-plot of plasma renin concentration amongst pregnant women 
according to genotype. Data were available from 17 and 19 Hb AA and SS women 
respectively. 
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As there were no differences in plasma volume measurements when all the pregnant 
women were compared according to genotype (Table 4.2) although significant 
differences had been identified in the non-pregnant women, I decided to compare 
non-pregnant with pregnant women of the same genotype, first to see if there were 
any differences in plasma volume as previously found (Abudu & Sofola, 1988), and 
to examine the electrolytes and hormones in this context.     
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4.2. PREGNANT VERSUS NON-PREGNANT WOMEN  
These comparisons enable us examine what happens in pregnancy in each individual 
genotype. 
 
4.2.1. Pregnant versus non-pregnant Hb AA women  
The comparisons were made between all pregnant and non-pregnant Hb AA women. 
In cases where the findings were felt to merit further consideration, comparisons 
were also made between non-pregnant and each of the gestational age groups. 
 
4.2.1.1. Haematological variables in pregnant and non-pregnant AA 
women  
Haematocrit, haemoglobin concentration and red cell count were lower in 
pregnancy, as expected whilst white cell count and neutrophil count were 
significantly higher (Table 4.5). 
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Table 4.5. Comparison of haematological values in non-pregnant and 
pregnant Hb AA women 
 Non-pregnant  Pregnant 
Hb concentration (g/L) 115±11 (N=19) 102±12 (N=19) *** 
Haematocrit (%) 0.37±0.02 (N=14) 0.32±0.04 (N=17) *** 
Mean cell volume (fl) 89.6±6.7 (N=14) 87.7±5.3 (N=16) 
Mean cell haemoglobin (pg) 28.6±2.0 (N=14) 28.1±2.2 (N=16) 
Mean cell Hb concentration 
(g/L) 
319.4±9.8 (N=14) 320.8±12.1 (N=16) 
RBC count x 109 (cells/L) 4.1±0.4  (N=14) 3.7±0.4  (N=16) * 
WBC count x 109 (cells/L) 4.3±0.8 (N=14) 5.9±2.2 (N=16) * 
Lymphocyte count x 109 (cells/L) 2.1±0.3 (N=13) 1.5±0.5 (N=15) *** 
Neutrophil count x 109 (cells/L) 1.7±0.6 (N=11) 4.2±1.8 (N=14) **** 
Platelet count x 109 (cells/L) 183±54 (N=14) 192±60 (N=16)  
Hb – haemoglobin concentration, fl – femtolitres, pg – picograms, WBC – white 
blood cell, RBC – red blood cell. (N) refers to number of women studied in each 
group. Data are reported as mean ± standard deviation.  *P<0.05, ***P < 0.005, 
****P<0.001. 
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4.2.1.2. Plasma volume indices in pregnant and non-pregnant women  
The expected rise in plasma volume in Hb AA pregnancy was seen and found to be 
significant both at 16 weeks and at 36 weeks pregnancy when compared to non-
pregnant women (Table 4.6). The increase appeared to be almost complete by 16 
weeks. There was also a rise in the other plasma volume indices but none of these 
reach statistical significance at either 16 or 36 weeks, although the rise in plasma 
volume per unit body surface area overall in pregnancy (Table 4.6) did achieve 
statistical significance.  
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Table 4.6. Comparison of PV in pregnant and non-pregnant women  
 AA (N=39) 
 NP (N=19) 16 weeks P 
(N=10) 
36 weeks P 
(N=10) 
All P (N=20) 
Plasma volume 
(ml) 
2165±497 2911±1020* 3089±1035* 3000±1004*** 
PV/bodyweight 
(ml/kg) 
36.1±8.3 40.1±14.4 40.6±16.1 40.3±14.9 
PV/BMI 
(ml/kg/m2) 
97.1±24.4 108.9±37.8 107.8±40.0 108.3±37.9 
PV/BSA 
(ml/m2) 
1308±281 1593±564 1659±603 1626±569* 
 SS (N=47) 
 NP 
(N=25) 
16 weeks P 
(N=11) 
36 weeks P 
(N=11) 
All P (N=22) 
PV (ml) 2714±949 2758±913 3003±1382 2881±1150 
PV/weight 
(ml/kg) 
51.1±16.8 50.2±19.7 48.9±25.3 49.5±22.1 
PV/BMI 
(ml/kg/m2) 
131.4±42.8 126.5±51.9 129.5±66.0 128.0±57.9 
PV/BSA 
(ml/m2) 
1762±593 1768±623 1801±879 1785±744 
N = number of women studied, P = pregnant, NP = non-pregnant. Data are reported 
as mean ± SD. *P<0.05, ***P<0.005. * refers to comparison with non-pregnant. 
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4.2.1.3. Plasma and urinary osmolality, electrolytes and renal indices   
Only limited data could be obtained at 36 weeks’ gestation; these are shown in Table 
4.7 but were not subjected to separate statistical analysis other than trend analysis as 
indicated. Urine volume increased significantly in pregnancy as expected and 
plasma osmolality decreased also as expected. Trend analysis showed the fall in 
plasma osmolality and rise in urine volume to deepen progressively as gestation 
advanced in HbAA women (P = 0.014; P<0.001), but not in HbSS (P = 0.084; 
P>0.5). Overall, both plasma and urinary osmolality were inversely associated with 
urine volume (P =0.027; P<0.001). The only other significant changes were the 
reduction in plasma potassium concentration and the higher total urinary sodium 
output in pregnancy but there were no significant changes in plasma or urinary 
sodium concentration.  
 
4.2.1.4. Hormone concentrations   
As expected in normal Hb AA pregnancy, there was an increase in pregnancy of all 
the hormones measured except for arginine vasopressin (Table 4.8). 
 
 106
Table 4.7. Urine volume, plasma and urinary osmolality and electrolyte concentrations in Hb AA women 
 Non-pregnant 16 weeks pregnant  36 weeks pregnant  All pregnant 
Urine volume (L) 1.1 (0.8,1.3) N=18 1.5(1.2,2.2) N=10* 2.0(1.2,3.1) N=7 1.8(1.2,2.4) N=17*** 
Posmo (mosmo/kg) 277(269,283) N=18 270(267,278) N=10 264(262,274) N=5 270(264,275) N=15* 
Usomo (mosmo/kg) 377(231,486) N=18 323(171,421) N=10 227(87,417) N=6 323(122,379) N=16 
Plasma Na (mmol/L) 142(138,145) N=15 138(135,146) N=9 144(140,149) N=9 142(138,147) N=18 
Urinary Na (mmol/L) 86 (59,118) N=17 87(71,123) N=10 56(43,79) N=7 77 (59,113) N=17 
Plasma K (mmol/L) 3.8 (3.6,3.9) N=16 3.4(3.0,3.7) N=10** 3.5(3.4,4.1) N=9 3.4 (3.2,3.8) N=19* 
Urinary K (mmol/L) 8.7 (6.8,22.8) N=17 8.3(6.3,25.9) N=10 11.5(4.8,41.9) N=7 8.8 (5.8,31.2) N=17 
Urinary Na:K ratio 8.1 (4.4,10.3) N=17 9.5(4.7,15.2) N=10 3.7(2.4,7.9) N=7 7.0 (3.2,11.6) N=17 
Total urine Na (mmol/day) 78.9(64.9,128.1)N=17 151.3(83.8,216.5)N=10* 99.4 (65.2,129.2) N=6 124.2(79.9,171.8)N=16* 
GFR (ml/min) 133.9 (92.2,156.3) N=16 131.3 (94.8,196.1) N=10 140.4 (N=3) 132.6 (107.1,182.6) N=13 
Posmo – plasma osmolality, Uosmo – urinary osmolality, Na – sodium, K – potassium. Data are reported as median (interquartile range). N – 
number of women studied. *P<0.05, **P<0.01, ***P<0.005. * refers to comparison with non-pregnant women.
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Table 4.8. Hormone concentrations in Hb AA women 
 Non-pregnant 
 
16 weeks 
pregnant  
36 weeks 
pregnant  
All pregnant 
PRC  
(ng/ml/hr) 
12.59(6.58,20.
79) 
N=16 
32.04(19.15,58.
64) 
N=8**  
52.38(32.05,70.
74) 
N=9*** 
49.85(20.53,66.
88) 
N=17**** 
Aogen  
(g/ml) 
0.95 
(0.45,1.20)   
N=15 
1.78 (1.03,2.16) 
N=8* 
3.58(2.39,4.28) 
N=9**** 
2.19(1.59,3.64) 
N=17**** 
ADH  
(pg/ml) 
4.00 
(3.40,4.58)   
N=16 
3.90(3.55,6.90) 
N=10 
4.20(3.90,8.50) 
N=9 
4.00(3.80,8.20) 
N=19 
Aldosteron
e  
(ng/ml) 
80.1(55.8,96.7
) 
N=19 
103.1(74.5,158.
3) 
N=9 
197.1(149.4,20
5.6) 
N=9*** 
149.4(87.1,200.
6) 
N=18*** 
Progestero
ne (ng/ml) 
0.8 (0.1,2.1)   
N=18 
17.9(9.3,28.1) 
N=8**** 
61.6(46.4,74.7) 
N=8**** 
41.4(17.9,68.0) 
N=16**** 
Prolactin  
(ng/ml) 
80.1 
(31.6,138.0)   
N=19 
134.0(105.8,16
0.1) 
N=9* 
295.2(148.5,41
9.5) 
N=10**** 
156.1(133.0,31
2.2) 
N=19**** 
PRC – Plasma renin concentration, Aogen – angiotensinogen, ADH – arginine 
vasopressin. Data are reported as median (interquartile range).*P<0.05, **P<0.01, 
***P<0.005, ****P<0.001. 
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4.2.1.5. Association between hormones and plasma volume indices 
(Figures 4.2 to 4.6) 
There was a significant positive correlation between plasma volume and PV per unit 
BSA respectively, and log10 angiotensinogen (P=0.01; P=0.018) in all pregnant AA 
women. At 16 weeks gestation, there was a significant positive correlation between 
PV and PV per unit BSA, and log 10 aldosterone (P=0.046; P=0.044) and at 36 
weeks gestation, there was also a significant positive correlation between PV and 
log 10 angiotensinogen. 
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  Figure 4.2. A scatter plot showing the relationship between angiotensinogen 
concentration and plasma volume in all pregnant Hb AA (N=17) women. The 
computed best line of fit derived from a linear equation, y = mx + c, is displayed, 
where y = PV, x = log 10 angiotensinogen, c = constant and m = slope.  
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Figure 4.3. A scatter plot showing the relationship between angiotensinogen 
concentration and plasma volume per unit body surface area in all pregnant Hb AA 
(N=17) women. The computed best line of fit is displayed as in Fig 4.2 above. 
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Figure 4.4. A scatter plot showing the relationship between aldosterone 
concentration and plasma volume in 16 weeks pregnant Hb AA (N=9) women. The 
computed best line of fit is displayed as in Fig 4.2 above. 
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Figure 4.5. A scatter plot showing the relationship between aldosterone 
concentration and plasma volume per unit body surface area in 16 weeks pregnant 
Hb AA (N=9) women. The computed best line of fit is displayed as in Fig 4.2 above. 
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Figure 4.6. A scatter plot showing the relationship between angiotensinogen 
concentration and plasma volume in 36 weeks pregnant Hb AA (N=9) women. The 
computed best line of fit is displayed as in Fig 4.2 above. 
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4.2.2. Pregnant versus non-pregnant Hb SS women 
The same comparisons done in Hb AA women were repeated in Hb SS women. 
 
4.2.2.1. Haematological variables in pregnant and non-pregnant SS 
women  
Unlike in Hb AA women, although both haematocrit and haemoglobin 
concentrations fell slightly in pregnant Hb SS women when compared with the non-
pregnant, the difference was not significant. Similar to the AA women however, red 
cell count was significantly lower whilst white cell count and neutrophil count were 
significantly higher in Hb SS pregnancy (Table 4.9). 
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Table 4.9. Comparison of haematological values in Hb SS women 
 Non-pregnant  Pregnant 
Hb concentration (g/L) 79±11 (N=24)  73±12 (N=23)  
Haematocrit (%) 0.24±0.04 (N=23)  0.22±0.04 (N=23)  
Mean cell volume (fl) 87.3±8.3 (N=22) 91.8±8.9 (N=23) 
Mean cell haemoglobin (pg) 29.0±3.4 (N=23) 30.2±3.5 (N=23)  
Mean cell Hb concentration (g/L) 329.4±19.0 (N=23)  329.0±13.5 (N=23) 
RBC count x 109 (cells/L) 2.8±0.5 (N=23)  2.4±0.4  (N=23)*  
WBC count x 109 (cells/L) 8.4±2.2 (N=21)  10.4±2.6 (N=22)*  
Lymphocyte count x 109 (cells/L) 3.5±1.0 (N=18)  3.0±1.3 (N=22)  
Neutrophil count x 109 (cells/L) 3.9±1.6 (N=13)  6.5±1.8 (N=20)****  
Platelet count x 109 (cells/L) 367±141 (N=23)  429±129 (N=23) 
Hb – haemoglobin concentration, fl – femtolitres, pg – picograms, WBC – 
white blood cell, RBC – red blood cell. (N) refers to number of women 
studied in each group. Data are reported as mean ± standard deviation.  
*P<0.05, ****P<0.001. 
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4.2.2.2. Plasma volume indices in pregnant and non-pregnant women 
(Table 4.6)  
There were no statistically significant differences in plasma volume indices in 
pregnant Hb SS women, compared with non-pregnant. This is unlike Hb AA 
pregnancy where there is an increase in PV at 16 and 36 weeks and in PV/BSA 
overall. 
 
4.2.2.3. Plasma volume at different gestational age groups 
There were no statistically significant differences in any of the plasma volume 
measurements between Hb SS and Hb AA women, at 16 and at 36 weeks gestation 
(Table 4.6). Thus PV does not rise in Hb SS pregnancy and neither is it significantly 
different from the volumes in Hb AA pregnancy, regardless of the form of PV 
measurement.   
 
4.2.2.4. Plasma and urinary osmolality and electrolytes 
There were no significant differences in any of the renal indices that had sufficient 
data for a meaningful statistical analysis to be performed. All the available data are 
shown in Table 4.10 below. 
 
4.2.2.5. Hormones 
As in Hb AA pregnancy, there was an increase in most hormones in both early and 
late pregnancy and in pregnancy as a whole from the non-pregnant state (Table 
4.11). The only exceptions to this rule were arginine vasopressin, which did not rise 
at all, and plasma renin concentration, which rose in early pregnancy and in 
pregnancy in general, but did not rise significantly in late pregnancy. 
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Table 4.10. Urinary volume, plasma and urinary electrolyte concentrations in Hb SS women 
 Non-pregnant 
 
16 weeks pregnant 36 weeks pregnant All pregnant 
Urine volume (L) 1.9 (1.4,2.4)N=23 2.4 (1.4,2.8)N=11 1.6  (1.2,3.7)  N=8 2.4 (1.3,2.8)  N=19 
Posmo (mosmo/kg) 273(268,280)N=25 267(263,272)N=9 268                N=3 268 (264,272)N=12 
Usomo (mosmo/kg) 306(158,386)N=24 239(229,282)N=11 281(136,386) N=5 245 (222,287)N=16 
Plasma Na(mmol/L) 143(138,146)N=22 144(137,148)N=9 134(131,139) N=10 138 (132,144)N=19 
Urinary 
Na(mmol/L) 
58 (46,77) N=23 57(51,122)N=9 72                   N=2 68   (51,120)  N=11 
Plasma K (mmol/L) 3.9 (3.7,4.3)  N=25 3.7(3.2,4.5)N=11 4.1  (3.7,4.6)   N=10 3.9   (3.6,4.6) N=21 
Urinary K(mmol/L) 13.1(7.5,22.4)N=22 12.4(8.0,15.8)N=9 6.3                   N=2 11.6(7.6,14.7)N=11 
Urinary Na:K ratio 5.7 (3.0,7.2)N=22 6.4(4.0,9.3)N=9 11.8                 N=2 8.4  (4.9,10.0)N=11 
GFR (ml/min) 92(68,118) N=14 133(105,153)N=5 138                   N=1 135   (117,146)N=6 
Posmo – plasma osmolality, Uosmo – urinary osmolality, Na – sodium, K – potassium. Data are reported as median (interquartile 
range). N – number of women studied. 
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Table 4.11. Hormone concentrations in Hb SS women 
 Non-pregnant 
 
16 weeks pregnant  36 weeks pregnant  All pregnant 
PRC  
(ng/ml/hr) 
11.81 (7.18,18.20)  N=23 21.63(12.39,35.17) 
N=10* 
21.97(9.27,34.97) 
N=9 
21.97(11.15,33.93) 
N=19* 
Aogen  
(g/ml) 
0.98 (0.46,1.48)  N=24 2.26(1.18,3.87) 
N=10*** 
3.17(1.37,4.46) 
N=8** 
2.37(1.30,4.11) 
N=18**** 
ADH  
(pg/ml) 
3.80 (3.40,4.73)  N=22 3.60(3.40,4.68) 
N=6 
3.17(1.37,4.46) 
N=4 
3.65(3.40,4.28) 
N=10 
Aldosterone  
(ng/ml) 
62.7 (42.6,104.0)  N=24 114.6(71.6,141.1) 
N=11* 
186.3(126.4,253.4) 
N=5*** 
126.4(81.4,151.3) 
N=16*** 
Progesterone (ng/ml) 0.6 (0.3,1.0)  N=23 22.9(19.0,33.8) 
N=11**** 
76.9(61.9,83.3) 
N=5*** 
31.1(19.4,65.1) 
N=16**** 
Prolactin  
(ng/ml) 
35.0 (16.3,104.3)*  N=25 126.6(74.6,168.2) 
N=11*** 
305.2(227.0,434.9) 
N=6*** 
162.1(83.9,291.1) 
N=17**** 
PRC – Plasma renin concentration, Aogen – angiotensinogen, ADH – arginine vasopressin. Data are reported as median (interquartile range). 
*P<0.05, **P<0.01, ***P=0.005, ****P<0.001. 
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4.2.2.6. Association between hormones and plasma volume indices 
There was significant correlation between plasma renin concentration and plasma 
volume per unit body surface area and between serum aldosterone concentration and 
plasma volume, both at 16 weeks gestation in Hb SS women (Figures 4.7 and 4.8). 
There was also a significant positive correlation between log10 aldosterone and PV 
in Hb SS pregnancy in general (Figure 4.9). 
 
4.2.2.7. Association between plasma volume and measured indices in 
all pregnant women  
As done in non-pregnant women, I also examined correlations between plasma 
volume and other parameters in all pregnant women, regardless of genotype. The 
only statistically significant one is shown in figure 4.10 below. 
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Figure 4.7. A scatter plot showing the relationship between plasma renin 
concentration and plasma volume per unit body surface area in 16 weeks’ pregnant 
Hb SS (N=10) women. The computed best line of fit is displayed as in Fig 4.2 
above. 
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Figure 4.8. A scatter plot showing the relationship between serum aldosterone 
concentration and plasma volume in 16 weeks’ pregnant Hb SS (N=11) women. The 
computed best line of fit is displayed as in Fig 4.2 above. 
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Figure 4.9. A scatter plot showing the relationship between aldosterone 
concentration and plasma volume in all pregnant Hb SS (N=16) women. The 
computed best line of fit is displayed as in Fig 4.2 above. 
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Figure 4.10. A scatter plot showing the relationship between aldosterone 
concentration and plasma volume, in all pregnant women (N=34). The computed 
best line of fit is displayed as in Fig 4.2 above. 
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4.3. BIRTH WEIGHT AND PLASMA VOLUME 
Having examined the plasma volume indices and hormones and electrolytes known 
to affect them, I proceeded to examine birth weights of the babies between the 
genotypes and their association with plasma volume and other known determinants.  
 
4.3.1. Birth weight and gestational age at delivery 
As expected there was a significant difference in both birth weight and gestational 
age at delivery between Hb AA and Hb SS women (Table 4.12).   
 
Table 4.12. Birth weight and gestational age at delivery between pregnant 
women 
 Hb AA Hb SS 
Birth weight (kg) 3.3±0.4(N=19) 2.7±0.5 
(N=23)*****  
Gestational age at delivery (weeks) 38.7±1.3 (N=19)  37.4±2.0 (N=21) *   
Babies below 2.5kg 0 (N=19) 26.1% (N=23)* 
Birth weights of babies  37 weeks 
gestation at delivery 
3.3±0.4 (N=18) 2.9±0.4 (N=16)*** 
Number of babies below 2.5kg in 
babies  37 weeks gestation at 
delivery  
0 (N=18) 2 (N=16) 
N = number of women studied in each group. Data are reported as mean ± standard 
deviation. *P<0.05, ***P<0.005, *****P<0.0001. 
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4.3.2. Plasma volume and birth weight  
As birth weight is a single outcome and I was analysing it in relation to all my 
various other measurements, I used all the initial data I had i.e. including the 
repeated measurements of some of the women as shown in the figures below. 
Historically increase in plasma volume is known to correlate positively with birth 
weight thus I examined the relationship between the two parameters. As there is a 
difference in plasma volume expansion in both gestational age groups studied, each 
gestational age group was examined separately. There was no significant correlation 
at 16 weeks gestation but at 36 weeks’ gestation, there was an unexpected 
significant negative correlation between birth weight and plasma volume 
measurements (Figures 4.11 and 4.12) in Hb SS women.  
 
There was a significant negative correlation between birth weight and plasma 
potassium concentration in Hb AA women at 16 weeks gestation (Figure 4.13) but 
there was no significant correlation with any other haematological, hormonal or 
electrolyte parameters.  
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Figure 4.11. A scatter plot showing the relationship between birth weight and 
plasma volume, in 36 weeks pregnant Hb AA (N=13) and Hb SS (N=14) women. 
The computed best lines of fit are displayed as in Fig 4.2 above. There is a 
significant negative correlation overall as shown and a significant negative 
correlation in the Hb SS women as well (r= -0.583, P=0.029).  
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Figure 4.12. A scatter plot showing the relationship between birth weight and 
plasma volume per unit body surface area, in 36 weeks pregnant Hb AA (N=13) and 
Hb SS (N=14) women. The computed best lines of fit are displayed as in Fig 4.2 
above. There is a significant negative correlation overall as shown and a significant 
negative correlation in the Hb SS women as well (r= -0.601, P=0.023). 
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Figure 4.13. A scatter plot showing the relationship between birth weight and 
plasma potassium, in 16 weeks pregnant Hb AA (N=18) and Hb SS (N=14) women. 
The computed best lines of fit are displayed as in Fig 4.2 above. There is a 
significant negative correlation in Hb AA women as shown. 
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5. DISCUSSION 
In this chapter, I will discuss the characteristics of all the women in the study then 
go on to discuss the results obtained from the non-pregnant women, followed by 
those from the pregnant women. 
 
5.1. CHARACTERISTICS OF STUDIED WOMEN 
Hb SS individuals are usually smaller, often in weight and sometimes height than 
their Hb AA counterparts, leading to a lower BMI (Table 3.2). The causes of this are 
unclear as despite their chronic anaemia, their oxygen carrying capacity is usually 
compensated for by a shift in the oxygen dissociation curve to the right, indicating a 
low oxygen affinity and thus a higher availability for use. However, a high demand 
for nutrients due to the constant breakdown of cells is usually not matched by 
appropriate intake and a small study on Hb SS children (Heyman et al., 1985) 
showed a positive effect of dietary supplementation on their growth. Hb SS children 
with high levels of haemoglobin F (Hb F) have also been found to have a more 
normal weight gain pattern than their Hb AA counterparts (Lowry et al., 1977).  
 
It was noted also that the Hb SS women were younger which reflects their early 
health-seeking behaviour due to frequent illness and knowledge of their health 
condition. There is a sickle cell clinic in the hospital dedicated to the management of 
people with this disorder and they attend regularly from early childhood. This is in 
contrast to the poor health-seeking behaviour of the Hb AA population who seek 
medical attention mainly for serious or life threatening illness. The many Hb AA 
female nurses and house officers that were recruited to the non-pregnant AA would 
also have contributed to the difference in age, as they have undertaken professional 
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training and are therefore likely to be older than their non-pregnant counterparts. On 
the other hand, they were younger than the pregnant AA women as in recent times, 
these women tend to have completed tertiary education before starting their family 
(Odumosu et al., 1999). The age groups for all non-pregnant women and for the 
pregnancy groups were all similar however (Table 3.2) and the differences found 
were not likely to be clinically significant. 
 
5.2. NON-PREGNANT WOMEN 
5.2.1. Haematological variables  
The differences of lower haemoglobin levels and higher white cell counts that were 
seen in Hb SS women here were as expected. The known haematological variability 
of the disease was also seen from the greater degree of scatter, particularly in the 
white cell, neutrophil and lymphocyte counts of the Hb SS women.  
  
5.2.2. Plasma volume measurements 
The mean plasma volume of 2477ml found in the 44 non-pregnant women studied 
cannot be put in the context of previous studies, as it is a combination of Hb AA and 
Hb SS women. That of Hb AA women alone was 2165ml, which is very similar to 
data from the U.S.A. – 2036ml from 21 normal non-pregnant women with an 
average age of 29.7 years (Bernstein et al., 2001) and from Nigeria – 2044 ml from 
20 Hb AA non-pregnant women with an average age of 24.8 (Abudu & Sofola, 
1988). A U.K. study found a mean of 2378 ml from 52 non-pregnant women in the 
reproductive age group (Whittaker & Lind, 1993) but this was still well below the 
2714ml found in the 25 Hb SS women examined in this study.  
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Plasma volume is often quoted per unit weight or per unit body surface area as it has 
been found to depend on size (Hutchins, 1980). A study found it to be even better 
correlated with lean body mass than with body weight or body surface area (Boer, 
1984). I did not use lean body mass however as it is a bit cumbersome to measure, is 
not widely used and would thus make comparison difficult.  Using plasma volume 
per unit weight, the non-pregnant PVs of women with Hb SS of 51.1ml/kg is still 
much higher than the non-sickle cell female European figures of 42.7ml/kg (Boer, 
1984) and the 46 ml/kg found in non-sickle cell postpartum Nigerian women 
(Harrison, 1966). A study done in the USA found 15 Hb SS adult females to have a 
mean plasma volume of 65ml/kg (Barreras et al., 1966) (Steinberg et al., 1977), 
which is even higher than my findings. A possible reason for this difference is the 
difference in climate. Nigeria, particularly the southern region where Lagos State is 
situated is a very hot and humid tropical country with an average annual temperature 
of 280C (Lagos, 2010) and more body fluids are lost from perspiration. Another U.S. 
study of young Hb SS men and women with a mean age of 27.4 which found a mean 
plasma volume of 55.0 ml/kg, used 51Cr labelled autologous erythrocytes to estimate 
total blood volume and from this, with the haematocrit, the plasma volume 
(Steinberg et al., 1977). They also felt that they probably underestimated the plasma 
volume of their population because they used a higher whole body-to-venous 
haematocrit ratio than they should have for their population, who were likely to be 
asplenic.  
 
It can be seen from Fig 3.1 that the range of values was considerably higher in HbSS 
women, and an F test showed this to be statistically significant (F = 5.092, P 
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=0.029). This is most likely due to the variability of the severity of the 
manifestations of the disease but could also be due to different levels of hydration in 
the women studied. 
 
As mentioned in the Introduction (1.1.1.1), the cause of the higher plasma volume in 
non-pregnant Hb SS individuals is unknown as it exceeds the expansion in other 
anaemias with similar red cell mass (Erlandson et al., 1960; Steinberg et al., 1977). 
We know that Hb SS women drink a lot of water although we did not measure their 
intake in this study. However, they also excrete large amounts of urine as shown in 
this study. Their urine is known to be dilute as well (Allon et al., 1988) and in this 
study, the urinary osmolality in the Hb SS women was lower than in Hb AA 
although this did not reach statistical significance (Table 3.5). Thus urinary 
osmolality cannot explain their expanded PV. 
 
The osmolar clearance in the Hb SS was significantly higher in the small number of 
women in whom I could calculate it, and as this suggests a smaller free water 
clearance for a given urine volume, it would appear that the Hb SS women clear less 
free water than their AA counterparts and this may be one of the causes of the 
supranormal plasma volume. However the free water clearance as calculated from 
the urine volumes and osmolar clearance was not significantly different from that of 
the Hb AA women (Table 3.6).  
 
Although the difference in GFR is just short of clinical significance, it is close 
enough (p=0.051) to be biologically relevant. A beta (Type II) error is also a 
possible reason for it not to have been significant. As such, it is possible that the 
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increased plasma volume seen in the non-pregnant Hb SS women is as a result of a 
lower GFR in them. Normally GFR is known to be raised in childhood and normal 
by adolescence in Hb SS individuals. It then falls although it is not clear at what age 
group this fall occurs. A recent study found GFR to still be supranormal at age 20 in 
Hb SS individuals. However, when the women in the study were examined 
separately, their GFR was not significantly different from their Hb AA counterparts 
(Thompson et al., 2007). If GFR were to be the cause of the fall, one would expect 
plasma volume to be normal or low in childhood and only begin to rise as GFR 
declines. As far as this postulation goes, there are no reported studies of low or 
normal plasma volume measurements specifically in Haemoglobin SS children; in 
fact a study of 16 Hb SS children aged between 2 and 14 years showed a higher 
plasma volume than non-sickle cell controls (Jenkins et al., 1956). Also as there is 
no correlation between any plasma volume measurement and GFR in Hb SS, it 
would appear that there are other factors driving the plasma volume apart from just 
the GFR. 
 
Another possibility would be that plasma volume is high from childhood with an 
accompanying high GFR and then the GFR begins to fall with age but the PV 
remains the same. This would also suggest that other factors apart from, or as well 
as, the GFR are responsible for the plasma volume increase.   
 
Urinary sodium concentration was found to be significantly lower in the Hb SS 
women as would be expected in the presence of sodium retention and an increased 
plasma volume. It is therefore possible that renal conservation of sodium may be 
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partly responsible for their steady state supranormal plasma volume as it is in other 
anaemias.   
 
In exploring relationships between plasma volume measurements and the different 
indices that could affect them, I found the Hb AA women behaved as expected with 
there being a positive relationship between plasma volume measurements and 
related variables such as plasma renin concentration (PRC) and serum prolactin and 
a negative one with serum progesterone (Schrier & Niederberger, 1994; Ganong, 
2005). Plasma renin through its production of angiotensin II as well as aldosterone, 
leads to an increase in the reabsorption of sodium from the proximal nephron, which 
is known to increase plasma volume. The prolactin relationship upholds previous 
findings in mammals where it is expected to increase renal reabsorption of sodium 
and water (Horrobin, 1980; Campbell & MacGillivray, 1982). For the total urinary 
sodium however, it may be expected that the higher the amount of sodium excreted 
from the kidneys, the more the accompanying water loss would be and as such the 
lower the plasma volume. However, it is more likely that the higher the plasma 
volume is, the higher the total excreted sodium and water would be and that the 
plasma volume probably drives the urinary sodium output.                                 
 
Regarding the negative relationships, as progesterone is known to be natriuretic, 
because it acts as a competitive inhibitor of aldosterone due to their marked 
structural similarity (Berl & Better, 1980), it was expected that an increase would 
increase sodium excretion and water loss. Also, although there are some exceptions, 
when GFR is increased plasma volume usually reduces and vice-versa (Ganong, 
2005).  
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In the Hb SS women, the only relationship between plasma volume and all the 
appropriate indices examined against it was a negative one with ADH, which was 
seen with all the plasma volume measurements. This implies that ADH and PV are 
very tightly linked in non-pregnant Hb SS women. Normally, an increase in ADH 
should lead to an increase in plasma volume. As the relationship is inverse in the 
case of these women, it would appear that the plasma volume drives the ADH 
concentration in them. Volume control of ADH is very strong and overrides that of 
osmotic stimuli (Ganong, 2005) thus a decrease in ADH secretion would be 
expected in those with a supranormal plasma volume such as these women. It would 
therefore appear that ADH secretion in Hb SS women might be highly dependent on 
plasma volume. This implies, presumably, that some other stimulus (or stimuli), is 
driving the plasma volume expansion.  
 
The finding of significantly lower prolactin concentration in the non-pregnant Hb SS 
women was unexpected.  The reason for this is not immediately clear. One would 
have expected it to be higher in them, explaining the supranormal plasma volume 
since prolactin has been implicated in the retention of sodium and water in other 
mammals (Horrobin, 1980). If it was low due to haemodilution or because the high 
plasma volume was driving the process, one would expect some of the other 
hormones such as aldosterone to be low as well and this was not the case.  
 
A more recent study found prolactin to be natriuretic in euvolaemic, anaesthetised 
rats (Ibarra et al., 2005). As there have been many contradictory findings on the role 
 136
of prolactin in sodium regulation however, and there are no definitive confirmatory 
studies in humans, this particular result should be interpreted with caution. 
 
It therefore appears that the mechanism responsible for the supranormal plasma 
volume in non-pregnant Hb SS women is one that involves a reduction in the 
excretion of sodium. However there is no correlation between PV measurements and 
any of the sodium controlling hormones measured in them. It is therefore possible 
that there are several factors controlling the PV, that there is a single factor that was 
not measured, perhaps ANP or prostacyclin, both of which are natriuretic (Pocock, 
2004) or that the reduction in sodium excretion is primarily a renal compensation 
mechanism. 
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5.3. PREGNANT WOMEN 
5.3.1. Haematological variables  
The lower haemoglobin concentration, haematocrit and red cell count, and higher 
white cell count, neutrophils, lymphocytes and platelets when compared to Hb AA 
women, is as expected. However, unlike in the non-pregnant women, the degree of 
scatter in the Hb SS women was similar to that in the AA women except for platelet 
count in which the scatter was significantly higher than that in Hb AA. This suggests 
a relative haematological homogeneity in Hb SS women in pregnancy. This could be 
due to the physiological demands of pregnancy or that it is only those Hb SS women 
with certain haematological or physiological capabilities who can achieve pregnancy 
and thus manifest similar traits when pregnant. 
 
5.3.2. Plasma volume measurements 
The only other reported study of plasma volume measurement in sickle cell disease 
in pregnancy (Abudu & Sofola, 1988) had some similarities as well as differences 
from my findings. They found no significant difference in mean plasma volume 
between Hb AA and Hb SS women at 16 weeks, as I did. However, at 36 weeks 
gestation, I found no significant difference in mean plasma volume between the two 
genotypes whilst Abudu et al found a significant reduction in plasma volume in the 
Hb SS women, compared to the Hb AA. 
 
What was clear with my findings was that women with SCD did not have a 
significant change in their plasma volume (PV) during pregnancy, or between the 
non-pregnant state and pregnancy. Hb AA women however behaved as expected 
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with a significant rise in PV and PV/BSA at 36 weeks and in PV at 16 weeks. All 
the hormone levels also rose in them as expected in pregnancy.  
 
The reason for the constancy of PV in the Hb SS women is unclear. PRC did not rise 
at 36 weeks from the value at 16 weeks: 
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Figure 5.1. Boxplots of PRC across genotypes and in the gestational age groups. 
 
whereas PRC continued to rise in HbAA women, and was also significantly lower at 
36 weeks and in pregnancy overall than that in Hb AA pregnancy. It is possible that 
as Hb SS women enter pregnancy with an already raised plasma volume, the RAAS 
does not get activated as it usually would. This is because the usual response to a 
volume increase is a lack of activation of the RAAS (Ganong, 2005). If this were to 
be the case, I would expect PRC to be low from early in pregnancy and for there to 
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be no rise or perhaps even a fall in plasma volume in Hb SS pregnancy. However, 
although there is no change in plasma volume, there is a rise in PRC at 16 weeks of 
the sickle cell pregnancies, albeit a smaller rise than in the Hb AA pregnancies at the 
same gestational age. It may therefore be that the RAAS initially responds to the 
usual arterial under-filling of pregnancy, which we presume occurs in the Hb SS 
women in early pregnancy as it does in Hb AA women (Al Kadi et al., 2005). 
However as the pregnancy progresses, PRC eventually falls in HbSS. A possible 
cause of this may be similar to that which occurs in pre-eclampsia, where there is 
thought to be a relative deficiency of prostacyclin (Fitzgerald et al., 1987; Granger 
et al., 2001) which leads to vasoconstriction and a reduction in renin concentration 
(Brown et al., 1997). A deficiency of other vasodilatory substances such as nitric 
oxide has also been postulated in pre-eclampsia (Begum et al., 1996; Savvidou et 
al., 2003).  
 
If vasoconstriction and a subsequent reduction in renin obtains, one would have 
expected aldosterone to be equally low or unchanged at 36 weeks. Renin is one of 
the main regulators of aldosterone secretion and changes in its concentration would 
be expected to be in the same direction as aldosterone concentration. However, in 
pregnancy, angiotensinogen, not renin, is rate-limiting in the synthesis of 
angiotensin II (Al Kadi et al., 2005) and plasma angiotensinogen concentrations 
were not significantly different in HbAA and HbSS women (Table 4.4). In women 
with preeclampsia and idiopathic intrauterine growth restriction (IUGR), aldosterone 
as well as renin concentration is reportedly low (Brown et al., 1992b). Although 
serum aldosterone was lower in Hb SS pregnant women, the difference was not 
statistically significant. Other authors have found aldosterone reduction in pre-
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eclamptic patients to be proportionally less than renin reduction. This was thought 
possibly to be due to a non-Angiotensin II dependent route of stimulation of 
aldosterone synthesis or release such as plasma potassium or atrial natriuretic 
peptide (Brown et al., 1997). Potassium increases aldosterone secretion by 
depolarizing the plasma membrane of zona glomerulosa cells and opening a voltage-
gated calcium channel, with a resultant increase in cytoplasmic calcium and the 
stimulation of calcium-dependent processes (King, 2010). In this study, plasma 
potassium was significantly higher in pregnant Hb SS women, which might explain 
the non-significant reduction of aldosterone despite the lower PRC. Although some 
of the relative hyperkalaemia could be attributed to in vitro haemolysis in the SS 
women, a common phenomenon in them (Serjeant & Serjeant, 2001), they are also 
known to have potassium secretory problems that result in high potassium levels 
(DeFronzo et al., 1979). 
 
Continuing with this line of thought, I would expect there to also be a fall in PV in 
the Hb SS women as is the case with pregnancies where the RAAS is inhibited, 
especially as both PRC and serum aldosterone are significantly correlated with PV at 
16 weeks gestation. A reduction in glomerular filtration could explain the lack of 
change in PV in them but an effect on GFR could not be shown due to limited 
available data. It is interesting to note that their urine volume did not change in 
pregnancy and in fact fell at 36 weeks from non-pregnant and 16 week values 
although this was not statistically significant. Meanwhile the urine volume of Hb 
AA women rose significantly in pregnancy as expected. As there is no increase in 
urine output, one can surmise that there is unlikely to be an increase in GFR either 
and it could explain the lack of change in PV despite the low PRC.  
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5.3.3. Plasma volume and birth weight 
Many authors have found a significant correlation between plasma volume (Pirani et 
al., 1973; Rosso et al., 1992; Salas et al., 1993), or at least an increment in plasma 
volume (Hytten & Paintin, 1963; Gibson, 1973) and birth weight especially in late 
pregnancy. However, a previous report on healthy pregnant women in my centre did 
not find any correlation in PV and birth weight at 30 or 36 weeks gestation (Abudu 
& Sofola, 1985). On analysing raw published data of healthy pregnant women in 
their third trimester from a study with a similar population to mine, I found no 
significant correlation either (Fig 5.1). In fact when I removed a possible outlier 
(circled) from the scatter plot, the relationship between plasma volume and birth 
weight was also negative though not significantly so. 
 
I was however surprised to find a significant negative correlation between PV and 
birth weight in pregnant Hb SS women at 36 weeks gestation. If plasma volume 
reflected the haematocrit or haemoglobin concentration in them, it may explain this 
phenomenon as one would expect a low haematocrit with a high plasma volume as 
well as a low haematocrit with a low birth weight. However, there was no significant 
correlation between birth weight and haematocrit or haemoglobin concentration, or 
between plasma volume and haematocrit or haemoglobin concentration. It appears 
that for Hb SS women at least, a raised plasma volume in late pregnancy is not a 
positive sign as it is associated with a lower birth weight. The numbers are too small 
to determine the possible reasons for this now.  
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Figure 5.2. A scatter plot showing the relationship between birth weight and plasma 
volume in healthy pregnant Nigerian women in their third trimester (N=20) 
(Harrison, 1966).  
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In summary, it is possible that Hb SS pregnant women have a generalised increase 
in peripheral resistance in late pregnancy leading to a reduction in some components 
of the RAAS, but do not reduce their plasma volumes from their pre-pregnant 
supranormal levels as their urine output remains the same in pregnancy.  There may 
be an abnormality at either the hypothalamo-pituitary level or in the renal sodium 
sensing system. To test this latter hypothesis I would need to measure vasodilatory 
substances such as prostacyclin and nitric oxide, and also explore the renal function 
of these women in late pregnancy. It might be possible also to study the effects of 
salt loading on renal function in non-pregnant HbSS women. 
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6. CONCLUSIONS 
This thesis attempts to increase the knowledge base concerning plasma volume and 
its hormonal and electrolyte determinants in pregnant women with sickle cell 
disorder.  
 
I was able to recruit and examine a considerable number of women with sickle cell 
disorder (49 in total), despite the invasive nature of the examination I had to carry 
out on them. This is only the second study ever to measure PV in pregnant women 
with SCD and the first to measure so many different variables in them – 24 different 
hormones, electrolytes and haematological parameters. I found that non-pregnant Hb 
SS women already had a supranormal plasma volume which did not increase 
significantly in pregnancy; thus unlike in uncomplicated pregnancy, pregnant 
women with sickle cell disorder did not expand their PV. I also found that although 
PRC rose in them at 16 weeks, it rose significantly less than it does in AA 
pregnancy and there was no further increase by 36 weeks unlike in AA pregnancy. 
Although aldosterone was increased in them as expected, the increase was to a lesser 
extent than in AA women and could have been due to non Angiotensin II dependent 
mechanisms. I surmised this lack of PV rise, therefore, to be due to a general 
vasoconstriction as pregnancy progresses in Hb SS women, caused by a deficiency 
of vasodilatory substances and similar to what occurs in pre-eclampsia, which 
prevents the RAAS and the PV in turn from rising. To support this hypothesis, I 
would need to prove that the aldosterone rise in SS women is significantly lower 
than that in AA women and that there is a relative deficiency of vasodilatory 
substances such as prostacyclin or nitric oxide in them.  
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I plan to research further on this subject by designing a study to examine plasma 
prostacyclin, nitric oxide and aldosterone concentrations. I would also like to 
measure GFR and other indices of renal function in both pregnant and non-pregnant 
women with sickle cell disorder. 
 
Another prospective study will look at the outcome of pregnancies of women with 
sickle cell disorder including the incidence of pre-eclampsia and other maternal 
complications as well as intrauterine growth restriction, prematurity and other 
perinatal complications.  
 
Finally, whilst carrying out the literature review, I found that there have been 
separate reports of enlarged cardiac chambers in pregnant and non-pregnant women 
with SCD respectively. I would like to carry out blinded echocardiographic 
measurements in a comparative study of both pregnant and non-pregnant women to 
see if their cardiac chambers are larger during pregnancy and if they revert to normal 
postpartum. 
 
The ideal would have been to perform a longitudinal study and continue to measure 
the same women up to 8 weeks post-partum, which was my initial intention. 
However, due to several constraints (see section 2.9.6), I could only do a cross-
sectional one. As a result of this change in methodology, a lot of data could not be 
used. Data from 34 women was not used for this reason mainly because, in order to 
avoid autocorrelation, which is the likelihood of all data from the same woman to 
behave in the same way, all repeated measures of the women had to be removed. 
This reduced the power of the study. If I were starting this study all over again, I 
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would carry out a cross-sectional study ab initio and thus ensure that I measure each 
woman only once and achieve recruitment of my full sample size with fewer 
resources and less time wasted.  I would also prefer to use another method for 
measuring PV that is more accurate than Evans blue such as Dextran 70 (see section 
2.9.4).  
 
In conclusion, this thesis was the first to investigate reasons for the lack of PV rise 
in pregnant Hb SS women and to examine so many hormones and electrolytes in 
them. It showed that with perseverance and organisation, it is possible to obtain 
meaningful results from such a major study, in an environment with relatively poor 
infrastructure such as Nigeria. It also provides more ideas for research into the 
apparently saturated area of blood pressure in pregnancy.
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APPENDIX 1 
RESEARCH INFORMATION SHEET FOR VOLUNTEERS 
Title of Project 
Plasma volume expansion and osmoregulatory hormones in pregnant patients 
with sickle cell disorder 
Name of Investigator 
Dr Bosede AFOLABI (Consultant Obstetrician and Gynaecologist). 
Background 
There is a blood condition known as sickle cell disorder, which is very common 
in Nigeria. Women with sickle cell disorder usually have more problems in 
pregnancy and smaller babies. We know that women whose plasma (the liquid 
part of blood) increases in pregnancy usually have good-sized babies. A 
previous study done in this hospital found that the plasma of women with sickle 
cell does not rise much in pregnancy.  
 
We wish to try to discover the cause of this in the hope that we can correct the 
problem in future. We will need pregnant women and non-pregnant women, both 
with sickle cell disease and without i.e. Haemoglobin AA women.  
What does the study involve? 
We will admit you to a comfortable ward for 24 hours. For non-pregnant 
women, this will only be once while for pregnant women, you will need to be 
admitted 3 times – at 16 and 36 weeks of pregnancy, and 8 weeks after delivery. 
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The admissions will be at no cost to you. 
 
To measure the plasma, a small amount of a substance called Evans blue will be 
injected into your veins. This dose is completely safe and has been used 
thousands of times in both pregnant and non-pregnant human beings.  
 
Also, we will take a little blood from you and ask you to collect all your urine so 
we can test it as well.  
 
The admission is because of the urine collection. If you would prefer not to be 
admitted, we can arrange for you to collect your urine at home and just come in 
with it for your blood tests. 
What are the side effects of taking part?     
The insertion of the small tube for the injection (just like when on ‘drip’) may 
be associated with slight pain. There are no other risks of taking part.  
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RESEARCH VOLUNTEERS CONSENT FORM 
Title of Project: 
Plasma volume expansion and osmoregulatory hormones in pregnant patients 
with sickle cell disorder 
 
Please read this form and sign it once the investigator or her representative has 
explained fully the aims and procedures of the study to you: 
• I agree to take part in this study 
• I confirm that I fully understand the attached information sheet. 
• I authorise the investigator to disclose the results of my participation in 
the study but not my name. 
• I understand I am free to withdraw from this study at any time without 
having to give a reason for withdrawing. 
• I confirm that I have disclosed relevant medical information before the 
study. 
Name:__________________________________________________________ 
Address:________________________________________________________ 
_______________________________________________________________ 
Telephone number:________________________________________________ 
Signature:_______________________________________________________ 
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APPENDIX 2 
INSTRUCTIONS TO VOLUNTEERS AND PATIENTS REGARDING 24-
HOUR URINE COLLECTION 
 
1. To begin your 24-hour collection, empty your bladder (pass urine) and flush 
urine down the toilet.  
 
2. Record the date and time you emptied your bladder on the label attached to 
your 24-hour urine container. 
 
3. For the next 24 hours, add ALL urine that you pass into the container. 
Refrigerate container between additions if possible. 
 
4. When you are about to have your bath, pass urine before and after and add to 
the container. Ensure you do not pass urine away DURING your bath.  
 
5. Even when you go to pass stool, collect the urine beforehand and add it to the 
container; don’t let it run into the toilet.  
 
6. End collection 24 hours after start time by emptying bladder at the same time 
you started but on the next day and adding the final sample to the collection 
container. 
 
7. Record the ending date and time on the label attached to your 24-hour urine 
container. 
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APPENDIX 3 
ALDOSTERONE ASSAY 
Reagent preparation 
All standards and controls were in ready-to-use solutions. Wash buffer 
concentrate was prepared by diluting 50ml concentrate in 450ml water (1:10 
dilution). The Aldosterone-Avidin Horseradish-peroxidase (HRP) conjugate was 
also prepared as in the instructions. All reagents were allowed to equilibrate to 
room temperature before use.  
 
About 250µl of wash buffer was dispensed to all wells and aspirated after 
mixing for 5 seconds. 50µl of standards and samples were then pipetted into 
appropriate wells immediately so the wells were not allowed to dry at any time. 
One well was saved for a blank and nothing was added. 100µl of (1:50) Avidin 
conjugate solution was added to each well except the blank. This was mixed 
gently for 10 seconds and incubated at room temperature for 60 minutes on a 
plate shaker set at 200 rpm. 
The reaction mixture was removed and the plate washed three times with wash 
buffer, tapping the plates over paper towels between washings. 150µl of 
Tetramethyl benzidine (TMB) substrate solution was added to each well – blue 
colour developed. This was mixed gently for 10 seconds, the plate was covered 
and incubated at room temperature for 15 minutes on the plate shaker or until 
calibrator A attained the dark blue colour for the desired optical density. 
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The reaction was stopped by adding 50µl of Stop solution to the wells. This was 
mixed gently for 10 seconds whereupon the blue colour turned yellow. The 
absorbance was measured at 450 nm using an automated ELISA reader (Stat Fax 
2100) reader within 15-20 minutes.    
  
Calculation of results 
All tests (i.e. standards and controls) were done in duplicate. The mean 
absorbance of standards and samples were calculated and the blank values are 
subtracted. The standard curve and concentrations of all samples were plotted 
and calculated automatically by the ELISA reader.  
ARGININE-VASOPRESSIN ASSAY 
Extraction procedure 
In order to have accurate determinations of vasopressin, extraction of the 
samples is recommended. Ice-cold acetone of twice the sample volume was 
added to the sample, vortex-mixed and centrifuged at 12000g for 20 minutes. 
The supernatant was aspirated and transferred to a new tube and five times its 
volume of ice cold petroleum ether was added, vortex-mixed and centrifuged at 
10000g for 10 minutes. The top ether layer was discarded and the remaining 
aqueous layer was transferred to a glass tube and dried down under gas. The 
sample was reconstituted with assay buffer at the time of assay. 
Reagent preparation 
All reagents were allowed to equilibrate to room temperature.  
The Vasopressin Standard: Serial dilutions were made from a stock standard of 
10,000pg/ml into 7 tubes using the assay buffer (Concentrations of vasopressin 
were 1000, 400, 160, 64, 25.6, 10.24 and 4.10pg/ml for tubes #1- #7). The wash 
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buffer was prepared by diluting 5ml of the concentrate with 95ml of deionised 
water. The maximum binding (Bo) well was 100% bound and had 0pg/ml of 
vasopressin; the non-specific binding (NSB) well was 0.00% bound. These were 
used in calculating the % bound and the results of the samples. 
 
 
Assay procedure 
All the standards and samples were run in duplicate. The appropriate number of 
wells was laid out and 100µl of assay buffer was pipetted into the NSB and the 
Bo wells. 100µl of standards and samples were pipetted into the appropriate 
wells.   
50ul of assay buffer was pipetted into each of the NSB wells. Finally 50µl of the 
blue conjugate was added into each well except the Total Activity (TA) and 
Blank wells.  
At this point all the used wells were green in colour except the NSB wells, 
which were blue. The Blank and TA wells were empty. 
 
The plate was tapped gently, sealed and incubated at 40C for 24 hours. The plate 
contents were emptied and washed by adding 400µl of wash solution to every 
well; this was repeated twice for a total of 3 washes. After the final wash, the 
wells were emptied and the plate tapped dry on a lint free paper towel. 
 
5ul of the blue conjugate was then added to the TA wells. 200µl of the p-
NitroPhenyl Phosphate (pNpp) substrate solution was added to every well and 
incubated at room temperature without shaking. Finally, 50µl of Stop solution 
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was added to every well and the plate read immediately using an automated 
ELISA reader (Stat Fax 2100) with primary filter of 405nm and secondary filter 
of 570nm.   
Calculation of results 
The average net optical density (OD) for each standard and sample were 
calculated as follows:       
Average Net OD = Average Bound OD – Average NSB OD. Percent Bound = 
Net OD/Net Bo OD x 100. 
Using Log paper, the percent bound versus the concentration of AVP was plotted 
for the standards. A straight line was approximated through the points and the 
concentration of AVP in the samples was interpolated from the curve. 
 
PROGESTERONE ASSAY 
Principle 
The progesterone EIA is based on the principle of competitive binding between 
progesterone in the test specimen and progesterone –HRP conjugate for a 
constant amount of rabbit anti-progesterone. 
Reagent preparation 
All reagents were allowed to equilibrate to room temperature before use.  
Working Progesterone-HRP conjugate reagent was reconstituted according to 
manufacturer’s instructions.  
Assay procedure 
25µl of standards, specimens and controls were dispensed into the appropriate 
wells. 100µl of Working Reagent and 50µl of rabbit anti-progesterone reagent 
was dispensed into wells. The wells were vortex mixed for 30 seconds and 
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incubated at room temperature for 90 minutes. The microwells were rinsed and 
flicked 5 times with distilled water. 100µl of TMB reagent was dispensed into 
each well and gently mixed for 10 seconds. This was then incubated again at 
room temperature for 20 minutes and the reaction stopped by adding 100µl of 
Stop solution to each well and gently mixed for 30 seconds to ensure that all the 
blue colour changed to yellow completely. The absorbance was read at 450nm 
with a microtiter automated well reader (Stat Fax 2100) within 15 minutes.    
Calculation of results 
The microwell reader plotted the standard curve and gave concentrations of all 
samples analysed in ng/ml.  
PROLACTIN ASSAY 
Principle 
The prolactin quantitative test kit was based on a solid phase ELISA. The assay 
system utilised an anti-prolactin antibody for solid phase immobilization and 
another mouse monoclonal antiprolactin antibody in the antibody-enzyme 
conjugate solution. 
Reagent preparation 
All reagents were equilibrated to room temperature before use. Lyophilized 
standards were reconstituted with distilled water and allowed to stand for 20 
minutes before mixing.  
Assay procedures 
50µl of standard, specimens and controls were dispensed into appropriate wells. 
50µl of enzyme conjugate reagent was also dispensed into each well, vortex 
mixed for 10 seconds and then incubated at 370C for 30 minutes. The incubation 
mixture was removed and the contents flicked into the sink. The microtiter wells 
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were rinsed and flicked 5 times with distilled water. 100µl of TMB solution was 
dispensed into each well and gently mixed for 5 seconds. The reaction wells 
were incubated at room temperature for 10 minutes and the reaction stopped by 
adding 100 l of Stop solution to each well. This was then gently mixed for 5 
seconds until the entire blue colour changed to yellow completely. The 
absorbances were read at 450nm and concentration of samples calculated from a 
standard curve by an automated microtiter well reader (Stat Fax 2100). 
 
OSMOLALITY MEASUREMENTS 
The Wescor Vapor Pressure Osmometer (Wescor Inc, Utah, USA) was used for 
all the osmolality measurements.  
Procedure 
The instrument was allowed to warm up for about 20 minutes and then it was 
calibrated using the 290mmol/Kg and then the 1000mmol/Kg standards. The 
100mmol/Kg standard was processed to determine the cleanliness of the 
thermocouple. A set of controls (low, normal and high) provided by the 
manufacturers was assayed with each batch of samples. 10µl sample of the 
plasma or urine was pipetted onto a small solute-free paper disc that was then 
inserted into a sample chamber and sealed. The dew point temperature 
depression, which is a function of solution vapour pressure, was then measured 
and displayed.  
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CREATININE 
Reagents 
1. Base – Disodium Phosphate  (6.4mmol/l) and Sodium hydroxide 
(150mmol/l) 
2. Dye – Sodium dodecyl sulphate (0.75mmol/l) and picric acid (4mmol/l) 
at pH 4 
3. Creatinine Standard – 2mg/dl (177umol/l) 
Working reagent: equal volumes of base and dye. 
Procedure 
Standards and samples were not measured in duplicates as the method had been 
validated and in use in our laboratory for many years. Each batch was run with 
controls and this guided the reporting of results. The Westgard rule of 2 SD was 
used to accept or reject runs.  
 
ELECTROLYTES ASSAY (SODIUM AND POTASSIUM) 
Principle  
Plasma separated from lithium heparin tubes was used.  
 
 
 Equipments and Reagents 
• Jenway Flame Photometer by Barloworld Scientific 
• 10ml Bijou Bottles 
• Adjustable micropipette (100-1000ul) 
• Deionised water 
• Sodium/Potassium commercial standard 
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• Sodium/Potassium commercial control 
 
Procedure 
The flame of the photometer was ignited and adjusted. 1:100 dilution of 
standard/control/samples were made into bijou bottles and mixed gently. The 
standards were assayed and so were the samples and controls. The concentration 
of sodium and potassium were displayed on the readout apparatus. As with 
creatinine, standards and samples were not measured in duplicate as the method 
has been validated and been in use in our laboratory for many years. 
 
PLASMA ANGIOTENSINOGEN (AOGEN) CONCENTRATION (PAC) 
ASSAY 
 
Determination of endogenous (sample) Aogen in the presence of excess 
exogenous Renin using an indirect radioimmunoassay (RIA) for Angiotensin-I 
(A1) 
 
Molar excess of human renin was added to highly diluted plasma samples 
(containing Aogen). Under these conditions the amount of Aogen substrate is the 
rate-limiting factor in the production of A1. Thus the amount of A1 produced over a 
given period of time is directly relative to the starting amounts of Aogen substrate. 
Relative concentrations of sample Aogen were determined by comparing the 
concentrations of A1 produced in a set period (usually 2hrs) in each sample.  
 
Materials: 
Acetone (Fisher Scientific – A/0600/PB17) 
Acid washed activated charcoal (Sigma – C5510) 
Angiotensin-I 125I (NEN, Perkin Elmer) 
Bovine Serum Albumin (BSA) (Sigma – A7030) 
Dextran (Sigma – D4876) 
Dimercalprol 
EDTA (disodium, Sigma – E5134) 
8-Hydroxyquinoline (hemi) sulphate (8-HQS)(Sigma – H6752) 
Disodium hydrogen (ortho) phosphate [dibasic sodium phosphate] (Sigma – S3264) 
Sodium dihydrogen (ortho) phosphate [monobasic sodium phosphate] (Sigma – 
S3139) 
Sodium Chloride (Fisher Scientific – S/3160/63) 
 
 
 
 
 176
Preparation: 
Sufficient quantities of Buffer ‘B’ (Buffer ‘A’ containing 0.3% BSA) were 
determined and made up. 0.6ml eppendorfs, LB3 and LP5 tubes were labelled as 
appropriate. Water bath was set at 37oC. The centrifuge was pre-cooled and all 
procedures performed at 4oC or less.  
 
Procedure 
 
 
1. The samples were diluted as follows: 10µl in 10ml Buffer ‘A’. 
 
 
2. One tube of human renin (5ml) was added to 5ml buffer ‘A’. Angiotensinase 
inhibitors were added to the 10 ml as follows: 0.1ml/ml (1ml) 0.3M EDTA; 
0.05ml/ml (0.5ml) 8-HQS; 0.01ml/ml (100µl) dimercalprol injection. 
 
3. To 400µl of each diluted sample, 100µl of the prepared human Renin/Buffer ‘A’ 
(see 2. above) was added and mixed well. 
 
4. 100µl (0hr time point) was added to a fresh 0.6ml eppendorf. The remaining 
400µl was placed into a water bath preheated to 37oC and incubated for 2 hours. 
 
5. An equal volume (100µl) of ice-cold acetone was immediately added to each 
100µl (0hr time point from 3. above). 
 
6. This was mixed and centrifuged at 2500rpm for 10 minutes at 4oC. 
 
7. 100µl of the supernatant was transferred to LP3 tubes containing 400µl of Buffer 
‘B’ (Buffer ‘A’/0.3% BSA, see appendix ‘A’), and held under ‘cling-wrap’ at 4oC 
until the 2hr time point samples had reached the same stage. 
 
8. Standard Curve preparation. 
The A1 serial dilutions were prepared as below:- 
 
1st dil: 10µl of 1mg/ml A1 was added to 50ml of 0.9% Saline (NaCl2) [200.0pg/µl]. 
2nd dil: 1ml of above dilution was added to 4ml Buffer ‘A’/0.3% BSA [40.0pg/µl]. 
Seven LP3 tubes ‘A’ to ‘G’ were labelled and 1ml Buffer ‘A’/0.3% BSA was added 
to each.  
 
Std.        Tubes. 
‘A’: 1ml of 2nd dilution into 1ml Buffer ‘B’ [20.0pg/µl]. 25,26,27. 
‘B’: 1ml of ‘A’ into 1ml Buffer ‘B’ [10.0pg/µl].  22,23,24. 
‘C’: 1ml of ‘B’ into 1ml Buffer ‘B’ [5.0pg/µl].  19,20,21. 
‘D’: 1ml of ‘C’ into 1ml Buffer ‘B’ [2.5pg/µl].  16,17,18. 
‘E’: 1ml of ‘D’ into 1ml Buffer ‘B’ [1.25pg/µl].  13,14,15. 
‘F’: 1ml of ‘E’ into 1ml Buffer ‘B’ [0.625pg/µl].  10,11,12. 
‘G’: 1ml of ‘F’ into 1ml Buffer ‘B’ [0.3125pg/µl].  7, 8, 9. 
 
The first 27 tubes were utilised for the standards. 
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1-3 Non-specific binding (NSB) 
4-6 Nil Standard 
7-27 Standards as above 
 
To tubes 1 – 3 (NSBs), 450µl Buffer ‘B’ was added, to tubes 4 – 6 (Nil stds), 400µl 
Buffer ‘B’ was added, and to tubes 7 – 27, 300µl Buffer ‘B’ and 100µl of the 
relevant standard were added (as above).  
 
N.B. The total amounts of A1 in each 100µl of standard was ‘A’ – 2000pg, ‘B’  - 
1000pg, ‘C’ – 500pg, ‘D’ – 250pg, ‘E’ – 125pg, ‘F’ – 62.5pg, ‘G’ – 31.25pg, and 
Nil stds – 0.00pg. 
 
5ml of Buffer ‘B’ was placed into a universal tube and 5ml of ice-cold acetone was 
added. This was mixed well and centrifuged at 2500rpm for 10 minutes at 4oC. Then 
100µl was added to all the Standard curve tubes (1 – 27 inclusive). 
 
The standard curve tubes were held under ‘cling-wrap’ at 4oC while Aogen samples 
completed their 2hr incubation. 
 
9. After 2hrs, 300µl of the incubated Aogen samples was transferred to fresh 0.6ml 
eppendorfs and equal volumes (300µl) of ice-cold acetone were added. 
 
10. These were mixed and centrifuged at 2500rpm for 10 minutes at 4oC. 
 
11. 100µl of the supernatant was transferred to three separate LP3 tubes containing 
400µl of Buffer ‘B’. 
 
12. 50µl of freshly prepared Angiotensin I -125I was added to every tube (standards 
and samples). 
 
13. 50µl of freshly diluted antiserum was added to all tubes except 1, 2 and 3. 
 
14. These were mixed well and incubated under ‘cling-wrap’ at 4oC for at least 48 
hours. 
 
15. After incubation – 500µl of Dextran coated charcoal suspension (freshly 
diluted 1part + 3parts Buffer ‘B’) was added and centrifuged at 2500rpm for 15 
minutes at 4oC. Free A1 (both hot and cold) was trapped in the pellet while the 
antibody ‘bound’ A1 remained in solution in the supernatant.  
 
16. The supernatant was decanted into another LP3 tube and radioactivity of both 
the pellet and the supernatant was counted using a Gamma counter. 
 
Calculations 
 
The gamma counter on board software was utilised to calculate the % of total 
sample radioactivity in each fraction and this was used to derive from the standard 
curve the quantity of A1 in each of the fractions. 
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The mean amount of A1at the 2-hour time point was calculated and the zero time 
point amount was subtracted from it. This gave the amount of A1 in pg for each 
sample (X). 
 
To correct for the original dilution and convert to µg of A1 per ml, the following 
formula was used: (‘X’/1000) x 25. 
 
 
PLASMA RENIN CONCENTRATION (PRC) ASSAY 
 
Determination of endogenous renin in the presence of excess exogenous 
Angiotensinogen (Aogen) substrate using an indirect radioimmunoassay (RIA) 
of Angiotensin-I production 
 
Molar excess of sheep angiotensinogen (Aogen) substrate was added to undiluted 
plasma samples (containing renin). Under these conditions the amount of renin 
available is the rate-limiting factor in the production of A1. Thus the rate of A1 
production over a given period of time is directly relative to the specific activity of 
renin and thus to the amount of active Renin. Therefore relative amounts of sample 
renin were determined by comparing the rates of A1 production over a set period 
(usually 2hrs) in each sample.  
 
Materials: 
Acetone (Fisher Scientific – A/0600/PB17) 
Acid washed activated charcoal (Sigma – C5510) 
Angiotensin-I 125I (NEN, Perkin Elmer) 
Bovine Serum Albumin (BSA) (Sigma – A7030) 
Dextran (Sigma – D4876) 
Dimercalprol 
EDTA (disodium, Sigma – E5134) 
8-Hydroxyquinoline (hemi) sulphate (8-HQS)(Sigma – H6752) 
Disodium hydrogen (ortho) phosphate [dibasic sodium phosphate] (Sigma – S3264) 
Sodium dihydrogen (ortho) phosphate [monobasic sodium phosphate] (Sigma – 
S3139) 
Sodium Chloride (Fisher Scientific – S/3160/63) 
 
 
Preparation: 
Sufficient quantities of Buffer ‘B’ (Buffer ‘A’ containing 0.3% BSA) were 
determined and made up. 0.6ml eppendorfs, LB3 and LP5 tubes were labelled as 
appropriate. Water bath was set at 37oC. The centrifuge was pre-cooled and all 
procedures performed at 4oC or less.  
 
 
1. One tube of Sheep substrate (Aogen, 5ml) was added to 5ml buffer ‘A’. 
Angiotensinase inhibitors was added to the 10ml: 0.1ml/ml (1ml) 0.3M EDTA; 
0.05ml/ml (0.5ml) 8-HQS; 0.01ml/ml (100µl) dimercalprol injection. 
 
2. 400µl of the prepared sheep Aogen/Buffer ‘A’ (see 1. above) was added to 200µl 
of each undiluted sample, and mixed well. 
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3. 100µl (0hr time point) was transferred to a fresh 0.6ml eppendorf. The remaining 
400µl was placed into a water bath preheated to 37oC and incubated for 2 hours. 
 
4. An equal volume (100µl) of ice-cold acetone was immediately added to each 
100µl (0hr time point from 2. above). 
 
5. This was centrifuged at 2500rpm for 10 minutes at 4oC. 
 
6. 100µl of the supernatant was transferred to LP3 tubes containing 400µl of Buffer 
‘B’, and held under ‘cling-wrap’ at 4oC until the other time point samples had 
reached the same stage. 
 
7. Steps 2 – 5 were repeated after a further 30min, 1hr and 2hrs of incubation. 
 
8. Standard Curve preparation. 
Prepare A1 serial dilutions as below:- 
 
1st dil: 10µl of 1mg/ml A1 was added to 50ml of 0.9% Saline (NaCl2) [200.0pg/µl]. 
2nd dil: 1ml of above dilution was added to 4ml Buffer ‘A’/0.3% BSA [40.0pg/µl]. 
Seven LP3 tubes ‘A’ to ‘G’ were labelled and 1ml Buffer ‘A’/0.3% BSA was added 
to each. 
 
Std.        Tubes. 
‘A’: 1ml of 2nd dilution into 1ml Buffer ‘B’ [20.0pg/µl]. 25,26,27. 
‘B’: 1ml of ‘A’ into 1ml Buffer ‘B’ [10.0pg/µl].  22,23,24. 
‘C’: 1ml of ‘B’ into 1ml Buffer ‘B’ [5.0pg/µl].  19,20,21. 
‘D’: 1ml of ‘C’ into 1ml Buffer ‘B’ [2.5pg/µl].  16,17,18. 
‘E’: 1ml of ‘D’ into 1ml Buffer ‘B’ [1.25pg/µl].  13,14,15. 
‘F’: 1ml of ‘E’ into 1ml Buffer ‘B’ [0.625pg/µl].  10,11,12. 
‘G’: 1ml of ‘F’ into 1ml Buffer ‘B’ [0.3125pg/µl].  7, 8, 9. 
 
The first 27 tubes were utilised for the standards. 
 
1-3  Non-specific binding (NSB) 
4-6  Nil Standard 
7-27 Standards as above 
 
To tubes 1 – 3 (NSBs), 450µl Buffer ‘B’ was added, to tubes 4 – 6 (Nil stds), 400µl 
Buffer ‘B’ was added, and to tubes 7 – 27, 300µl Buffer ‘B’ and 100µl of the 
relevant standard were added (as above). 
 
N.B. The total amounts of A1 in each 100µl of standard was ‘A’ – 2000pg, ‘B’  - 
1000pg, ‘C’ – 500pg, ‘D’ – 250pg, ‘E’ – 125pg, ‘F’ – 62.5pg, ‘G’ – 31.25pg, and 
Nil stds – 0.00pg. 
 
5ml of Buffer ‘B’ was placed into a universal tube and 5ml of ice-cold acetone was 
added. This was mixed well and centrifuged at 2500rpm for 10 minutes at 4oC. Then 
100µl was added to all the Standard curve tubes (1 – 27 inclusive). The standard 
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curve tubes were held under ‘cling-wrap’ at 4oC while Aogen samples completed 
their 2hr incubation. 
 
9. 50µl of freshly prepared Angiotensin I -125I was added to every tube (standards 
and samples). 
 
10. 50µl of freshly diluted antiserum was added to all tubes except 1, 2 and 3. 
 
11. These were mixed well and incubated under ‘cling-wrap’ at 4oC for at least 48 
hours. 
 
12. After incubation, 500µl of Dextran coated charcoal suspension (freshly diluted 
1part + 3parts Buffer ‘B’) was added and centrifuged at 2500rpm for 15 minutes at 
4oC. Free A1 (both hot and cold) was trapped in the pellet while the antibody 
‘bound’ A1 remained in solution in the supernatant.  
  
 
13. The supernatant was decanted into another LP3 tube and radioactivity of both 
the pellet and the supernatant was counted using a Gamma counter. 
 
Calculations 
 
The gamma counter on board software was utilised to calculate the % of total 
sample radioactivity in each fraction and this was used to derive from the standard 
curve the quantity of A1 in each of the fractions. This was in pg for each sample. 
 
‘EXCEL’ was used to determine (for each set of 4 time points – 0hr, 30min, 60min, 
120min) the slope (m) and the intersection point of the line on the ‘y’ axis (c). Using 
the formula y = mx + c, y was deduced when x = 60min. This gave pg/hr, which was 
divided by 1000 to convert to ng/hr and multiplied by 60 (the correction factor for 
this assay) to give ng/ml/hr. 
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APPENDIX 4 
WORKSHEET FOR PLASMA VOLUME EXPERIMENT 
Materials 
Evans blue dye – 15 ml 
20ml syringes x 3 
5ml syringe x 5 
10ml syringe x 2 
Pink intravenous cannula (20 gauge) x 2 
3-way tap 
Heparin saline (Hepsal) 1000IU in 100ml saline 
Stopwatch 
Prelabelled tubes – three plain (STANDARD-15ml), three plain (labelled 10, 20 
and 30 minutes), one LiH (3ml), one cold EDTA (4ml), one EDTA (2ml)  
Cotton wool 
Spirit 
Tourniquet 
Plaster 
 
Procedure 
Put ice in flask or icebox and precool EDTA bottle.  
Put 15 ml of Evans blue dye into a 20 ml syringe. 
Fill 2 syringes with Hepsal, one 10ml syringe and one 5ml. 
Pre label tubes. 
2 kidney dishes – 1 by patient, 1 for syringes. 
 
Insert cannula into arm. Take out 25ml blood and put gently into the specimen 
bottles as per volumes stated above. Attach 3-way tap, push in some Hepsal and 
stick down with plaster. Close 3-way tap. Set the stopwatch to 10 minutes. 
 
Inject 15 ml of Evans blue dye into the cannula through the pink stopper of the 
cannula itself (not the 3-way tap). As you start the injection, start the stopwatch. 
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This should all go in within one minute. Then flush the cannula with hepsal 
through the pink covered outlet and through the 3-way tap, till all traces of dye 
are gone. Push in about one millilitre more of Hepsal and close 3-way tap. 
 
When the stopwatch reads 1min 30 seconds, withdraw about 5ml of blood into 
the syringe with hepsal in it. Then position an empty 5ml syringe and start 
withdrawing 5ml of blood, slowly into it when the stopwatch reads 10 seconds. 
As soon as the stopwatch begins to beep, press the Start/Stop button, 3 times, 
while still continuing to withdraw blood into the 5ml syringe, gently with the 
other hand. Hand the 5 ml syringe to your assistant to empty gently into the 10 
minutes plain bottle. Push in 5ml of the blood and hepsal mixture.  
 
Repeat the cycle again 10 minutes after and another 10 minutes after, putting the 
blood into the 20 and 30-minute plain bottles, respectively. Re-inject all the 
blood/hepsal mixture after the 30-minute sample has been taken.  
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APPENDIX 5 
 
PATIENT BIODATA FOR SICKLE CELL PLASMA VOLUME 
RESEARCH 
Name:  
Date of birth:  
Address: 
 Home:  
 Business:  
Phone number (s):  
Occupation:  
Genotype (patient’s account):  
Genotype (confirmed): 
Weight:  
Height:  
Body mass index: 
Current medication and doses:  
LMP: (first day of Last Menstrual Period):  
Parity: 
Pregnant patients: 
Gestational age by LMP:  
Gestational age by scan …….. done on…………(date of scan).  
  
Date: 
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APPENDIX 6 
STUDY RAW DATA 
 
subjno age parity weight height BMI genotype gestage plasvol BSA2 PVBSA2 plvolwt PVBMI PRC AOGEN 
0130 37 1 62 1.7 21.45329 1 0 2460.88 1.711075 1438.207 39.69161 114.7088 41.06 0 
0103 26 0 51.5 1.55 21.436 1 0 1112 1.489081 746.7695 21.59223 51.87534 2.613992 0.948234 
0038 25 0 72 1.6 28.125 1 0 1977.4 1.788854 1105.4 27.46389 70.30756 16.91872 1.239812 
0001 25 0 57.5 1.72 19.43618 1 0 2594.7 1.657475 1565.454 45.12522 133.4984 47.88 0.66 
0046 25 0 45.5 1.64 16.91701 1 0 2168.2 1.439714 1505.993 47.65275 128.1668 7.839511 1.203786 
0027 20 0 43.5 1.6 16.99219 1 0 1551.2 1.390444 1115.615 35.65977 91.28901   
0011 22 0 56.5 1.59 22.3488 1 0 2410.4 1.579689 1525.87 42.66195 107.8537 35.6092 0.461682 
0024 20 0 61 1.7 21.10727 1 0 1845.4 1.69722 1087.308 30.25246 87.42961 6.48173 0.679636 
0030 22 0 59.5 1.55 24.76587 1 0 2432.7 1.600564 1519.902 40.88571 98.22793 10.86614 1.847692 
0018 25 0 59 1.59 23.33768 1 0 2449.6 1.614259 1517.476 41.51864 104.9633 6.891238 1.225662 
0009 26 0 60 1.64 22.30815 1 0 2506.6 1.65328 1516.138 41.77667 112.3625 20.72693 0.334745 
0012 18 0 60 1.7 20.76125 1 0 1977.4 1.683251 1174.751 32.95667 95.24477 20.81083 0.997589 
0017 27 0 59 1.63 22.20633 1 0 2489.4 1.634438 1523.092 42.19322 112.1032   
0021 27 0 62.5 1.67 22.41027 1 0 2189.9 1.702735 1286.108 35.0384 97.71859 14.77 0 
0048 29 0 62 1.48 28.30533 1 0 1336.87 1.596524 837.3629 21.56242 47.23032 4.220426 1.183588 
0004 25 0 66.75 1.65 24.51791 1 0 3105.2 1.749107 1775.306 46.51985 126.6503 14.3122  
0010 31 0 59 1.66 21.41095 1 0 2355.5 1.649411 1428.086 39.92373 110.0138 3.70515 0.449688 
0013 22 0 67 1.65 24.60973 1 0 1607.3 1.752379 917.2101 23.98955 65.31156 9.753348 1.142139 
0005 25 0 85.1 1.72 28.76555 1 0 2565 2.016405 1272.066 30.14101 89.16917   
0068 25 0 67.5 1.65 24.79339 1 1 2432.72 1.758906 1383.087 36.0403 98.11971 23.26645 1.902966 
0041 27 0 64.5 1.64 23.98126 1 1 3076.7 1.714157 1794.877 47.70078 128.296   
0003 37 2 60.6 1.64 22.53123 1 1 2118.8 1.661525 1275.214 34.9637 94.03836 106.0539 1.663572 
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subjno age parity weight height BMI genotype gestage plasvol BSA2 PVBSA2 plvolwt PVBMI PRC AOGEN 
0045 24 0 71 1.71 24.28098 1 1 2270.3 1.836437 1236.253 31.97606 93.50119 42.50193 2.185199 
0064 28 0 64.5 1.64 23.98126 1 1 4084.07 1.714157 2382.553 63.31892 170.3026 15.77626 1.518032 
0042 24 0 74.5 1.57 30.22435 1 1 2667.4 1.802506 1479.829 35.80403 88.25335 34.90201 0.865847 
0031 32 3 81 1.67 29.04371 1 1 4689.11 1.938427 2419.028 57.89025 161.4501 17.77761 3.308612 
0006 27 2 87 1.7 30.10381 1 1 1324.6 2.026902 653.5095 15.22529 44.00108 29.17624 0.355314 
0015 28 3 91.5 1.74 30.22196 1 1 2606.7 2.102974 1239.53 28.48853 86.25186   
0014 36 2 78 1.59 30.85321 1 1 3837.9 1.856071 2067.755 49.20385 124.3922 64.02482 2.082923 
0114 31 0 90.5 1.69 31.68657 1 2 4376.14 2.061182 2123.121 48.35514 138.1071 98.87 4.85 
0116 32 0 58 1.64 21.56455 1 2 3112.7 1.625491 1914.929 53.66724 144.3434 49.84763 3.772316 
0124 39 1 84.1 1.62 32.04542 1 2 2466.56 1.945379 1267.907 29.32889 76.97075   
0115 36 2 87.5 1.67 31.37438 1 2 2576.86 2.014703 1279.027 29.44983 82.13263 14.24594 4.777789 
0104 28 1 83 1.64 30.85961 1 2 2432.72 1.944508 1251.072 29.30988 78.83185 11.78471 2.090901 
0092 30 0 85 1.69 29.76086 1 2 2779.9 1.997568 1391.642 32.70471 93.40791 52.3822 3.690103 
0086 28 0 77 1.6 30.07813 1 2 4208.2 1.849925 2274.795 54.65195 139.909 51.21143 3.475439 
0044 26 0 68.5 1.61 26.42645 1 2 3062.6 1.750278 1749.779 44.70949 115.8915 55.63234 2.68031 
0076 32 2 85 1.62 32.38836 1 2 1276.7 1.955761 652.7895 15.02 39.41849 69.73 1.2 
0036 22 0 67 1.57 27.18163 1 2 4594 1.70937 2687.54 68.56716 169.0112 71.75874 3.583383 
0037 20 0 41 1.51 17.98167 2 0 1542 1.311382 1175.859 37.60976 85.75401 13.57833 1.097228 
0091 20 0 55 1.49 24.77366 2 0 2891.3 1.508771 1916.328 52.56909 116.7086 7.18235 1.421391 
0096 19 0 48 1.57 19.47341 2 0 2193.27 1.446836 1515.908 45.69313 112.629 6.139827 1.980001 
0089 22 0 46 1.52 19.90997 2 0 2218.66 1.393636 1591.994 48.23174 111.4346 18.1986 0.309012 
0099 21 0 57.5 1.6 22.46094 2 0 3278.5 1.598611 2050.844 57.01739 145.9645 4.985357 1.258894 
0029 20 0 57.5 1.66 20.8666 2 0 3327.3 1.628309 2043.409 57.86609 159.4558   
0094 22 0 62 1.62 23.62445 2 0 3133.94 1.670329 1876.241 50.54742 132.6566 11.80584 0.241587 
0098 20 0 49 1.58 19.62827 2 0 2070.58 1.466477 1411.941 42.25674 105.4897 10.75857 1.533319 
0088 23 0 59 1.64 21.93635 2 0 3885.2 1.639444 2369.827 65.85085 177.1124 13.26 0.98 
0055 26 0 57 1.59 22.54658 2 0 5322.2 1.586663 3354.335 93.37193 236.0536 17.96477 0.827179 
0095 20 0 42.5 1.46 19.93808 2 0 1901.5 1.312864 1448.361 44.74118 95.37029 13.76032 1.690117 
0022 32 1 57.3 1.6 22.38281 2 0 2259.9 1.595828 1416.13 39.43979 100.9659 4.492524 0.615771 
0026 25 0 56.5 1.71 19.32219 2 0 2884.6 1.638215 1760.818 51.05487 149.2895 20.30433 0.436598 
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subjno age parity weight height BMI genotype gestage plasvol BSA2 PVBSA2 plvolwt PVBMI PRC AOGEN 
0002 22 0 49 1.65 17.99816 2 0 2524 1.49861 1684.227 51.5102 140.2365  0.96327 
0008 19 0 47 1.56 19.31295 2 0 2992.9 1.427118 2097.163 63.67872 154.9685 19.11163 0.604841 
0016 23 0 52.5 1.64 19.51963 2 0 2793.1 1.546501 1806.077 53.20191 143.0918 8.012748 0.987795 
0007 20 0 55.5 1.62 21.14769 2 0 4188.8 1.580348 2650.555 75.47387 198.0736 85.46859 1.234742 
0028 19 0 55.5 1.69 19.43209 2 0 2547.4 1.61413 1578.187 45.8991 131.0924 5.946752 1.091239 
0032 21 0 59 1.65 21.67126 2 0 1954.8 1.644435 1188.737 33.1322 90.20242 26.44 0 
0063 19 0 50 1.62 19.05197 2 0 1002.5 1.5 668.3333 20.05 52.61922 8.782523 1.85515 
0020 22 0 42.5 1.56 17.46384 2 0 2377.3 1.35708 1751.776 55.93647 136.127 16.48111 1.501491 
0067 26 0 56 1.65 20.56933 2 0 3148.4 1.602082 1965.193 56.22143 153.0628 7.307226 0.306803 
0079 28 0 61 1.68 21.61281 2 0 1406.3 1.687207 833.5078 23.0541 65.06789 97.25 0.52 
0047 22 0 46.5 1.55 19.35484 2 0 3811.5 1.41495 2693.735 81.96774 196.9275 10.69012 1.658387 
0051 26 0 69 1.73 23.05456 2 0 2193.27 1.820943 1204.469 31.78652 95.13388 6.525372 0.114257 
0127 24 0 48.5 1.61 18.7107 2 1 4689.12 1.472762 3183.895 96.68289 250.6117   
0138 33 0 57 1.55 23.72529 2 1 2667.4 1.566578 1702.692 46.79649 112.4286 38.89 0.67 
0052 27 0 65.5 1.56 26.91486 2 1 1534.9 1.684735 911.063 23.43359 57.02798 9.507903 3.792488 
0109 32 1 68 1.56 27.94214 2 1 3177.5 1.716586 1851.058 46.72794 113.7171 33.9349 3.822622 
0107 32 0 56 1.58 22.4323 2 1 1534.9 1.56773 979.0588 27.40893 68.42365 11.1549 2.237475 
0074 37 0 56.5 1.65 20.75298 2 1 3133.94 1.609218 1947.492 55.46797 151.0115   
0106 30 1 46 1.49 20.71979 2 1 2924.77 1.379815 2119.683 63.58196 141.1583 46.98034 5.034665 
0053 29 0 52.5 1.6 20.50781 2 1 2825.49 1.527525 1849.717 53.81886 137.7763 25.1622 1.403991 
0062 31 0 55.5 1.63 20.88901 2 1 3083.8 1.585218 1945.347 55.56396 147.6279 32.09287 1.26998 
0059 25 0 67.5 1.65 24.79339 2 1 3516.3 1.758906 1999.14  141.8241 15.82 4.03 
0049 32 1 47.5 1.55 19.77107 2 1 1722.24 1.430084 1204.293 36.25768 87.10909 12.79916 0.922548 
0087 29 0 66 1.64 24.53897 2 1 3048.5 1.733974 1758.1 46.18939 124.231 18.1 2.28 
0133 27 0 55.5 1.62 21.14769 2 2 6547.7 1.580348 4143.201 117.9766 309.6177   
0122 34 1  1.58  2 2 4838.28     3.727331 2.467812 
0121 23 0 66.6 1.63 25.06681 2 2 4227.57 1.73652 2434.508 63.47703 168.6521 10.71856 4.485159 
0134 27 1 69 1.67 24.74094 2 2 2832 1.789087 1582.93 41.04348 114.4662 36.8 1.54 
0139 33 0 68 1.67 24.38237 2 2 2667.4 1.776076 1501.851 39.22647 109.3987   
0131 36 0 69.5 1.68 24.62443 2 2 2307.3 1.800926 1281.174 33.19856 93.69962 23.34 3.88 
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subjno age parity weight height BMI genotype gestage plasvol BSA2 PVBSA2 plvolwt PVBMI PRC AOGEN 
0123 24 0 69 1.71 23.597 2 2 2377.34 1.810387 1313.167 34.4542 100.7475   
0132 27 0 58 1.51 25.43748 2 2 1992.9 1.559736 1277.716 34.36035 78.34502 61.68 4.55 
0135 33 0 54 1.53 23.06805 2 2 2667.4 1.514926 1760.746 49.3963 115.6318 33.13  
0097 26 0 54.5 1.65 20.01837 2 2 1336.9 1.58048 845.8823 24.53028 66.78367 11.45473 4.368936 
0058 29 0 56 1.62 21.33821 2 2 2799.6 1.587451 1763.582 49.99286 131.2013 7.822756 1.311007 
0137 22 0 65 1.64 24.16716 2 2 3281.6 1.720788 1907.033 50.48615 135.7876 21.97 0 
 
subjno pADH aldos progest prolactin posmolality uosmolality urinevol psodium ppotassium usodium upotassium ucreat pcreat 
0130 3.4 185  15.4          
0103 4.5 55.1 3.8 30.1 274 701 0.805 145 3.8 146 41.9 4896  
0038  23.9 1.9 29.5 269 234 0.62 142 3.1 86 6.9 10384  
0001 3.4 72.4 0 166 298 413 0.866 138 3.9 183 43.1 19040 132 
0046 4.1 86.6 4.1 35.8 268 357 1.72 138 3.6 110 12.2 2902.6 71.8 
0027 3.8 100.1 1.2 36.3 283 102 1.13 142 3.6 53 6.6 3264 67.8 
0011 4.1 96.7 0.9 148 285 506 0.53  3.8 135 30 6528 76 
0024 5 66.6 2.5 80.1 287 409 0.87 140 3.8 54 8.7 4080 80 
0030 4 118.1 1 45.3 267 115 1.8 145 3.7 51 15 4352 68 
0018 4 55.8 0.1 146 277 251 1.2 150 4.9 75 7.1 4080 64 
0009  95.1 0.6 108 276 210 1.8 139 3.7 77 7.1 1122.5 55 
0012 3.4 80.1 0 101 284 362 0.73 147 3.8 53 5.3 4652.5 55 
0017 5.1 80.1 0.2 106 282 506 1.18 134 3.9 97 40.7 8160 48 
0021 3.6 30 1.9 31.6 276 414 0.802 144  89 4.2 5168 49 
0048 4.6 97.1 3.8 23.4 276 757 0.6 138 3.6 126 15.6 13190 46 
0004  72.3 0 138 283 235 0.999 150 3.9 79 7.8  51 
0010 3.4 90.6 0.1 134 277 392 1.48  4.2 97 12.6 1632 42 
0013 3.2 58.9 0 148 268 220 1.11 140 3.8 63 6.7 1632 48 
0005 6.2 54 0.7 78 265 479 1.116     1904 46 
0068 8.7 89.4 26.7 56.6 270 304 2.6 136 2.8 84 7.1 5546.6 130 
0041 3.9 103.1 17.8 133 271 383 3.04 134.4 3 71 29.6 4624 85.6 
0003 9.2 68.9  134 269 79 1.28  4.5 67 8.8  67 
 188
subjno pADH aldos progest prolactin posmolality uosmolality urinevol psodium ppotassium usodium upotassium ucreat pcreat 
0045 6.3 214.6 56.1  264 366 1.305 125.9 3.3 125 24.6 7072 80 
0064 3.8 144.3 28.6 156.2 270 533 1.8 147 3.8 122 21.3 4896 57.8 
0042 3.6 80.1 17.8 133.1 275 607 0.6 136 3 130 36.2 13751 67.8 
0031 3.9 172.3 18 78.6 285 325 1.79 138 3.6 89 4.8 4209.5 58 
0006 3.4 30.5  164 287 321 1 140 3.4 77 6.8 2592.2 56 
0015 4.4  6.3 147 268 135 2.017 147 3.4 71 3.9 1403 45 
0014 3.4 116.1 6.5 179 265 183 1.21 145 3.2 111 7.8 1632 33 
0114 9.4 150.2 72 390.5    142 3.9     
0116 8.8 285.7 75 506.4    150 4.3 61 41.9   
0124 4.2 197.1 79.5 823   2.1       
0115 4 205.2 73.9 380.2    144 4.3     
0104 8.2 206 37.8 156.1  118 3.4 144 3.5 16 2.3   
0092 4 148.6 45 278.2 262 610 1 141 3.4 114 42 1088  
0086 3.5 66.3 50.6 312.2 262 353 1.6 149 3.4 43 11.5 3367.6  
0044 4.2 199.1  124.1 264 90 2 138.3 3.2 52 4.8 2176 63 
0076  168.4 51.2 156.1 277 335 1.2 148 3.8 79 32.7 3648 68 
0036 3.8   125.6 270 77 3.12 139 3.4 56 7.1 3264 41 
0037 5.7  1.1 27.8 269    3.3     
0091 3.8 50 0.7 32 277 432  150 4.4     
0096 3.6 187.1 0.3 18.6 274 330 1.2 144 3.8 60 12 2806.3  
0089 3.9 52.4  3.2 266 232 2.2 153 3.9 53 6.6 2992  
0099 6.8 43.1 0.3 16.5 284 445 1.2 143 4.4 55 9.5 3264  
0029 3.4 49.3 0.4 43.5 245 182 2.3 140 4.1 58 8.4 3264  
0094 3.4 61.4 0.6 30.6 300 313 2.4 145 4 55 9.3 3536  
0098 4.8 34.5 1.9 16.1 272 299 1.2 150 4.4 77 19 4770.7  
0088 3.8 63.9  10.7 279 385 2 149 4.3 101 17.1 4770.8  
0055  102.1 1 35 274 256 1.5 125.1 3.7 65 41.6 5712  
0095 4.3 66.6 0.5 16.9 270 437 1.4 144 5.2 77 25.5 8432  
0022 3.7 156.1 1 180 273 98 2.559 137 3.4 77 11.1 1403 118.6 
0026 3.9 107.1 0.7 44.5 268 108 1.88 143 4.3 45 15.7 2720 116 
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subjno pADH aldos progest prolactin posmolality uosmolality urinevol psodium ppotassium usodium upotassium ucreat pcreat 
0002 8.5 69.6 1.3 108 277 458 1.62  3.8 205 37.1 3087 98 
0008 3.2 39.8 0 124 270 128 1.27 148 4.6 41 14.2 5331 84 
0016  104.6 3.5 118 282 150 1.87 145 4 45 3.8 2176 90 
0007 3.2 42.3 0.1 121 280 221 1.93  3.9 78  1088 78 
0028 3.6 224.6 1 45.3 265 186 2.19 137 3.5 46 7.7 3264 77.3 
0032  42.4 0.8 100.6 268 74 4.875 143 3.4 44 4.3 1632 78 
0063 3.4 58.5 0.3 13.4 282 316 2.8 141 4 96 21.4 2806.3 65.4 
0020 3.4 111.1 0.1 108 269 145 2.35 135 3.8 33 3.6 2720 54 
0067 3.8 38.2 0.3 14.4 248 386 1.9 140 3.7 53 6.7 2992 58 
0079 8 16.5 0.3 12.2 250 511 2.4 142 4 79 41.9 8704 56 
0047 3.4 64.6 0.3 88.1 278 330 1.6 138 3.6 51 16 2448 38 
0051 4.7 64.1 1.4 88.1 289 382 1.3 137 3 76 36.5 11093 43.5 
0127  141.6 24.8 157.9   2       
0138      252 2.8  3.6     
0052 3.4 89.6 20.5 260 267 95 3.01 137 3.5 57 11.6 3367.6  
0109  154.5 19 93.1 261 229 2.4 142 3.9 134 12.7 3929  
0107  43 13.3 113.1 269 239 2.405 144 3.9 120 12.4 5332  
0074 3.8 62.9 22.9 64.1 264 354 1.405 150 5.5 51 16.8 5440  
0106  78.7 33.8 74.6 270 282 2.7 145 4.5 71 27.4 5612.6  
0053  114.6 16.5 162.1 257 233 1 128.8 3.2 124 14.7 4624 75 
0062 3.4 132.2 19 126.6 273 232 3.2 137 3.7 52 5.8 1403 49 
0059 3.4 141.1 36.8 168.2 277 216 2.4  3.1 51 8.4 1360 60.5 
0049 4.5 71.6 50.7 15.9  250 1.3 148 3.2 49 7.6 2525.7 39 
0087 5.2 120.6 28.4 200 267 289  147 4.6    45 
0133        132.3 4.6     
0122 4.2 317.4 68.2 67.7   1.8 144 4.3     
0121 3.5 132.2 80 308.4   4 138 3.9     
0134        132 3.2     
0139     279 402 2.6       
0131        130 4.8     
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subjno pADH aldos progest prolactin posmolality uosmolality urinevol psodium ppotassium usodium upotassium ucreat pcreat 
0123  186.3 76.9 566.4   1.4       
0132    391  370 1.2 131 4     
0135 4.2     51 1.2 128 4.1     
0097 3.4 120.6 55.6 302 268 220 4 140 4.7 68 5 3166.5  
0058  189.3 86.6 280.1 264 281 1.2 138 3.7 76 7.6 3264  
0137        135.5 3.6    57.8 
 
             
 
 
subjno totalUsod totalUpot GFR FENa Cosmo FWC FEK WBC RBC hbconc HCT MCV MCH MCHC 
0130        3.3 3.74 114 0.356 95.2 30.2 320 
0103 117.53 33.7295   2.059507 -1.25451  4.3 4.16 119 0.366 88 28.6 325 
0038 53.32 4.278   0.539331 0.080669  3.1 4.24 106 0.33 79 25 317 
0001 158.478 37.3246 52.09849 0.919346 1.200195 -0.3342 7.661603 6.3 4.73 128 0.402 85 27.1 318 
0046 189.2 20.984 75.79109 1.971745 2.291194 -0.57119 8.382906 3.6 3.3 109 0.354 107.3 33 308 
0027 59.89 7.458 80.0708 0.775295 0.407279 0.722721 3.808211   88     
0011 71.55 15.9 91.23263  0.940982 -0.41098 9.191176   116     
0024 46.98 7.569 95.16 0.756303 1.239826 -0.36983 4.489164 5 3.84 118 0.365 95.1 30.7 323 
0030 91.8 27 107.38 0.549569 0.775281 1.024719 6.334459 4.2 4.34 127 0.382 88 29.3 332 
0018 90 8.52 110.2563 0.784314 1.087365 0.112635 2.272909 4.3 4.7 132 0.409 87 28.1 323 
0009 138.6 12.78 129.3382 2.714265 1.369565 0.430435 9.402275   96     
0012 38.69 3.869 138.4145 0.426221 0.930493 -0.20049 1.648802   126     
0017 114.46 48.026 144.4517 0.425812 2.117305 -0.93731 6.138763 5.3 4 122 0.36 90 30.5 339 
0021 71.378 3.3684 149.898 0.586005 1.203 -0.401  4.6 4.04 110 0.354 87.6 27.2 311 
0048 75.6 9.36 155.593 0.318423 1.645652 -1.04565 1.511246 4 4.19 119 0.389 92.8 28.4 306 
0004 78.921 7.7922 156.5353 4.9375 0.829558 0.169442 18.75 4 4.21 114 0.375 89.1 27.1 304 
0010 143.56 18.648 159.2438  2.09444 -0.61444 7.720588 3.7 4.16 113 0.348 83.7 27.2 325 
0013 69.93 7.437 171.2967 1.323529 0.911194 0.198806 5.185759   123     
0005   221.26  2.017223 -0.90122  4.1 3.88 107 0.334 86.1 27.6 320 
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subjno totalUsod totalUpot GFR FENa Cosmo FWC FEK WBC RBC hbconc HCT MCV MCH MCHC 
0068 218.4 18.46 62.1 1.447628 2.927407 -0.32741 5.943152 4.4 3.7 100 0.306 82.7 27 327 
0041 215.84 89.984 88.55187 0.977946 4.296384 -1.25638 18.26528 3.4  83 0.25    
0003 85.76 11.264 96.88764  0.375911 0.904089  9 4.2 121 0.363 86.4 28.8 333 
0045 163.125 32.103 107.068 1.123135 1.809205 -0.50421 8.432744 4.7 3.27 97 0.306 93.6 29.7 317 
0064 219.6 38.34 129.982 0.979781 3.553333 -1.75333 6.617325   94     
0042 78 21.72 132.5617 0.471303 1.324364 -0.72436 5.949531 5.1 4.11 93 0.324 78.8 22.6 287 
0031 159.31 8.592 156.8607 0.888604 2.041228 -0.25123 1.837114 3.3 3.69 105 0.337 91.3 28.5 312 
0006 77 6.8 182.5757 1.18818 1.118467 -0.11847 4.320654 2.3 3.9 118 0.361 92.6 30.3 327 
0015 143.207 7.8663 236.8427 1.549159 1.016026 1.000974 3.679091  3.05 84 0.263 86.2 27.5 319 
0014 134.31 9.438 255.6509 1.547921 0.835585 0.374415 4.928768   97     
0114        7.5 4.03 103 0.321 79.7 25.6 321 
0116        8.6 3.24 95 0.295 91 29.3 322 
0124        6.4 3.38 98 0.301 89.1 29 326 
0115        4.9 3.33 106 0.312 94.9 31.08 335 
0104 54.4 7.82      5.5 4.48 122 0.374 83.5 27.2 326 
0092 114 42   2.328244 -1.32824  6.5 3.67 109 0.322 87.7 29.7 339 
0086 68.8 18.4   2.155725 -0.55573  10.2 3.63 97 0.312 86 26.7 311 
0044 104 9.6 128.9105 1.088586 0.681818 1.318182 4.342831 7.6 4.18 127 0.401 95.9 30.4 317 
0076 94.8 39.24 140.4 0.994992 1.451264 -0.25126 16.04051 5.1 3.63 95 0.303 83.5 26.2 314 
0036 174.72 22.152 200.5424 0.506066 0.889778 2.230222 2.62309        
0037        5.8 3.6 85 0.281 78.1 23.6 302 
0091        8.9 2.46 68 0.205 83.3 27.6 332 
0096 72 14.4   1.445255 -0.24526  9.1 2.83 80 0.24 85 29.3 345 
0089 116.6 14.52   1.918797 0.281203  5.5 3.4 83 0.255 75 24.4 325 
0099 66 11.4   1.880282 -0.68028  10.9 2.36 68 0.195 82.6 28.8 349 
0029 133.4 19.32  0.209428 1.708571 0.591429 1.035689 8.4 2.91 75 0.235 80.8 25.8 319 
0094 132 22.32   2.504 -0.104  10.6 3.5 89 0.263 75.1 25.4 338 
0098 92.4 22.8   1.319118 -0.11912  6.8 2.53 69 0.21 83 28.7 348 
0088 202 34.2   2.759857 -0.75986  9.9 2.44 73 0.216 88.5 29.9 338 
0055 97.5 62.4  0.20012 1.40146 0.09854 4.330381 10.5 2.81 73 0.232 82.6 26 315 
 192
subjno totalUsod totalUpot GFR FENa Cosmo FWC FEK WBC RBC hbconc HCT MCV MCH MCHC 
0095 107.8 35.7   2.265926 -0.86593  10 2.15 65 0.2 91 33.2 363 
0022 197.043 28.4049 54.2659 4.751133 0.918615 1.640385 27.59759 11.2 2.55 69 0.213 83.5 27.1 324 
0026 84.6 29.516 58.25345 1.34204 0.757612 1.122388 15.57114 6.3 2.99 96 0.297 99.3 32.1 323 
0002 332.1 60.102 61.36  2.678556 -1.05856 30.99415   83     
0008 52.07 18.034 70.41048 0.436509 0.602074 0.667926 4.864085  3.33 86 0.285 85.6 25.8 302 
0016 84.15 7.106 70.98 1.283595 0.994681 0.875319 3.929228  3.35 102 0.32 95.5 30.4 319 
0007 150.54  88.8  1.523321 0.406679  5.2 2.57 83 0.26 101 32.3 319 
0028 100.74 16.863 90.35084 0.795182 1.537132 0.652868 5.210172        
0032 214.5 20.9625 93.61333 1.470588 1.346082 3.528918 6.04455 8.4 2.47 85 0.256 103.6 34.4 332 
0063 268.8 59.92 96.20795 1.586703 3.137589 -0.33759 12.46802 6.7 2.85 83 0.246 86.3 29.1 337 
0020 77.55 8.46 96.58519 0.485294 1.266729 1.083271 1.880805 10.1 2.74 86 0.25 91.2 31.4 344 
0067 100.7 12.73 114.4717 0.733862 2.957258 -1.05726 3.510262 7.4 2.04 76 0.206 101 37.3 369 
0079 189.6 100.56 126.88 0.357938 4.9056 -2.5056 6.73943 9.1 2.47 71 0.217 87.9 28.7 327 
0047 81.6 25.6 150.1705 0.573671 1.899281 -0.29928 6.899056 11.8 1.83 57 0.196  31.1 291 
0051 98.8 47.45 188.0607 0.217537 1.718339 -0.41834 4.771027 4.4 3.82 97 0.308 80.6 25.4 315 
0127        13.2 2.06 63 0.192 93.2 30.6 328 
0138        9.5 2.21 75 0.216 97.7 33.9 347 
0052 171.57 34.916   1.070974 1.939026  7 2.89 78 0.251 86.9 27 311 
0109 321.6 30.48   2.105747 0.294253  8.8 2.95 87 0.262 88.8 29.5 332 
0107 288.6 29.822   2.136784 0.268216  8.1 2.02 66 0.191 94.6 32.7 346 
0074 71.655 23.604   1.883977 -0.47898         
0106 191.7 73.98   2.82 -0.12  11.2 2.18 67 0.192 88.1 30.7 349 
0053 124 14.7 80.808 1.561526 0.906615 0.093385 7.450935 12.4 2.54 79 0.246 96.9 31.1 321 
0062 166.4 18.56 128.3976 1.325627 2.719414 0.480586 5.474755 5.4 2.58 73 0.215 83.3 28.3 340 
0059 122.4 20.16 133.438  1.87148 0.52852 12.05408 9.3 2.11 73 0.212 100.5 34.6 344 
0049 63.7 9.88 136.8 0.511231   3.6673 8 2.26 88 0.26 115 38.9 338 
0087   169.312     12 2.72 72 0.22 80.9 26.5 327 
0133        13.2 2.15 57 0.191 88.8 26.5 298 
0122        8.4 2.79 62 0.206 73.8 22.2 301 
0121         2.39 70 0.214 89.5 29.3 327 
 193
subjno totalUsod totalUpot GFR FENa Cosmo FWC FEK WBC RBC hbconc HCT MCV MCH MCHC 
0134        15 1.88 59 0.179 95.2 31.4 330 
0139     3.746237 -1.14624  11.4 3.65 98 0.29 80.5 26.8 333 
0131        16.1 1.88 58 0.173 92 30 335 
0123        10.5 1.97 66 0.195 99 33.5 338 
0132        10.1 2.29 78 0.238 103.9 34.1 328 
0135        9.8 2.56 79 0.249 97.3 30.9 317 
0097 272 20   3.283582 0.716418  8.8 2.24 66 0.198 88.4 29.5 333 
0058 91.2 9.12  0.232843 1.277273 -0.07727 0.868442 9.9 2.49 68 0.209 83 27.3 325 
0137   138.0069     10.8 3.26 99 0.31 95.1 30.4 319 
 
              
 
subjno PLT LYM NEUT LBW birthwt GADelivery Gender Modelivery           
0130 113 1.7 0.9            
0103 209 1.9 1.7            
0038 230              
0001 74 2.9             
0046 191 1.9 1.1            
0027               
0011               
0024 204 2.2 2.1            
0030 246 2.1 1.9            
0018 205 2.6             
0009               
0012               
0017 87 2.1 2.6            
0021 183 1.8 2.5            
0048 181 2.1 1.5            
0004 241 1.9 1.1            
0010 210 1.7 1.8            
0013               
 194
subjno PLT LYM NEUT LBW birthwt GADelivery Gender Modelivery           
0005 185 1.9 1.3            
0068 169 1.4 2.2 2 3.2 38 1 2       
0041    2 4.1 41 1 2       
0003 228 2.7 5.1 2 2.9 40 1 1       
0045 148 1.3 2.8 2 3.45 39 1 1       
0064    2 2.7 38         
0042 58 1.5 3 2 3.75 40 1        
0031 210 1.4 1.5 2 3 38 2 1       
0006 99 1.7  2 3.9 39 1 1       
0015 330              
0014    2 3.8 40 1 1       
0114 198 1.5 5.6 2 3.2 38 1 1       
0116 203 0.6 7 2 3.1 36         
0124 182 1.6 4.4 2 3.5 38         
0115 201 1.3 3.1 2 2.6 37 1 2       
0104 250 2.2 2.9 2 3.2 40 1 1       
0092 183 1.3 4.7 2 3.2 39 2 1       
0086 228 1.6 7.7 2 3.05 38 1 1       
0044 190 1.1 5.4 2 3.3 37 2 1       
0076 190 1.7 2.9 2 3.9 39 2 1       
0036    2 3.45 40 1 1       
0037 588 2.9 2.3            
0091 368 4.5 3.9            
0096 346              
0089 311 2.6 2.4            
0099 264 3 6.6            
0029 373 2.7 4.6            
0094 637 3.8 6.1            
0098 336              
0088 334 3.6 4.8            
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subjno PLT LYM NEUT LBW birthwt GADelivery Gender Modelivery           
0055 283 4.2             
0095 368              
0022 317 4.4             
0026 289 2.4 2.9            
0002               
0008 470              
0016 132              
0007 392 3.9             
0028               
0032 309 3.4 3.3            
0063 472 3.5 2.4            
0020 206 4.5             
0067 375 2.8             
0079 283 2.9 5            
0047 753 6 5.1            
0051 230 2.1 1.8            
0127 562 3.9 8.3 1 2 36 1 2       
0138 306 2.4 5.8 1 1.5 31 1 2       
0052 365 2.2 3.9 2 3.1 38         
0109 393 2  2 3.4          
0107 401 2.1 4.8 2 3.2 40 1 1       
0074    2 2.9 37 1 1       
0106 535 3.2 6.9 1 2.45 37 2 1       
0053 436 2.4 9.3 1 2.35 39 2 2       
0062 196 1.9 3 2 2.8 36 1        
0059 379 1.9 7.1 2 2.9 38 2 1       
0049 430 2.2 4.5 2 2.75 39 2 2       
0087 281 3.3 7.7 2 3.2 38 1 1       
0133 494 4.4 8.2 1 2.2 35 2 2       
0122 344 2.1 5.3 2 2.7 37 2 2       
 196
subjno PLT LYM NEUT LBW birthwt GADelivery Gender Modelivery           
0121 448   1 2.1 36 2 2       
0134 533 2.5 10.6            
0139 525 3.3 7.2 2 3.1 37 1 2       
0131 326 7.7 7 2 2.5 39 1 2       
0123 722 3.4 6.1 2 3.5 39         
0132 232 3.9  2 3 39 2 2       
0135 505 2.4 6.6 2 2.6 37         
0097 382 3 5.2 2 3.6 39 1 1       
0058 395 2.8 5.6 2 2.5          
0137 672 3 6.4 2 2.6 39 2 1       
 
              
 
              
 
              
 
 
 
 
 
 
Key: 
Genotype: 1 = AA; 2 = SS 
Gestage: 0 = non-pregnant, 1 = 16 weeks pregnant, 2 = 36 weeks pregnant. 
P refers to plasma samples eg pcreat is plasma creatinine, whilst u refers to urinary samples. 
Gender: 1 = male, 2 = female 
Mode of delivery: 1 = vaginal delivery, 2 = emergency caesarean section, 3 = elective caesarean section 
